WO2018208132A1 - Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient - Google Patents

Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient Download PDF

Info

Publication number
WO2018208132A1
WO2018208132A1 PCT/KR2018/005478 KR2018005478W WO2018208132A1 WO 2018208132 A1 WO2018208132 A1 WO 2018208132A1 KR 2018005478 W KR2018005478 W KR 2018005478W WO 2018208132 A1 WO2018208132 A1 WO 2018208132A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyrimidine
pyrazolo
dimethylphenyl
tetrahydroisoquinoline
Prior art date
Application number
PCT/KR2018/005478
Other languages
French (fr)
Inventor
Pilho KIM
Sung Yun Cho
Jae Du Ha
Hyoung Rae Kim
Jong Yeon Hwang
Chang Soo Yun
Hee Jung Jung
Chi Hoon Park
Chong Ock Lee
Chang Hoon Lee
Sunjoo Ahn
Original Assignee
Korea Research Institute Of Chemical Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180051686A external-priority patent/KR102128018B1/en
Application filed by Korea Research Institute Of Chemical Technology filed Critical Korea Research Institute Of Chemical Technology
Priority to US16/612,592 priority Critical patent/US11084824B2/en
Publication of WO2018208132A1 publication Critical patent/WO2018208132A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/56—Flavouring or bittering agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/68—Acidifying substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease.
  • Cancer is defined by the abnormal state of cells, wherein cell death is not controlled normally because of various changes in gene expression, and abnormal cell growth is induced. Cancer cells penetrate into neighboring tissues and destroy thereof, and migrate to other regions, which can result in human death.
  • the cause of cancer that is, the mechanism by which normal cells are transfected into cancer cells, has not been clearly identified. It is known that the causes of cancer include environmental factors, external factors such as chemicals, radiation, and viruses, and internal factors such as genetic factors and immunological factors, and those factors interact complicate to cause cancer.
  • Cancer is largely divided into blood cancer characterized by abnormal blood cell number and solid cancer in the form of cell mass that has a certain degree of hardness and shape in the body. Cancer can be developed in blood and almost all parts of the body, which can be exemplified by lung cancer, stomach cancer, breast cancer, oral cancer, liver cancer, uterine cancer, esophageal cancer and skin cancer.
  • Major treatment methods for cancer are surgery, radio-therapy, and chemo-therapy using a chemotherapeutic agent inhibiting cell proliferation.
  • a chemotherapeutic agent is not a target-specific agent that directly acts on the target of each cancer. Therefore, repeated chemotherapy treatments result in side effects due to cytotoxicity and resistance to the drugs, indicating that, despite the initial successful response to the anticancer drug, if the cancer treatment duration is prolonged or the cancer recurs, the treatment will fail because of such side effects and drug resistance.
  • molecular biological factors are widely used to predict the prognosis of cancer or to determine the treatment method, either chemo-therapy or radio-therapy.
  • the conventional cancer drugs have been constructed by targeting the rapid cell division characteristics of tumor cells, indicating they are targeting not only tumor cells but also normal cells showing relatively fast cell division (for example, hair follicle cells, gastrointestinal cells, bone marrow cells, reproductive cells), which causes serious side effects. Therefore, it is required to develop a novel anticancer agent that is specifically expressed only in tumor cells and not expressed in normal cells or has no effect on normal cells.
  • Bruton's tyrosine kinase is a nonreceptor tyrosine kinase located on chromosome Xq22, which belongs to Tec family kinase.
  • Bruton's tyrosine kinase plays an important role in the downstream signaling of growth factors, B-cell antigens, chemokine receptors and innate immune receptors. That is, BTK is an important protein that plays an important role in various cell activities such as cell growth, survival, differentiation, pathogenesis, angiogenesis, signaling molecule production, and antigen presentation, and thus it is known to play a crucial role in signal transduction of B-cell immunity, inflammation, and anticancer.
  • BTK Bruton's tyrosine kinase
  • BTK Bruton's tyrosine kinase
  • the present inventors have tried to overcome the problems of resistance and side effects according to the co-treatment with immuno-therapy of the conventional BTK inhibitors and to develop a compound with significantly excellent anticancer effect by reversibly inhibiting BTK.
  • the present inventors confirmed that the compound of the present invention exhibited significantly excellent Bruton's tyrosine kinase inhibitory effect in animal tests, so that the compound could be used effectively in the treatment of cancer, autoimmune disease and Parkinson's disease, leading to the completion of the present invention.
  • It is also an object of the present invention to provide a pharmaceutical composition comprising the pyrazolopyrimidine compound above as an active ingredient for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
  • the present invention provides a compound represented by formula 1 below or a pharmaceutically acceptable salt of the same:
  • R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in this specification).
  • the present invention also provides a preparation method of the compound represented by formula 1 comprising the step of preparing the compound represented by formula 1 by reacting the compound represented by formula 2 with the compound represented by formula 3 (step 1), as shown in reaction formula 1 below:
  • R 1 , R 2 , R 3 , R 4 , R 5 , and X are as defined in this specification).
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
  • the present invention also provides a health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of cancer, autoimmune disease or Parkinson's disease.
  • the present invention also provides a method for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease comprising the step of administering the pharmaceutical composition or the health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient to a subject in need.
  • the present invention provides a use of the pharmaceutical composition or the health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
  • the present invention also provides a method of treating a subject having a cancer comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of treating a subject having an autoimmune disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of treating a subject having a Parkinson's disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  • the present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer.
  • the present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease.
  • the present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a Parkinson's disease.
  • the present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer.
  • the present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease.
  • the present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a Parkinson's disease.
  • the present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use as a medicament.
  • the present invention also provides a medicament comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  • the pyrazolopyrimidine derivative of the present invention demonstrates an excellent Bruton's tyrosine kinase (BTK) inhibitory activity, so that a pharmaceutical composition comprising the compound of the invention as an active ingredient can be effectively used for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
  • BTK Bruton's tyrosine kinase
  • the pyrazolopyrimidine derivative of the present invention can be used for immunotherapy because it does not inhibit ITK (Interlukin-2 receptor inducible T-cell kinase) and can be used as an autoimmune disease therapeutic agent for long-term administration because it is a reversible inhibitor.
  • ITK Interlukin-2 receptor inducible T-cell kinase
  • the derivative of the invention also shows an excellent pharmaceutical effect on Abl and Abl mutants along with excellent BBB permeability, so that it can be effectively used for the treatment of Parkinson's disease.
  • Figure 1 is a schematic diagram illustrating the enzyme liked immuosrobent assay performed for measuring the concentration of TNFa.
  • Heterocyclic ring means a saturated or partially unsaturated heterocyclic ring of 3 to 8 ring atoms (refers to a carbocyclic radical having one or more double or triple bonds in the ring without directionality) which contains at least one of hetero atoms selected from the group consisting of N, O and S and the remaining ring atoms are carbon. In a preferred embodiment of the present invention, it refers to monoheterocyclic consisting of one ring, wherein the hetero atom means a nitrogen atom or an oxygen atom.
  • it can be pyrrolidine, dihydrofuran, tetrahydrothiophene, tetrahydropyrane, dihydropyrane, tetrahydrothiopyran, piperidine, morpholine, thiomorpholine, thioxane, piperazine, azetidine, oxetane, thietane, oxepan, oxazepine, diazepine, thiazepine, 2-pyrroline, or 3-pyrroline.
  • “Cycloalkane” is a saturated or partly unsaturated (i.e., nonaromatic) group containing all carbon ring atoms.
  • it can be cyclohexene, cyclohexane, cyclopentene, cyclopentane, cyclobutene, cyclobutane, or cyclopropane.
  • Alkyl is a branched or straight-chain saturated aliphatic hydrocarbon group.
  • the alkyl contains 1 ⁇ 5 carbon atoms or 1 ⁇ 3 carbon atoms.
  • it can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, t-pentyl, or neopentyl.
  • Alkenyl is a branched or straight-chain aliphatic hydrocarbon group having at least one carbon-carbon double bond that can occur along the chain at a stable point.
  • the alkenyl contains 2 ⁇ 5 carbon atoms.
  • it can be ethenyl or propenyl.
  • Alkynyl is a branched or straight-chain aliphatic hydrocarbon group having at least one carbon-carbon triple bond that can occur along the chain at any stable point.
  • the alkynyl contains 2 ⁇ 5 carbon atoms.
  • it can be ethynyl, propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, or 4-pentynyl.
  • Dialkyl indicates an alkyl substituted group as defined above wherein two same or different alkyls are substituted.
  • Alkoxy is an alkyl group as defined above covalently bonded through an oxygen bridge (-O-).
  • Hydroalkyl is an alkyl group as described above substituted with one or more hydroxy substituents.
  • Haloalkyl indicates a branched or straight alkyl group substituted with one or more halogen atoms and up to a maximum number of halogen atoms. For example, it can be trifluoromethyl, monofluoromethyl, difluoromethyl, 2-fluoroethyl, or penta-fluoroethyl.
  • Cycloalkyl is a saturated or partly unsaturated (i.e., nonaromatic) group containing all carbon ring atoms.
  • it can be cyclohexenyl, cyclohexyl, cyclopentenyl, cyclopentyl, cyclobutenyl, cyclobutyl, or cyclopropyl.
  • Alkyloxyalkyl is an alkyl group as defined above wherein additional alkyl is covalently bonded through an oxygen bridge (-O-).
  • Aryl indicates an aromatic group containing only carbon in the aromatic ring. In a preferred embodiment of the present invention, it may be phenyl or naphthalenyl.
  • Heteroaryl indicates a stable 5 ⁇ 12 membered monocyclic aromatic ring, bicyclic or tricyclic system containing one or more hetero atoms selected from the group consisting of N, O and S and the remaining ring atoms are carbon. In a preferred embodiment of the present invention, the only hetero atom is nitrogen.
  • the monocyclic heteroaryl group typically has 5 ⁇ 7 ring atoms.
  • the bicyclic heteroaryl group is a 9 or 10 membered heteroaryl group wherein a 5 ⁇ 7 membered aromatic ring is fused with the second aromatic or non-aromatic ring and 9 ⁇ 10 ring atoms are contained.
  • the heteroaryl group is exemplified by pyridinyl (including 2-hydroxypyridinyl), imidazolyl, imidazolopyridinyl, pyrimidinyl (including 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazoly
  • Halo or "halogen” independently represents any fluoro, chloro, bromo, and iodo.
  • the present invention provides a compound represented by formula 1 below or a pharmaceutically acceptable salt of the same:
  • A is 3 ⁇ 8 membered heterocyclic ring containing one or more hetero atoms selected from the group consisting of N, O and S or C 3-10 cycloalkane;
  • R 3 , R 4 , and R 5 are independently hydrogen, straight or branched C 1-5 alkyl or C 3-8 cycloalkyl. At this time, the alkyl or cycloalkyl can be substituted with hydroxy; and
  • A is 3 ⁇ 6 membered heterocyclic ring containing one or more hetero atoms selected from the group consisting of N, O and S or C 5-7 cycloalkane;
  • R 3 , R 4 , and R 5 are independently hydrogen, straight or branched C 1-3 alkyl or C 3-6 cycloalkyl. At this time, the alkyl or cycloalkyl can be substituted with hydroxy; and
  • R 10 is straight or branched C 1-3 alkyl or C 1-3 alkyloxy C 1-3 alkyl; C 5-10 aryl; or 6 ⁇ 10 membered heteroaryl containing one or more nitrogen atoms; and the aryl or heteroaryl can be substituted with one or more substituents selected from the group consisting of straight or branched C 1-3 alkyl, C 1-3 alkoxy and C 1-3 haloalkyl.
  • A is piperidine, tetrahydropyrane, pyrrolidine, or cyclohexane
  • R 2 is hydrogen or methoxy
  • R 3 is hydrogen
  • R 4 is hydrogen, methyl, isopropyl, cyclopentyl, cyclohexyl, or (4-hydroxy)cyclohexyl;
  • R 5 is hydrogen
  • R 6 is one or more substituents selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, methoxy, chloro, fluoro, methoxyethoxy, phenoxy, , , , and .
  • the compound represented by formula 1 above is any one selected from the group consisting of the following compounds:
  • the compound represented by formula 1 of the present invention can be used as a form of a pharmaceutically acceptable salt, in which the salt is preferably acid addition salt formed by pharmaceutically acceptable free acids.
  • the acid addition salt herein can be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, and phosphorous acid; non-toxic organic acids such as aliphatic mono/dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate, alkandioate, aromatic acids, and aliphatic/aromatic sulfonic acids; or organic acids such as acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, and fumaric acid.
  • inorganic acids such as hydrochloric acid, nitric
  • the pharmaceutically non-toxic salts are exemplified by sulfate, pyrosulfate, bisulfate, sulphite, bisulphite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutylate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, cabacate, fumarate, maliate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, tolu
  • the acid addition salt in this invention can be prepared by the conventional method known to those in the art.
  • the derivative represented by formula 1 is dissolved in an organic solvent such as methanol, ethanol, acetone, methylenechloride, or acetonitrile, to which organic acid or inorganic acid is added to induce precipitation.
  • the precipitate is filtered and dried to give the salt.
  • the solvent and the excessive acid are distillated under reduced pressure, and dried to give the salt.
  • the precipitate is crystallized in an organic solvent to give the same.
  • a pharmaceutically acceptable metal salt can be prepared by using a base.
  • Alkali metal or alkali earth metal salt is obtained by the following processes: dissolving the compound in excessive alkali metal hydroxide or alkali earth metal hydroxide solution; filtering non-soluble compound salt; evaporating the remaining solution and drying thereof.
  • the metal salt is preferably prepared in the pharmaceutically suitable form of sodium, potassium, or calcium salt.
  • the corresponding silver salt is prepared by the reaction of alkali metal or alkali earth metal salt with proper silver salt (ex; silver nitrate).
  • the present invention includes not only the compound represented by formula 1 but also a pharmaceutically acceptable salt thereof, and a solvate, an optical isomer, or a hydrate possibly produced from the same.
  • the present invention also provides a preparation method of the compound represented by formula 1 comprising the step of preparing the compound represented by formula 1 by reacting the compound represented by formula 2 with the compound represented by formula 3 (step 1), as shown in reaction formula 1 below:
  • R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in formula 1, and
  • X is halogen
  • step 1 is to prepare the compound represented by formula 1 by reacting the compound represented by formula 2 with the compound represented by formula 3.
  • step 1 is a step of condensing an amine group (-NHR 5 ) of the compound represented by formula 2 and a halogen group (X) of the compound represented by formula 3 in the presence of an acid.
  • the acid is not particularly limited as long as it is an acid generally used in the field, but trifluoroacetic acid (TFA), p-toluenesulfonic acid (p-TSA), hydrochloric acid (HCl) and formic acid can be used.
  • TFA trifluoroacetic acid
  • p-TSA p-toluenesulfonic acid
  • HCl hydrochloric acid
  • formic acid formic acid can be used.
  • the reaction temperature is not limited but can be 10 ⁇ 150°C, preferably 30 ⁇ 120°C, and more preferably 50 ⁇ 100°C. Most preferably, the reaction temperature can be the boiling point of the organic solvent used in the reaction.
  • reaction solvent is not particularly limited as long as it is an organic solvent generally used in the field, but isopropanol, butanol, and 1,4-dioxane can be used.
  • step 1 preparing the compound represented by formula 3-3 by reacting the compound represented by formula 3-1 with the compound represented by formula 3-2 via amidation (step 1);
  • step 2 preparing the compound represented by formula 3-5 by reacting the compound represented by formula 3-3 prepared in step 1 with the compound represented by formula 3-4 with the addition of hydrazine (step 2);
  • step 3 cyclizing the compound represented by formula 3-5 prepared in step 2 (step 3).
  • R 3 , R 4, and R 5 are as defined in formula 1, and X is halogen.
  • reaction conditions for step 1 ⁇ step 3 shown in reaction formula 2 above are not particularly limited as long as they are generally used in the art, so that the detailed description is omitted herein.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer.
  • the compound is characterized by being effective in preventing or treating cancer by inhibiting Bruton's tyrosine kinase (BTK).
  • BTK Bruton's tyrosine kinase
  • the cancer can be solid cancer or blood cancer.
  • the solid tumor can be selected from the group consisting of brain tumor, benign astrocytoma, malignant astrocytoma, pituitary adenoma, meningioma, brain lymphoma, oligodendroglioma, intracranial tumor, ependymoma, brain stem tumor, head and neck tumor, laryngeal cancer, uveal cancer, nasal cancer, nasopharyngeal cancer, salivary gland cancer, hypopharyngeal cancer, thyroid cancer, oral cancer, thoracic tumor, small cell lung cancer, non-small cell lung cancer, thymic cancer, mediastinal tumor, esophageal cancer, breast cancer, male breast cancer, abdominal tumor, stomach cancer, liver cancer, gallbladder cancer, biliary cancer, pancreatic cancer, small bowel cancer, colon cancer, anal cancer, bladder cancer, kidney cancer, male genital tumor, penile cancer, prostate cancer, female genital tumor, cervix cancer, endometrial cancer
  • composition comprising the compound represented by formula 1, the optical isomer thereof or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer can be administered independently or co-administered with other anticancer agents in use.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of autoimmune disease.
  • the compound is characterized by being effective in preventing or treating autoimmune disease by inhibiting Bruton's tyrosine kinase (BTK).
  • the autoimmune disease can be selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, lupus, diabetes mellitus, myasthenia gravis, Hashimoto's thyroiditis, Graves' disease, Sjogren's syndrome, multiple sclerosis, Guilin Barre syndrome, acute sporadic encephalomyelitis, Addison's disease, ocular hepatocellular seizure-epileptic syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, chronic digestive dysfunction, Goodpasture syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary dysplasia cirrhosis, Takay
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of Parkinson's disease.
  • the compound represented by formula 1 or the pharmaceutically acceptable salt thereof included in the pharmaceutical composition of the present invention can be administered orally or parenterally and be used in general forms of pharmaceutical formulation. That is, the composition of the present invention can be prepared for oral or parenteral administration by mixing with generally used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants.
  • the formulations for oral administration are exemplified by tablets, pills, hard/soft capsules, solutions, suspensions, emulsions, syrups, granules, elixirs, and troches, etc.
  • These formulations can include diluents (for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycine) and lubricants (for example, silica, talc, stearate and its magnesium or calcium salt, and/or polyethylene glycol) in addition to the active ingredient.
  • Tablets can include binding agents such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrolidone, and if necessary disintegrating agents such as starch, agarose, alginic acid or its sodium salt or azeotropic mixtures and/or absorbents, coloring agents, flavours, and sweeteners can be additionally included thereto.
  • binding agents such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrolidone
  • disintegrating agents such as starch, agarose, alginic acid or its sodium salt or azeotropic mixtures and/or absorbents, coloring agents, flavours, and sweeteners can be additionally included thereto.
  • the pharmaceutical composition comprising the compound represented by formula 1 as an active ingredient can be administered by parenterally and the parenteral administration includes subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
  • the compound represented by formula 1 or the pharmaceutically acceptable salt thereof is mixed with a stabilizer or a buffering agent in water to produce a solution or suspension, which is then formulated as ampoules or vials.
  • the composition herein can be sterilized and additionally contains preservatives, stabilizers, wettable powders or emulsifiers, salts and/or buffers for the regulation of osmotic pressure, and other therapeutically useful materials, and the composition can be formulated by the conventional mixing, granulating or coating method.
  • the effective dosage of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof of the present invention can be determined according to age, weight, gender, administration method, health condition, and severity of disease.
  • the dosage is generally 0.1 ⁇ 1000 mg/day, and preferably 1 ⁇ 500 mg/day based on an adult patient weighing 70 kg, which can be administered once or several times a day at intervals of a certain time depending on the judgment of a doctor or a pharmacist.
  • composition comprising the compound represented by formula 1, the optical isomer, or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer can be administered as an individual therapeutic agent or in combination with other anticancer agents in use.
  • the present invention also provides a health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of cancer.
  • the present invention also provides a health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of autoimmune disease.
  • the present invention provides a health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of Parkinson's disease.
  • the compound represented by formula 1 of the present invention can be used as a food additive.
  • the compound represented by formula 1 of the present invention can be added as it is or as mixed with other food components according to the conventional method.
  • the mixing ratio of active ingredients can be regulated according to the purpose of use (prevention or improvement).
  • the compound of the present invention is preferably added to food or beverages by 0.1 ⁇ 90 weight part for the total weight of the food or beverages.
  • the content can be lower than the above but higher content can be accepted as well since the compound of the present invention has been proved to be very safe.
  • the health beverage composition of the present invention can additionally include various flavors or natural carbohydrates, etc, like other beverages.
  • the natural carbohydrates above can be one of monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xilytole, sorbitol and erythritol.
  • natural sweetening agents thaumatin, stevia extract, for example rebaudioside A, glycyrrhizin, etc.
  • synthetic sweetening agents sacharin, aspartame, etc.
  • the content of the natural carbohydrate is preferably 1 ⁇ 20 g and more preferably 5 ⁇ 12 g in 100 g of the composition of the invention.
  • the compound represented by formula 1 of the present invention can include in variety of nutrients, vitamins, minerals (electrolytes), flavors including natural flavors and synthetic flavors, coloring agents and extenders (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acid, protective colloidal viscosifiers, pH regulators, stabilizers, antiseptics, glycerin, alcohols, carbonators which used to be added to soda, etc.
  • the compound represented by formula 1 of the present invention can also include natural fruit juice, fruit beverages and fruit flesh addable to vegetable beverages.
  • the present invention also provides a method for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease comprising the step of administering the pharmaceutical composition or the health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient to a subject in need.
  • the present invention provides a use of the pharmaceutical composition or the health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
  • the present invention also provides a method of treating a subject having a cancer comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of treating a subject having an autoimmune disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of treating a subject having a Parkinson's disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  • the present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer.
  • the present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease.
  • the present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a Parkinson's disease.
  • the present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer.
  • the present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease.
  • the present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a Parkinson's disease.
  • the present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use as a medicament.
  • the present invention also provides a medicament comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  • novel pyrazolopyrimidine compound of the present invention demonstrates an excellent BTK inhibitory activity at a low concentration, and therefore it can be used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease, which is supported by the results of the following experiments.
  • Trifluoro acetic anhydride (0.43 mL, 2.99 mmol) was added to 2-(4-bromophenyl)ethane-1-amine (500 mg, 2.50 mmol) solution in DCM (25 mL), to which TEA (0.87 mL, 6.25 mmol) was added.
  • the reaction mixture was stirred at room temperature for 1 hour.
  • water 50 mL was added to the reaction mixture, followed by extraction with DCM (2 X 50 mL).
  • the combined organic layer was washed with saturated brine solution, which was dried over Na 2 SO 4 .
  • the solvent was eliminated in vacuum.
  • the crude mixture was purified by re-crystallization. As a result, N-(4-bromophenetyl)-2,2,2-trifluoroacetamide (700 mg, 2.36 mmol, 94%) was obtained as a white solid.
  • Step 2 Preparation of 1-(7-bromo-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • step 1 Compound of step 1 (250 mg, 0.844 mmol) was dissolved in HOAc (1.41 mL) and sulfuric acid (0.94 mL), to which paraformaldehyde (40 mg, 1.35 mmol) was added at room temperature, followed by stirring for 12 hours.
  • the reaction mixture was poured carefully into approximately 10 mL of ice.
  • the generated white sludge suspension was extracted with EtOAc.
  • the organic material was washed with saturated aqueous NaHCO 3 and brine, followed by drying over MgSO 4 .
  • the crude mixture was purified by column chromatography using EtOAc/Hx (1:4) as an eluent.
  • Step 3 Preparation of 1-(7-bromo-6-nitro-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • Step 4 Preparation of 1-(6-amino-3,4-dihydroisoquinoline-2(1 H )-yl)-2,2,2-trifluoroethane-1-one
  • Trifluoro acetic anhydride (6.22 g, 29.61 mmol) was added to 2-(4-nitrophenyl)ethane-1-amine (5.0 g, 24.67 mmol) solution in DCM (100 mL), to which TEA (8.6 mL, 61.67 mmol) was added.
  • the reaction mixture was stirred at room temperature for 2 hours.
  • water 50 mL was added to the reaction mixture, followed by extraction with DCM (2 X 50 mL).
  • the combined organic layer was washed with saturated brine solution, which was dried over Na 2 SO 4 .
  • the solvent was eliminated in vacuum.
  • the crude mixture was purified by re-crystallization. As a result, 2,2,2-trifluoro-N-(4-nitrophenetyl)acetamide (5.8 g, 22.1 mmol, 90%) was obtained as a grey-white solid.
  • step 1 Compound of step 1 (750 mg, 2.86 mmol) was dissolved in HOAc (4 mL), to which sulfuric acid (7.5 mL) and paraformaldehyde (137 mg, 4.57 mmol) were added at room temperature, followed by stirring at 50°C for 12 hours.
  • the reaction mixture was poured carefully into approximately 100 mL of ice.
  • the generated white sludge suspension was extracted with EtOAc.
  • the organic material was washed with saturated aqueous NaHCO 3 and brine, followed by drying over MgSO 4 .
  • the crude mixture was purified by column chromatography using hexane/EA (1:4) as an eluent.
  • Step 3 Preparation of 1-(7-amino-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • step 1 Compound of step 1 (4.0 g, 12.3 mmol) was dissolved in 30 mL of methanol, to which 30 mL of sodium hydroxide solution (2.7 g, 67.6 mmol) was added at room temperature, followed by stirring at room temperature for 5 hours. Most of methane was concentrated under reduced pressure, and pH of the residue was adjusted to 2 with conc. HCl. The solid was precipitated and filtered. The filtered cake was washed with water and dried. As a result, 2-(carboxymethyl)-5-nitrobenzoic acid (2.2 g, 9.77 mmol, 79%) was obtained as a cream type solid.
  • BH 3 THF (1.0 M) (21 mL, 21.03 mmol) was added to cold compound of step 1 (1.0 g, 5.25 mmol) THF (25 mL) solution at 0°C.
  • the reaction mixture was stirred at 70°C for 2 hours.
  • the reaction was terminated with methanol, followed by concentration and drying.
  • 1.5 N HCl (15.00 mL) was added to the residue, followed by extraction with EtOAc.
  • the aqueous layer was basified with NaOH solution and extracted with EtOAc (2 X 50 mL).
  • the combined organic layer was washed with sodium sulfate and the remaining mixture was subjected to the following steps without any purification process.
  • Step 3 Preparation of 1-(4,4-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1 H )-yl)-2,2,2-trifluoroethane-1-one
  • Step 4 Preparation of 1-(7-amino-4,4-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • Step 4 Preparation of 2,2,2-trifluoro-1-(1-isopropyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
  • Step 5 Preparation of 1-(7-amino-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • Step 3 Preparation of 2,2,2-trifluoro-1-(1,3,3-trimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
  • Step 4 Preparation of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • Trifluoroacetic anhydride (1.64 mL, 11.7 mmol) was added dropwise to cold isoindolin (400 mg, 3.35 mmol) acetonitrile (15 mL) solution at -10°C.
  • Potassium nitrate (366 mg, 3.62 mmol) was added to the stirred mixture at once. The mixture was stirred at -10°C for 1 hour. Saturated sodium bicarbonate aqueous solution (10 mL) was slowly added to the mixture. Active gas generation was observed. The mixture was stirred for 1 hour and then the temperature of the mixture was raised to room temperature. The mixture was basified with saturated sodium carbonate (10 mL). The sticky turbid solution was filtered.
  • a target compound was prepared by the same manner as described in step 4 of Preparative Example A-7 except that 2,2,2-trifluoro-1-(5-nitroisoindolin-2-yl)ethane-1-one prepared in step 1 was used instead of 2,2,2-TRIFLUORO-1-(1,3,3-TRIMETHYL-7-NITRO-3,4-DIHYDROISOQUINOLINE-2(1H)-YL)ETHANE-1-ONE.
  • Step 5 Preparation of 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
  • Step 6 Preparation of 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
  • Step 7 Preparation of 2,2,2-trifluoro-1-(6-hydroxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
  • Step 8 Preparation of 1,1-dimethyl-7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-yl trifluoromethanesulfonate
  • Step 9 Preparation of 1-(7-amino-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • N -(4-nitrophenyl)acrylamide 200 mg, 1.04 mmol was suspended in ethanol/water (5:1) mixture, to which Fe powder (116 mg, 2.08 mmol) and ammonium chloride solution (1 mL) were added. The mixture was heated to 80°C for 4 hours. The reaction mixture was cooled at room temperature and filtered with a celite pad. The celite above was washed with ethanol (10 mL) and ethyl acetate (50 mL). The solution above was concentrated under vacuum. The reaction residue was fractionated with DCM (50 mL) and water (20 mL). The combined organic layer was concentrated under reduced pressure. The obtained crude mixture was purified by column chromatography (EtOAc/Hexane (1:5)). As a result, N -(4-aminophenyl)acrylamide (100 mg, 0.616 mmol, 60%) was obtained as a yellow solid.
  • Fuming nitric acid (128 mg, 2.04 mmol) was added dropwise to -5°C conc. sulfuric acid (2.0 mL) containing 3,4-dihydroisoquinolin-1(2H)-one (400 mg, 2.31 mmol) at 0°C. The temperature of the mixture was raised to room temperature for 2 hours. The reaction mixture was placed in ice-water (10 mL) and basified with potassium hydroxide pellet (pH 9). The mixture was extracted with dichloromethane, followed by drying. The solvent was eliminated under reduced pressure. The crude product was purified by column chromatography (MeOH/DCM (1:9)). As a result, 7-nitro-3,4-dihydroisoquinoline-1(2H)-one (300 mg, 1.56 mmol, 76%) was obtained as brown oil.
  • a target compound was prepared by the same manner as described in step 4 of Preparative Example A-7 except that 7-nitro-3,4-dihydroisoquinoline-1(2H)-one prepared in step 1 was used instead of 2,2,2-TRIFLUORO-1-(1,3,3-TRIMETHYL-7-NITRO-3,4-DIHYDROISOQUINOLINE-2(1H)-YL)ETHANE-1-ONE.
  • 2,6-Dimethylaniline (5.81 g, 48 mmol) was added to 2,4-dichloropyrimidine-5-carbonyl chloride (10.2 g, 48 mmol) in EtOAc (400 mL) at room temperature, to which amberlyst 21 resin (2.0 g) was added. The mixture was stirred at room temperature for 12 hours, followed by filtering. The filtrate was washed serially with water, 1.5 N HCl (15 mL), NaOH, and brine in that order. The combined organic layer was dried over sodium sulfate, and then concentrated under reduced pressure. The obtained crude product was recrystallized by using DCM.
  • Methyl hydrazine (205 mg, 4.45 mmol) was added to 2,4-DICHLORO-N-(2,6-DIMETHYLPHENYL)PYRIMIDINE-5-CARBOXAMIDE(1.2 g, 4.05 mmol) in THF (30 mL) at room temperature, to which Et 3 N (1.42 mL, 10.1 mmol) was added. The mixture was stirred at room temperature for 24 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4).
  • PCl 5 (681 mg, 3.27 mmol) was added to 2-CHLORO-N-(2,6-DIMETHYLPHENYL)-4-(1-METHYLHYDRAZINYL)PYRIMIDINE-5-CARBOXAMIDE(1.0 g, 3.27 mmol) in toluene (40 mL) at room temperature. The mixture was stirred at room temperature for 24 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4).
  • 6-CHLORO-N-(2,6-DIMETHYLPHENYL)-1-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE-3-AMINE 800 mg, 2.78 mmol, 85 %) was obtained as a yellow solid.
  • PCl 5 (150 mg, 0.720 mmol) was added to 2-chloro-4-(1-methylhydrazinyl)-N-phenylpyrimidine-5-carboxamide (200 mg, 0.720 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 100°C for 18 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 6-chloro-1-methyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine (150 mg, 0.577 mmol, 80%) was obtained as a yellow solid.
  • 2,6-Dichloroaniline (383 mg, 2.36 mmol) was added to 2,4-dichloropyrimidine-5-carbonyl chloride (500 mg, 2.36 mmol) in EtOAc (40 mL) at room temperature, to which amberlyst 21 resin (100 mg) was added. The mixture was stirred for 12 hours, followed by filtering. The filtrate was washed with water, 1.5 N HCl (15 mL), NaOH, and brine in that order. The combined organic layer was dried over sodium sulfate, and then concentrated under reduced pressure. The obtained crude product was recrystallized by using DCM. As a result, 2,4-dichloro-N-(2,6-dichlorophenyl)pyrimidine-5-carboxamide (650 mg, 1.93 mmol, 81%) was obtained as a grey-white solid.
  • PCl 5 120 mg, 0.577 mmol was added to 2-chloro-N-(2,6-dichlorophenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide (200 mg, 0.577 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 100°C for 18 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4).
  • 6-chloro-N-(2,6-dichlorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine 130 mg, 0.395 mmol, 68%) was obtained as a yellow solid.
  • Step 1 Preparation of tert-butyl-2-(2-chloro-5-((2,6-dimethylphenyl)carbamoyl)pyrimidine-4-yl)hydrazine-1-carboxylate
  • tert-butyl-2-(2-chloro-5-((2,6-dimethylphenyl)carbamoyl)pyrimidine-4-yl)hydrazine-1-carboxylate 560 mg, 1.429 mmol, 84%) was obtained as a white solid.
  • PCl 5 (297 mg, 1.429 mmol) was added to tert-butyl-2-(2-chloro-5-((2,6-dimethylphenyl)carbamoyl)pyrimidine-4-yl)hydrazine-1-carboxylate (560 mg, 1.429 mmol) in toluene (50 mL) at room temperature. The mixture was stirred at 100°C for 18 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 6-chloro-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine (65 mg, 0.237 mmol, 16%) was obtained as a yellow solid.
  • Step 1 Preparation of 2-chloro-4-(1-cyclopentylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide
  • Step 2 Preparation of 6-chloro-1-cyclopentyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
  • PCl 5 (104 mg, 0.500 mmol) was added to 2-chloro-4-(1-cyclopentylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (180 mg, 0.500 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 100°C for 18 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by column chromatography using EtOAc/Hx (1/4).
  • 6-chloro-1-cyclopentyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine 120 mg, 0.351 mmol, 70% was obtained as a yellow solid.
  • Step 1 Preparation of 2-chloro-4-(1-cyclohexylhydrazinyl)- N -(2,6-dimethylphenyl)pyrimidine-5-carboxamide
  • Step 2 Preparation of 6-chloro-1-cyclohexyl- N -(2,6-dimethylphenyl)-1 H -pyrazolo[3,4-d]pyrimidine-3-amine
  • PCl 5 (72 mg, 0.347 mmol) was added to 2-chloro-4-(1-cyclohexylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (130 mg, 0.347 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 110°C for 3 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by column chromatography using EtOAc/Hx (1/4).
  • 6-chloro-1-cyclohexyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine 90 mg, 0.253 mmol, 73%) was obtained as a yellow solid.
  • Step 1 Preparation of 2-chloro- N -(2,6-dimethylphenyl)-4-(1-isopropylhydrazinyl)pyrimidine-5-carboxamide
  • Et 3 N (0.18 mL, 1.26 mmol) was added to 2,4-dichloro-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (150 mg, 0.506 mmol) in THF (10 mL), to which isopropyl hydrazine (41 mg, 0.577 mmol) was added at room temperature. The mixture was stirred at room temperature for 2 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4).
  • Step 2 Preparation of 6-chloro- N -(2,6-dimethylphenyl)-1-isopropyl-1 H -pyrazolo[3,4-d]pyrimidine-3-amine
  • PCl 5 (68.6 mg, 0.329 mmol) was added to 2-chloro-N-(2,6-dimethylphenyl)-4-(1-isopropylhydrazinyl)pyrimidine-5-carboxamide (110 mg, 0.329 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 110°C for 3 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4).
  • 6-chloro-N-(2,6-dimethylphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine 75 mg, 0.237 mmol, 72%) was obtained as a yellow solid.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide prepared in step 4 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • Step 5 Preparation of N-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-2,4-dimethylphenyl)-3-(trifluoromethyl)benzamide
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that N-(3-amino-2,4-dimethylphenyl)-3-(trifluoromethyl)benzamide prepared in step 4 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • Step 2 Preparation of 6-chloro-N-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 4-(2-methoxyethoxy)-2,6-dimethylaniline prepared in step 1 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,6-dimethyl-4-phenoxybenzamine was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • T3P (2.30 mL, 10.2 mmol) and TEA (1.42 mL, 10.2 mmol) were added to DCM (20 mL) solution containing 3,5-dimethyl-4-nitrobenzoic acid (1.00 g, 5.12 mmol) and 2-aminopyridine (482 mg, 5.12 mmol) at room temperature, followed by stirring at room temperature overnight.
  • the reaction was terminated with NaHCO 3 (aq), followed by extraction with DCM (2 X 25 mL).
  • the combined organic layer was dried over Na 2 SO 4 and the solvent was eliminated under reduced pressure.
  • the residue mixture was purified by silica gel column chromatography using EtOAc/Hex (3/7). As a result, the target compound (290 mg, 1.07 mmol, 21%) was obtained as a white solid.
  • Step 3 Preparation of 4-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-3,5-dimethyl-N-(pyridine-2-yl)benzamide
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 4-amino-3,5-dimethyl-N-(pyridine-2-yl)benzamide prepared in step 2 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • Step 2 Preparation of 6-chloro-N-(4-methoxy-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 4-methoxy-2,6-dimethylaniline prepared in step 1 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,4-diethylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,4-diisopropylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • Step 1 Preparation of 2,4-dichloro- N -(3,5-dimethylphenyl)pyrimidine-5-carboxamide
  • Step 2 Preparation of 2-chloro- N -(3,5-dimethylphenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide
  • Step 3 Preparation of 6-chloro- N -(2-chloro-3,5-dimethylphenyl)-1-methyl-1 H -pyrazolo[3,4-d]pyrimidine-3-amine
  • PCl 5 (82 mg, 0.392 mmol) was added to 2-chloro-N-(3,5-dimethylphenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide (120 mg, 0.392 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 110°C for 2 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4) as an eluent.
  • 6-chloro-N-(2-chloro-3,5-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine 40 mg, 0.124 mmol, 32%) was obtained as a yellow solid.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,4-dimethylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2-methylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 3,5-dimethylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,6-difluoroaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,6-dimethoxyaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,5-dimethyl-4-fluoroaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,5-dimethylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2-chloro-6-methylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 5-(2-methoxyethoxy)-2-methylaniline prepared in step 2 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2-methyl-5-nitroanilyl was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • Step 3 Preparation of N-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)picolineamide
  • Step 2 Preparation of 3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide
  • a target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that N-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide prepared in step 1 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
  • Step 1 Preparation of N 1 -(6-chloro-1-methyl-1 H -pyrazolo[3,4-d]pyrimidine-3-yl)-6-methylbenzene-1,3-diamine
  • N 1 -(6-chloro-1-methyl-1 H -pyrazolo[3,4-d]pyrimidine-3-yl)-6-methylbenzene-1,3-diamine 60 mg, 0.207 mmol, 66%) was obtained as a yellow solid.
  • Step 2 Preparation of 1-(3-((6-chloro-1-methyl-1 H -pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea
  • N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine (20 mg, 0.050 mmol, 50%) was obtained as a grey-white solid.
  • Lithium hydroxide monohydrate (2.5 mg, 0.057 mmol) was added to THF (1.0 mL), MeOH (0.5 mL), and H 2 O (0.5 mL) containing the compound of Example 3 (1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone, 15 mg, 0.028 mmol) at room temperature, followed by stirring at room temperature for 1 hour. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was concentrated to eliminate THF and methanol.
  • a target compound was prepared by the same manner as described in Example 3 except that the compound prepared in Preparative Example A-2 was used instead of 1-(6-amino-7-methoxy-3,4 dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one in Example 3.
  • a target compound was prepared by the same manner as described in Example 4 except that the compound of Example 6 was used instead of the compound of Example 3 in Example 4.
  • a target compound was prepared by the same manner as described in Example 5 except that the compound of Example 7 was used instead of the compound of Example 4 in Example 5.
  • a target compound was prepared by the same manner as described in Example 3 except that the compound prepared in Preparative Example A-3 was used instead of 1-(6-amino-7-methoxy-3,4 dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one and the compound prepared in Preparative Example B-2 was used instead of the compound prepared in Preparative Example B-1 in Example 3
  • a target compound was prepared by the same manner as described in Example 4 except that the compound of Example 9 was used instead of the compound of Example 3 in Example 4.
  • a target compound was prepared by the same manner as described in Example 9 except that the compound of Preparative Example B-3 was used instead of the compound of Preparative Example B-2 in Example 9.
  • a target compound was prepared by the same manner as described in Example 10 except that the compound of Example 11 was used instead of the compound of Example 9 in Example 10.
  • Example 14 Preparation of 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)prop-2-en -1-one
  • Step 1 Preparation of 1-(6-((3-((2,6-dichlorophenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • a target compound was prepared by the same manner as described in Example 6 except that the compound prepared in Preparative Example B-3 was used instead of the compound of Preparative Example B-1 in Example 6.
  • Step 2 Preparation of N 3 -(2,6-dichlorophenyl)-1-methyl-N 6 -(1,2,3,4-tetrahydroisoquinoline-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
  • a target compound was prepared by the same manner as described in Example 7 except that the compound prepared in step 1 above was used instead of the compound of Example 6 in Example 7.
  • a target compound was prepared by the same manner as described in Example 13 except that the compound of Example 15 was used instead of the compound of Example 12 in Example 13.
  • Formalin (35%) (1.5 mg, 0.05 mmol) was added to MeOH (1.0 mL) and acetic acid (0.1 mL) containing the compound of Example 2 (1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)prop-2-en -1-one, 10 mg, 0.025 mmol) at 0°C, followed by stirring at room temperature for 30 minutes. NaCNBH 3 (2.3 mg, 0.037 mmol) was added to the reaction mixture, which was stirred for 30 minutes.
  • N3-(2,6-dimethylphenyl)-N6-(isochroman-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine 50 mg, 0.125 mmol, 75%) was obtained as a grey-white solid.
  • Step 1 Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
  • a target compound was prepared by the same manner as described in Example 9 except that the compound of Preparative Example B-4 was used instead of the compound of Preparative Example B-2 in Example 9.
  • Step 2 Preparation of N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
  • a target compound was prepared by the same manner as described in Example 10 except that the compound prepared in step 1 above was used instead of the compound of Example 9 in Example 10.
  • Step 1 A target compound was prepared by the same manner as described in Example 3 except that 1-methyl-1,2,3,4-tetrahydroisoquinoline-7-amine was used instead of 1-(6-amino-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one in Example 3.
  • Step 2 A target compound was prepared by the same manner as described in Example 4 except that the compound prepared in step 1 above was used instead of the compound of Example 3 in Example 4.
  • a target compound was prepared by the same manner as described in Example 22 except that cyclopropanecarboxylic acid was used instead of glycolic acid in Example 22.
  • a target compound was prepared by the same manner as described in Example 22 except that iodoethanol was used instead of glycolic acid in Example 22.
  • Example 25 Preparation of 1-cyclopentyl-N 3 -(2,6-dimethylphenyl)-N 6 -(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4- d ]pyrimidine-3,6-diamine
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-5 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-6 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-7 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-8 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-9 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-10 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 22 except that N , N -dimethylglycine was used instead of glycolic acid in Example 22.
  • a target compound was prepared by the same manner as described in Example 22 except that iodoethane was used instead of glycolic acid in Example 22.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-11 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-12 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-13 was used instead of the compound of Preparative Example B-4 in Example 19.
  • Example 36 Preparation of N 3 -(2,6-diethylphenyl)-1-methyl-N 6 -(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4- d ]pyrimidine-3,6-diamine
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-14 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-15 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 10 except that the compound of Preparative Example B-16 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-17 was used instead of the compound of Preparative Example B-4 in Example 19.
  • Example 40 Preparation of 1-methyl-N 6 -(1,2,3,4-tetrahydroisoquinoline-7-yl)-N 3 -o-tolyl-1H-pyrazolo[3,4- d ]pyrimidine-3,6-diamine
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-18 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-19 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-20 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-21 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-22 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-23 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 20 except that the compound of Preparative Example A-5 was used instead of 1-methyl-1,2,3,4-tetrahydroisoquinoline-7-amine in Example 20.
  • a target compound was prepared by the same manner as described in Example 20 except that the compound of Preparative Example B-8 was used instead of the compound of Preparative Example B-1 in Example 20.
  • Example 48 Preparation of N 3 -(2-chloro-6-methylphenyl)-1-methyl-N 6 -(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4- d ]pyrimidine-3,6-diamine
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-24 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 20 except that the compound of Preparative Example A-6 was used instead of 1-methyl-1,2,3,4-tetrahydroisoquinoline-7-amine in Example 20.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-25 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-26 was used instead of the compound of Preparative Example B-4 in Example 19.
  • Example 52 Preparation of 4-methyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4- d ]pyrimidine-3-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide
  • a target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-27 was used instead of the compound of Preparative Example B-4 in Example 19.
  • a target compound was prepared by the same manner as described in Example 20 except that 3,3-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-amine was used instead of 1-methyl-1,2,3,4-tetrahydroisoquinoline-7-amine in Example 20.
  • Example 54 Preparation of 4-(3-((2,6-dimethylphenyl)amino)-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-1-yl)cyclohexane-1-ol
  • Step 1 Preparation of tert-butyl2-(1,4-dioxaspiro[4.5]decane-8-yl)hydrazine-1-carboxylate
  • Step 2 Preparation of tert -butyl-2-(2-chloro-5-((2,6-dimethylphenyl)carbamoyl)pyridine-4-yl-2-(1,4-dioxaspiro[4.5]decane-8-yl)hydrazine-1-carboxylate
  • Step 3 Preparation of 6-chloro-N-(2,6-dimethylphenyl)-1-(1,4-dioxaspiro[4.5]decane-8-yl)-1H-pyrazole[3,4-d]pyrimidine-3-amine
  • PCl 5 (78 mg, 0.375 mmol) was added to toluene (20 mL) solution containing the compound prepared in step 2 above (200 mg, 0.375 mmol) at room temperature, followed by stirring at 110°C for 3 hours. The mixture was concentrated under reduced pressure to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The crude product was purified by column chromatography (EtOAc/Hx (1/4)). As a result, the target compound (80 mg, 0.193 mmol, 51%) was obtained as a yellow solid.

Abstract

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

Description

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT
The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease.
Cancer is defined by the abnormal state of cells, wherein cell death is not controlled normally because of various changes in gene expression, and abnormal cell growth is induced. Cancer cells penetrate into neighboring tissues and destroy thereof, and migrate to other regions, which can result in human death.
The cause of cancer, that is, the mechanism by which normal cells are transfected into cancer cells, has not been clearly identified. It is known that the causes of cancer include environmental factors, external factors such as chemicals, radiation, and viruses, and internal factors such as genetic factors and immunological factors, and those factors interact complicate to cause cancer.
Cancer is largely divided into blood cancer characterized by abnormal blood cell number and solid cancer in the form of cell mass that has a certain degree of hardness and shape in the body. Cancer can be developed in blood and almost all parts of the body, which can be exemplified by lung cancer, stomach cancer, breast cancer, oral cancer, liver cancer, uterine cancer, esophageal cancer and skin cancer. Major treatment methods for cancer are surgery, radio-therapy, and chemo-therapy using a chemotherapeutic agent inhibiting cell proliferation.
A chemotherapeutic agent is not a target-specific agent that directly acts on the target of each cancer. Therefore, repeated chemotherapy treatments result in side effects due to cytotoxicity and resistance to the drugs, indicating that, despite the initial successful response to the anticancer drug, if the cancer treatment duration is prolonged or the cancer recurs, the treatment will fail because of such side effects and drug resistance. To overcome the limitations of the chemotherapeutic agent, it is necessary to develop a targeted therapeutic agent with clear anticancer mechanism.
To develop a targeted therapeutic agent, studies focused on specific molecular biological factors involved in tumorigenesis have been under-going. In particular, molecular biological factors are widely used to predict the prognosis of cancer or to determine the treatment method, either chemo-therapy or radio-therapy.
The conventional cancer drugs have been constructed by targeting the rapid cell division characteristics of tumor cells, indicating they are targeting not only tumor cells but also normal cells showing relatively fast cell division (for example, hair follicle cells, gastrointestinal cells, bone marrow cells, reproductive cells), which causes serious side effects. Therefore, it is required to develop a novel anticancer agent that is specifically expressed only in tumor cells and not expressed in normal cells or has no effect on normal cells.
Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase located on chromosome Xq22, which belongs to Tec family kinase. Bruton's tyrosine kinase (BTK) plays an important role in the downstream signaling of growth factors, B-cell antigens, chemokine receptors and innate immune receptors. That is, BTK is an important protein that plays an important role in various cell activities such as cell growth, survival, differentiation, pathogenesis, angiogenesis, signaling molecule production, and antigen presentation, and thus it is known to play a crucial role in signal transduction of B-cell immunity, inflammation, and anticancer.
Bruton's tyrosine kinase (BTK) is rarely expressed in other tissues than blood cells. Among blood cells, it is present only in B cells, not in T cells. Therefore, BTK inhibitor does not attack other tissues and is targeting only B cell tumor showing BTK activity, suggesting that the side effects can be minimized in patients.
Accordingly, studies on Bruton's tyrosine kinase (BTK) inhibitors have been actively undergoing (Patent Reference 1, Korean Patent Publication No. 10-2016-0062103). The irreversible BTK inhibitor now being used in clinically is Ibrutinib. However, it is still requested to develop a drug that can overcome the problems of resistance, side effects, and immuno-therapy.
Thus, the present inventors have tried to overcome the problems of resistance and side effects according to the co-treatment with immuno-therapy of the conventional BTK inhibitors and to develop a compound with significantly excellent anticancer effect by reversibly inhibiting BTK. In the course of our study, the present inventors confirmed that the compound of the present invention exhibited significantly excellent Bruton's tyrosine kinase inhibitory effect in animal tests, so that the compound could be used effectively in the treatment of cancer, autoimmune disease and Parkinson's disease, leading to the completion of the present invention.
It is an object of the present invention to provide a pyrazolopyrimidine compound or a pharmaceutically acceptable salt thereof.
It is another object of the present invention to provide a preparation method of the pyrazolopyrimidine compound above.
It is also an object of the present invention to provide a pharmaceutical composition comprising the pyrazolopyrimidine compound above as an active ingredient for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
It is further an object of the present invention to provide a health functional food comprising the pyrazolopyrimidine compound above as an active ingredient for the prevention or improvement of cancer, autoimmune disease or Parkinson's disease.
To achieve the objects above, the present invention provides a compound represented by formula 1 below or a pharmaceutically acceptable salt of the same:
[Formula 1]
Figure PCTKR2018005478-appb-I000001
(In formula 1,
A, R1, R2, R3, R4, and R5 are as defined in this specification).
The present invention also provides a preparation method of the compound represented by formula 1 comprising the step of preparing the compound represented by formula 1 by reacting the compound represented by formula 2 with the compound represented by formula 3 (step 1), as shown in reaction formula 1 below:
[Reaction Formula 1]
Figure PCTKR2018005478-appb-I000002
(In reaction formula 1,
A, R1, R2, R3, R4, R5, and X are as defined in this specification).
In addition, the present invention provides a pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
The present invention also provides a health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of cancer, autoimmune disease or Parkinson's disease.
The present invention also provides a method for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease comprising the step of administering the pharmaceutical composition or the health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient to a subject in need.
In addition, the present invention provides a use of the pharmaceutical composition or the health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
The present invention also provides a method of treating a subject having a cancer comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
The present invention also provides a method of treating a subject having an autoimmune disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
The present invention also provides a method of treating a subject having a Parkinson's disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer.
The present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease.
The present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a Parkinson's disease.
The present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer.
The present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease.
The present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a Parkinson's disease.
The present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use as a medicament.
The present invention also provides a medicament comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
The pyrazolopyrimidine derivative of the present invention demonstrates an excellent Bruton's tyrosine kinase (BTK) inhibitory activity, so that a pharmaceutical composition comprising the compound of the invention as an active ingredient can be effectively used for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease. The pyrazolopyrimidine derivative of the present invention can be used for immunotherapy because it does not inhibit ITK (Interlukin-2 receptor inducible T-cell kinase) and can be used as an autoimmune disease therapeutic agent for long-term administration because it is a reversible inhibitor. The derivative of the invention also shows an excellent pharmaceutical effect on Abl and Abl mutants along with excellent BBB permeability, so that it can be effectively used for the treatment of Parkinson's disease.
The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein:
Figure 1 is a schematic diagram illustrating the enzyme liked immuosrobent assay performed for measuring the concentration of TNFa.
Hereinafter, the present invention is described in detail.
The terms for the compound of the present invention are defined as follows:
"Heterocyclic ring" means a saturated or partially unsaturated heterocyclic ring of 3 to 8 ring atoms (refers to a carbocyclic radical having one or more double or triple bonds in the ring without directionality) which contains at least one of hetero atoms selected from the group consisting of N, O and S and the remaining ring atoms are carbon. In a preferred embodiment of the present invention, it refers to monoheterocyclic consisting of one ring, wherein the hetero atom means a nitrogen atom or an oxygen atom. For example, it can be pyrrolidine, dihydrofuran, tetrahydrothiophene, tetrahydropyrane, dihydropyrane, tetrahydrothiopyran, piperidine, morpholine, thiomorpholine, thioxane, piperazine, azetidine, oxetane, thietane, oxepan, oxazepine, diazepine, thiazepine, 2-pyrroline, or 3-pyrroline.
"Cycloalkane" is a saturated or partly unsaturated (i.e., nonaromatic) group containing all carbon ring atoms. For example, it can be cyclohexene, cyclohexane, cyclopentene, cyclopentane, cyclobutene, cyclobutane, or cyclopropane.
"Alkyl" is a branched or straight-chain saturated aliphatic hydrocarbon group. In a preferred embodiment of the present invention, the alkyl contains 1 ~ 5 carbon atoms or 1 ~ 3 carbon atoms. For example, it can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, t-pentyl, or neopentyl.
"Alkenyl" is a branched or straight-chain aliphatic hydrocarbon group having at least one carbon-carbon double bond that can occur along the chain at a stable point. In a preferred embodiment of the present invention, the alkenyl contains 2 ~ 5 carbon atoms. For example, it can be ethenyl or propenyl.
"Alkynyl" is a branched or straight-chain aliphatic hydrocarbon group having at least one carbon-carbon triple bond that can occur along the chain at any stable point. In a preferred embodiment of the present invention, the alkynyl contains 2 ~ 5 carbon atoms. For example, it can be ethynyl, propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, or 4-pentynyl.
"Dialkyl" indicates an alkyl substituted group as defined above wherein two same or different alkyls are substituted.
"Alkoxy" is an alkyl group as defined above covalently bonded through an oxygen bridge (-O-).
"Hydroxyalkyl" is an alkyl group as described above substituted with one or more hydroxy substituents.
"Haloalkyl" indicates a branched or straight alkyl group substituted with one or more halogen atoms and up to a maximum number of halogen atoms. For example, it can be trifluoromethyl, monofluoromethyl, difluoromethyl, 2-fluoroethyl, or penta-fluoroethyl.
"Cycloalkyl" is a saturated or partly unsaturated (i.e., nonaromatic) group containing all carbon ring atoms. For example, it can be cyclohexenyl, cyclohexyl, cyclopentenyl, cyclopentyl, cyclobutenyl, cyclobutyl, or cyclopropyl.
"Alkyloxyalkyl" is an alkyl group as defined above wherein additional alkyl is covalently bonded through an oxygen bridge (-O-).
"Aryl" indicates an aromatic group containing only carbon in the aromatic ring. In a preferred embodiment of the present invention, it may be phenyl or naphthalenyl.
"Heteroaryl" indicates a stable 5 ~ 12 membered monocyclic aromatic ring, bicyclic or tricyclic system containing one or more hetero atoms selected from the group consisting of N, O and S and the remaining ring atoms are carbon. In a preferred embodiment of the present invention, the only hetero atom is nitrogen. The monocyclic heteroaryl group typically has 5 ~ 7 ring atoms. In a preferred embodiment of the present invention, the bicyclic heteroaryl group is a 9 or 10 membered heteroaryl group wherein a 5 ~ 7 membered aromatic ring is fused with the second aromatic or non-aromatic ring and 9 ~ 10 ring atoms are contained. The heteroaryl group is exemplified by pyridinyl (including 2-hydroxypyridinyl), imidazolyl, imidazolopyridinyl, pyrimidinyl (including 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, tetrahydrofuranyl, and furopyridinyl.
"Halo" or "halogen" independently represents any fluoro, chloro, bromo, and iodo.
The present invention provides a compound represented by formula 1 below or a pharmaceutically acceptable salt of the same:
[Formula 1]
Figure PCTKR2018005478-appb-I000003
In formula 1,
A is 3 ~ 8 membered heterocyclic ring containing one or more hetero atoms selected from the group consisting of N, O and S or C3-10 cycloalkane;
R1 and R2 are independently one or more substituents selected from the group consisting of hydrogen, carbonyl(=O), straight or branched C1-5 alkyl, C1-5 dialkyl, C1-5 alkoxy or hydroxy C1-5 alkyl, and -(C=O)R7, R7 is straight or branched C1-5 alkyl, C2-5 alkenyl having one or more double bonds, halo C1-5 alkyl or hydroxy C1-5 alkyl; C3-9 cycloalkyl; or -N(CH2)nR8R9; R8 and R9 are independently hydrogen or straight or branched C1-5 alkyl, and n is an integer of 0 ~ 5;
R3, R4, and R5 are independently hydrogen, straight or branched C1-5 alkyl or C3-8 cycloalkyl. At this time, the alkyl or cycloalkyl can be substituted with hydroxy; and
R6 is one or more substituents selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, straight or branched C1-5 alkyl, C2-5 alkenyl or C2-5 alkynyl, -OR10, -NH(C=O)R10, -(C=O)NHR10, and -NH(C=O)NHR10, R10 is straight or branched C1-5 alkyl or C1-5 alkyloxy C1-5 alkyl; C6-10 aryl; or 5 ~ 12 membered heteroaryl containing one or more hetero atoms selected from the group consisting of N, O, and S; and the aryl or heteroaryl can be substituted with one or more substituents selected from the group consisting of straight or branched C1-5 alkyl, C1-5 alkoxy and C1-5 haloalkyl.
Preferably,
A is 3 ~ 6 membered heterocyclic ring containing one or more hetero atoms selected from the group consisting of N, O and S or C5-7 cycloalkane;
R1 and R2 are independently one or more substituents selected from the group consisting of hydrogen, carbonyl(=O), straight or branched C1-3 alkyl, C1-3 dialkyl, C1-3 alkoxy or hydroxy C1-3 alkyl, and -(C=O)R7, R7 is straight or branched C1-3 alkyl, C2-3 alkenyl, halo C1-3 alkyl or hydroxy C1-3 alkyl; C3-6 cycloalkyl; or -N(CH2)nR8R9; R8 and R9 are independently hydrogen or straight or branched C1-3 alkyl, and n is an integer of 1 ~ 3;
R3, R4, and R5 are independently hydrogen, straight or branched C1-3 alkyl or C3-6 cycloalkyl. At this time, the alkyl or cycloalkyl can be substituted with hydroxy; and
R6 is one or more substituents selected from the group consisting of hydrogen, straight or branched C1-3 alkyl, -OR10, -NH(C=O)R10, -(C=O)NHR10, and -NH(C=O)NHR10, R10 is straight or branched C1-3 alkyl or C1-3 alkyloxy C1-3 alkyl; C5-10 aryl; or 6 ~ 10 membered heteroaryl containing one or more nitrogen atoms; and the aryl or heteroaryl can be substituted with one or more substituents selected from the group consisting of straight or branched C1-3 alkyl, C1-3 alkoxy and C1-3 haloalkyl.
More preferably,
A is piperidine, tetrahydropyrane, pyrrolidine, or cyclohexane;
R1 is one or more substituents selected from the group consisting of hydrogen, carbonyl(=O), -CH3, -CH2CH3, -(CH3)2, -CH(CH3)2, -CH2CH2OH, -(C=O)CH3, -(C=O)CF3,-(C=O)CHCH2, -(C=O)cyclopropyl, -(C=O)CH2OH, and -(C=O)CH2N(CH3)2;
R2 is hydrogen or methoxy;
R3 is hydrogen;
R4 is hydrogen, methyl, isopropyl, cyclopentyl, cyclohexyl, or (4-hydroxy)cyclohexyl;
R5 is hydrogen; and
R6 is one or more substituents selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, methoxy, chloro, fluoro, methoxyethoxy, phenoxy,
Figure PCTKR2018005478-appb-I000004
,
Figure PCTKR2018005478-appb-I000005
,
Figure PCTKR2018005478-appb-I000006
,
Figure PCTKR2018005478-appb-I000007
and
Figure PCTKR2018005478-appb-I000008
.
Most preferably, the compound represented by formula 1 above is any one selected from the group consisting of the following compounds:
(1) 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
(2) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(3) 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone;
(4) N3-(2,6-dimethylphenyl)-N6-(7-methoxy-1,2,3,4-tetrahydroisoquinoline-6-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(5) 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
(6) 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone;
(7) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(8) 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
(9) 2,2,2-trifluoro-1-(7-(1-methyl-3-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
(10) 1-methyl-N3-phenyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(11) 1-(7-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone;
(12) N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(13) 1-(7-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
(14) 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)prop-2-en -1-one;
(15) N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(16) 1-(6-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
(17) N3-(2,6-dimethylphenyl)-1-methyl-N6-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(18) N3-(2,6-dimethylphenyl)-N6-(isochroman-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(19) N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(20) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(21) N3-(2,6-dimethylphenyl)-N6-(2-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(22) 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxyethanone;
(23) cyclopropyl(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)methanone;
(24) 2-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-ol;
(25) 1-cyclopentyl-N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(26) 1-cyclohexyl-N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(27) N3-(2,6-dimethylphenyl)-1-isopropyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(28) N-(4-methyl-3-((1-methyl-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(trifluoromethyl)benzamide;
(29) N-(2,4-dimethyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)-3-(trifluoromethyl)benzamide;
(30) N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(31) 2-(dimethylamino)-1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethanone;
(32) N3-(2,6-dimethylphenyl)-N6-(2-ethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(33) N3-(2,6-dimethyl-4-phenoxyphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(34) 3,5-dimethyl-4-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)-N-(pyridine-2-yl)benzamide;
(35) N3-(4-methoxy-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(36) N3-(2,6-diethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(37) N3-(2,6-diisopropylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(38) N3-(2-chloro-3,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(39) N3-(2,4-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(40) 1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-o-tolyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(41) N3-(3,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(42) N3-(2,6-difluorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(43) N3-(2,6-dimethoxyphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(44) N3-(4-fluoro-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(45) N3-(2,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(46) N6-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(47) N-(4-methyl-3-(1-methyl-6-(1-methyl-1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)-3-(trifluoromethyl)benzamide;
(48) N3-(2-chloro-6-methylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(49) N3-(2,6-dimethylphenyl)-N6-(1-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(50) N3-(5-(2-methoxyethoxy)-2-methylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(51) N-(4-methyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)picolineamide;
(52) 4-methyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide;
(53) N6-(3,3-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(54) 4-(3-((2,6-dimethylphenyl)amino)-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-1-yl)cyclohexane-1-ol;
(55) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,3,3-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(56) tert-butyl-5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-carboxylate;
(57) 1-(4-methyl-3-((1-methyl-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea;
(58) N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(59) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,1,2-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(60) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
(61) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1-methyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
(62) N6-(1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(63) N3-(2,6-dimethylphenyl)-1-methyl-N6-(2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(64) N-(3-((6-((1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(trifluoromethyl)benzamide;
(65) N3-(2,6-dimethylphenyl)-N6-(1-isopropyl-2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(66) N3-(2,6-dimethylphenyl)-1-methyl-N6-(2,3,3-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(67) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,3-tetramethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(68) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-4,4-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
(69) N-(3-((6-((2-acetyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(trifluoromethyl)benzamide;
(70) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
(71) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,3-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
(72) 1-(5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-yl)ethane-1-one;
(73) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
(74) N3-(2,6-dimethylphenyl)-1-methyl-N6-(2-methylisoindolin-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(75) N3-(2,6-dimethylphenyl)-1-methyl-N6-(5,6,7,8-tetrahydronaphthalene-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(76) N-(4-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)phenyl)acrylamide;
(77) 7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-1(2H)-one;
(78) N6-(1-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
(79) N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
The compound represented by formula 1 of the present invention can be used as a form of a pharmaceutically acceptable salt, in which the salt is preferably acid addition salt formed by pharmaceutically acceptable free acids. The acid addition salt herein can be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, and phosphorous acid; non-toxic organic acids such as aliphatic mono/dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate, alkandioate, aromatic acids, and aliphatic/aromatic sulfonic acids; or organic acids such as acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, and fumaric acid. The pharmaceutically non-toxic salts are exemplified by sulfate, pyrosulfate, bisulfate, sulphite, bisulphite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutylate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, cabacate, fumarate, maliate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutylate, citrate, lactate, hydroxybutylate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate.
The acid addition salt in this invention can be prepared by the conventional method known to those in the art. For example, the derivative represented by formula 1 is dissolved in an organic solvent such as methanol, ethanol, acetone, methylenechloride, or acetonitrile, to which organic acid or inorganic acid is added to induce precipitation. Then, the precipitate is filtered and dried to give the salt. Or the solvent and the excessive acid are distillated under reduced pressure, and dried to give the salt. Or the precipitate is crystallized in an organic solvent to give the same.
A pharmaceutically acceptable metal salt can be prepared by using a base. Alkali metal or alkali earth metal salt is obtained by the following processes: dissolving the compound in excessive alkali metal hydroxide or alkali earth metal hydroxide solution; filtering non-soluble compound salt; evaporating the remaining solution and drying thereof. At this time, the metal salt is preferably prepared in the pharmaceutically suitable form of sodium, potassium, or calcium salt. And the corresponding silver salt is prepared by the reaction of alkali metal or alkali earth metal salt with proper silver salt (ex; silver nitrate).
The present invention includes not only the compound represented by formula 1 but also a pharmaceutically acceptable salt thereof, and a solvate, an optical isomer, or a hydrate possibly produced from the same.
The present invention also provides a preparation method of the compound represented by formula 1 comprising the step of preparing the compound represented by formula 1 by reacting the compound represented by formula 2 with the compound represented by formula 3 (step 1), as shown in reaction formula 1 below:
[Reaction Formula 1]
Figure PCTKR2018005478-appb-I000009
In reaction formula 1,
A, R1, R2, R3, R4, and R5 are as defined in formula 1, and
X is halogen.
In the preparation method of the compound represented by formula 1 according to the present invention, step 1 is to prepare the compound represented by formula 1 by reacting the compound represented by formula 2 with the compound represented by formula 3.
Particularly, step 1 is a step of condensing an amine group (-NHR5) of the compound represented by formula 2 and a halogen group (X) of the compound represented by formula 3 in the presence of an acid.
Herein, the acid is not particularly limited as long as it is an acid generally used in the field, but trifluoroacetic acid (TFA), p-toluenesulfonic acid (p-TSA), hydrochloric acid (HCl) and formic acid can be used.
The reaction temperature is not limited but can be 10 ~ 150℃, preferably 30 ~ 120℃, and more preferably 50 ~ 100℃. Most preferably, the reaction temperature can be the boiling point of the organic solvent used in the reaction.
Further, the reaction solvent is not particularly limited as long as it is an organic solvent generally used in the field, but isopropanol, butanol, and 1,4-dioxane can be used.
In the preparation method of the present invention, the compound represented by formula 3, which is the starting material, can be prepared by the following steps, as shown in reaction formula 2 below:
preparing the compound represented by formula 3-3 by reacting the compound represented by formula 3-1 with the compound represented by formula 3-2 via amidation (step 1);
preparing the compound represented by formula 3-5 by reacting the compound represented by formula 3-3 prepared in step 1 with the compound represented by formula 3-4 with the addition of hydrazine (step 2); and
cyclizing the compound represented by formula 3-5 prepared in step 2 (step 3).
[Reaction Formula 2]
Figure PCTKR2018005478-appb-I000010
In reaction formula 2,
R3, R4, and R5 are as defined in formula 1, and X is halogen.
The reaction conditions for step 1 ~ step 3 shown in reaction formula 2 above are not particularly limited as long as they are generally used in the art, so that the detailed description is omitted herein.
The present invention also provides a pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer. Herein, the compound is characterized by being effective in preventing or treating cancer by inhibiting Bruton's tyrosine kinase (BTK). The cancer can be solid cancer or blood cancer.
The solid tumor can be selected from the group consisting of brain tumor, benign astrocytoma, malignant astrocytoma, pituitary adenoma, meningioma, brain lymphoma, oligodendroglioma, intracranial tumor, ependymoma, brain stem tumor, head and neck tumor, laryngeal cancer, uveal cancer, nasal cancer, nasopharyngeal cancer, salivary gland cancer, hypopharyngeal cancer, thyroid cancer, oral cancer, thoracic tumor, small cell lung cancer, non-small cell lung cancer, thymic cancer, mediastinal tumor, esophageal cancer, breast cancer, male breast cancer, abdominal tumor, stomach cancer, liver cancer, gallbladder cancer, biliary cancer, pancreatic cancer, small bowel cancer, colon cancer, anal cancer, bladder cancer, kidney cancer, male genital tumor, penile cancer, prostate cancer, female genital tumor, cervix cancer, endometrial cancer, ovarian cancer, uterine sarcoma, vaginal cancer, female external gonadal cancer, female urethral cancer, and skin cancer. The blood cancer can be leukemia, malignant lymphoma, multiple myeloma, or aplastic anemia.
The pharmaceutical composition comprising the compound represented by formula 1, the optical isomer thereof or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer can be administered independently or co-administered with other anticancer agents in use.
Further, the present invention provides a pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of autoimmune disease.
Herein, the compound is characterized by being effective in preventing or treating autoimmune disease by inhibiting Bruton's tyrosine kinase (BTK). The autoimmune disease can be selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, lupus, diabetes mellitus, myasthenia gravis, Hashimoto's thyroiditis, Graves' disease, Sjogren's syndrome, multiple sclerosis, Guilin Barre syndrome, acute sporadic encephalomyelitis, Addison's disease, ocular hepatocellular seizure-epileptic syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, chronic digestive dysfunction, Goodpasture syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary dysplasia cirrhosis, Takayasu arteritis, temporal arteritis, autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, systemic alopecia, Behcet's disease, chronic fatigue, autonomic nystagmus, endometriosis, interstitial cystitis, neuromuscular dystrophy, scleroderma, and vulvar pain.
The present invention also provides a pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of Parkinson's disease.
The compound represented by formula 1 or the pharmaceutically acceptable salt thereof included in the pharmaceutical composition of the present invention can be administered orally or parenterally and be used in general forms of pharmaceutical formulation. That is, the composition of the present invention can be prepared for oral or parenteral administration by mixing with generally used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants.
The formulations for oral administration are exemplified by tablets, pills, hard/soft capsules, solutions, suspensions, emulsions, syrups, granules, elixirs, and troches, etc. These formulations can include diluents (for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycine) and lubricants (for example, silica, talc, stearate and its magnesium or calcium salt, and/or polyethylene glycol) in addition to the active ingredient. Tablets can include binding agents such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrolidone, and if necessary disintegrating agents such as starch, agarose, alginic acid or its sodium salt or azeotropic mixtures and/or absorbents, coloring agents, flavours, and sweeteners can be additionally included thereto.
The pharmaceutical composition comprising the compound represented by formula 1 as an active ingredient can be administered by parenterally and the parenteral administration includes subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
To prepare the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as a formulation for parenteral administration, the compound represented by formula 1 or the pharmaceutically acceptable salt thereof is mixed with a stabilizer or a buffering agent in water to produce a solution or suspension, which is then formulated as ampoules or vials. The composition herein can be sterilized and additionally contains preservatives, stabilizers, wettable powders or emulsifiers, salts and/or buffers for the regulation of osmotic pressure, and other therapeutically useful materials, and the composition can be formulated by the conventional mixing, granulating or coating method.
The effective dosage of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof of the present invention can be determined according to age, weight, gender, administration method, health condition, and severity of disease. The dosage is generally 0.1 ~ 1000 mg/day, and preferably 1 ~ 500 mg/day based on an adult patient weighing 70 kg, which can be administered once or several times a day at intervals of a certain time depending on the judgment of a doctor or a pharmacist.
The pharmaceutical composition comprising the compound represented by formula 1, the optical isomer, or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer can be administered as an individual therapeutic agent or in combination with other anticancer agents in use.
The present invention also provides a health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of cancer.
The present invention also provides a health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of autoimmune disease.
In addition, the present invention provides a health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of Parkinson's disease.
The compound represented by formula 1 of the present invention can be used as a food additive. In that case, the compound represented by formula 1 of the present invention can be added as it is or as mixed with other food components according to the conventional method. The mixing ratio of active ingredients can be regulated according to the purpose of use (prevention or improvement). In general, the compound of the present invention is preferably added to food or beverages by 0.1 ~ 90 weight part for the total weight of the food or beverages. However, if long term administration is required for health and hygiene or regulating health condition, the content can be lower than the above but higher content can be accepted as well since the compound of the present invention has been proved to be very safe.
The health beverage composition of the present invention can additionally include various flavors or natural carbohydrates, etc, like other beverages. The natural carbohydrates above can be one of monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xilytole, sorbitol and erythritol. Besides, natural sweetening agents (thaumatin, stevia extract, for example rebaudioside A, glycyrrhizin, etc.) and synthetic sweetening agents (saccharin, aspartame, etc.) can be included as a sweetening agent. The content of the natural carbohydrate is preferably 1 ~ 20 g and more preferably 5 ~ 12 g in 100 g of the composition of the invention.
In addition to the ingredients mentioned above, the compound represented by formula 1 of the present invention can include in variety of nutrients, vitamins, minerals (electrolytes), flavors including natural flavors and synthetic flavors, coloring agents and extenders (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acid, protective colloidal viscosifiers, pH regulators, stabilizers, antiseptics, glycerin, alcohols, carbonators which used to be added to soda, etc. The compound represented by formula 1 of the present invention can also include natural fruit juice, fruit beverages and fruit flesh addable to vegetable beverages.
The present invention also provides a method for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease comprising the step of administering the pharmaceutical composition or the health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient to a subject in need.
In addition, the present invention provides a use of the pharmaceutical composition or the health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
The present invention also provides a method of treating a subject having a cancer comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
The present invention also provides a method of treating a subject having an autoimmune disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
The present invention also provides a method of treating a subject having a Parkinson's disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
The present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer.
The present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease.
The present invention also provides a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a Parkinson's disease.
The present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer.
The present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease.
The present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of a Parkinson's disease.
The present invention also provides a composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use as a medicament.
The present invention also provides a medicament comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
The novel pyrazolopyrimidine compound of the present invention demonstrates an excellent BTK inhibitory activity at a low concentration, and therefore it can be used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease, which is supported by the results of the following experiments.
Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.
However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.
Preparative Example A-1: Preparation of 1-(7-amino-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Step 1: Preparation of N-(4-nitrophenetyl)acetamide
Figure PCTKR2018005478-appb-I000011
Acetic anhydride (1.36 mL, 14.4 mmol) was added to 2-(4-nitrophenyl)ethane-1-amine (2.0 g, 12.03 mmol) solution in DCM (50mL), to which TEA (4.2 mL, 30.07 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. Upon completion of the reaction, water (50 mL) was added to the reaction mixture, followed by extraction with DCM (2 X 50 mL). The combined organic layer was washed with brine solution, which was then dried over Na2SO4. The solvent was eliminated in vacuum. The crude mixture was purified by re-crystallization. As a result, 1-(7-amino-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (2.25g, 10.8 mmol, 90%) was obtained as a grey-white solid.
1H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 8.6 Hz, 2H), 7.36 (d, J = 8.5 Hz, 2H), 5.52 (s, br, 1H), 3.55 (q, J = 6.8 Hz, 2H), 2.95 (t, J = 7.0 Hz, 2H), 1.96 (s 3H); LC/MS 209.2 [M + H+].
Step 2: Preparation of 1-(7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000012
Compound of step 1 (1.0 g, 4.80 mmol) was dissolved in HOAc (5mL), to which sulfuric acid (7.5 mL) and paraformaldehyde (231 mg, 7.68 mmol) were added at room temperature, followed by stirring at 40℃ for 12 hours. The reaction mixture was poured carefully into approximately 100 mL of ice. The generated brown sludge suspension was extracted with EtOAc. The organic material was washed with saturated aqueous NaHCO3 and brine, followed by drying over MgSO4. The crude mixture was purified by column chromatography using MeOH/MC (1:4) as an eluent. As a result, 1-(7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (900 mg, 4.08 mmol, 85%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.07-8.03 (m, 2H), 7.35-7.30 (m, 1H), 4.83-4.72 (m, 2H), 3.88-3.71 (m, 2H), 3.03-2.93 (m, 2H), 2.21-2.20 (m, 3H); LC/MS 221.2 [M + H+].
Step 3: Preparation of 1-(7-amino-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000013
Pd/C (10 weight%) (20 mg, 0.93 mmol) was added to compound of step 2 (900 mg, 4.08 mmol) in MeOH (50 mL) at room temperature. The reaction mixture was stirred at room temperature under hydrogen balloon pressure for 12 hours. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was filtered with a celite bed and concentrated to remove MeOH. The obtained crude mixture was purified by column chromatography using EtOAc/hexane. As a result, 1-(7-amino-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one(580 mg, 3.04 mmol, 75%) was obtained as a grey-white solid.
1H NMR (300 MHz, CDCl3) δ 6.95-6.91 (m, 1H), 6.57-6.51 (m, 1H), 6.47-6.43 (m, 1H), 4.63-4.51 (m, 2H), 3.80-3.60 (m, 4H), 2.80-2.70 (m, 2H), 2.15 (s, 3H); LC/MS 191.2 [M + H+].
Preparative Example A-2: Preparation of 1-(6-amino-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Step 1: Preparation of N-(4-bromophenetyl)-2,2,2-trifluoroacetamide
Figure PCTKR2018005478-appb-I000014
Trifluoro acetic anhydride (0.43 mL, 2.99 mmol) was added to 2-(4-bromophenyl)ethane-1-amine (500 mg, 2.50 mmol) solution in DCM (25 mL), to which TEA (0.87 mL, 6.25 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour. Upon completion of the reaction, water (50 mL) was added to the reaction mixture, followed by extraction with DCM (2 X 50 mL). The combined organic layer was washed with saturated brine solution, which was dried over Na2SO4. The solvent was eliminated in vacuum. The crude mixture was purified by re-crystallization. As a result, N-(4-bromophenetyl)-2,2,2-trifluoroacetamide (700 mg, 2.36 mmol, 94%) was obtained as a white solid.
1H NMR (500 MHz, CDCl3) δ 7.48 (d, J = 8.3 Hz, 2H), 7.09 (d, J = 8.3 Hz, 2H), 6.37 (s, br, 1H), 3.62 (q, J = 6.6 Hz, 2H), 2.87 (t, J = 7.0 Hz, 2H); LC/MS 296.2 [M + H+].
Step 2: Preparation of 1-(7-bromo-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000015
Compound of step 1 (250 mg, 0.844 mmol) was dissolved in HOAc (1.41 mL) and sulfuric acid (0.94 mL), to which paraformaldehyde (40 mg, 1.35 mmol) was added at room temperature, followed by stirring for 12 hours. The reaction mixture was poured carefully into approximately 10 mL of ice. The generated white sludge suspension was extracted with EtOAc. The organic material was washed with saturated aqueous NaHCO3 and brine, followed by drying over MgSO4. The crude mixture was purified by column chromatography using EtOAc/Hx (1:4) as an eluent. As a result, 1-(7-bromo-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (225 mg, 0.730 mmol, 86%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 7.37-7.28 (m, 2H), 7.07-7.02 (m, 1H), 4.76-4.71 (m, 2H), 3.89-3.81 (m, 2H), 2.93-2.87 (m, 2H); LC/MS 308.2 [M + H+].
Step 3: Preparation of 1-(7-bromo-6-nitro-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000016
HNO3 (187 mg, 1.785 mmol) was added to compound of step 2 (500 mg, 1.622 mmol) in TFA (15 mL) at 0℃. The reaction mixture was stirred for 12 hours. Ice was added to the reaction mixture and the generated solid was filtered. The obtained crude product was washed with NaHCO3. The combined organic layer was dried over anhydrous Na2SO4. The solvent was eliminated under reduced pressure. The crude mixture was purified by column chromatography using EtOAc /Hx (1:4) as an eluent. As a result, 1-(7-bromo-6-nitro-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (300 mg, 0.849 mmol, 52%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 7.73-7.72 (m, 1H), 7.57-7.55 (m, 1H), 4.85-4.81 (m, 2H), 3.97-3.88 (m, 2H), 3.04-2.98 (m, 2H); LC/MS 355.2 [M + H+].
Step 4: Preparation of 1-(6-amino-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000017
Pd/C (10 weight%) (36 mg, 0.34 mmol) was added to compound of step 3 (300 mg, 0.849 mmol) in MeOH (50 mL) at room temperature. The reaction mixture was stirred at room temperature under hydrogen balloon pressure for 12 hours. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was filtered with a celite bed and concentrated to remove MeOH. The obtained crude mixture was purified by column chromatography using EtOAc/hexane. As a result, 1-(6-amino-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (100 mg, 0.409 mmol, 48%) was obtained as a grey-white solid.
1H NMR (500 MHz, CDCl3) δ 6.96-6.91 (m, 1H), 6.60-6.57 (m, 1H), 6.52-6.49 (m, 1H), 4.69-4.65 (m, 2H), 3.87-3.80 (m, 2H), 3.68 (s, br, 2H), 2.88-2.85 (m, 2H); LC/MS 245.2 [M + H+].
Preparative Example A-3: Preparation of 1-(7-amino-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Step 1: Preparation of 2,2,2-trifluoro-N-(4-nitrophenetyl)acetamide
Figure PCTKR2018005478-appb-I000018
Trifluoro acetic anhydride (6.22 g, 29.61 mmol) was added to 2-(4-nitrophenyl)ethane-1-amine (5.0 g, 24.67 mmol) solution in DCM (100 mL), to which TEA (8.6 mL, 61.67 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. Upon completion of the reaction, water (50 mL) was added to the reaction mixture, followed by extraction with DCM (2 X 50 mL). The combined organic layer was washed with saturated brine solution, which was dried over Na2SO4. The solvent was eliminated in vacuum. The crude mixture was purified by re-crystallization. As a result, 2,2,2-trifluoro-N-(4-nitrophenetyl)acetamide (5.8 g, 22.1 mmol, 90%) was obtained as a grey-white solid.
1H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 8.6 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H), 6.46 (s, br, 1H), 3.67 (q, J = 6.8 Hz, 2H), 3.02 (t, J = 7.1 Hz, 2H); LC/MS 262.2 [M + H+].
Step 2: Preparation of 2,2,2-trifluoro-1-(7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000019
Compound of step 1 (750 mg, 2.86 mmol) was dissolved in HOAc (4 mL), to which sulfuric acid (7.5 mL) and paraformaldehyde (137 mg, 4.57 mmol) were added at room temperature, followed by stirring at 50℃ for 12 hours. The reaction mixture was poured carefully into approximately 100 mL of ice. The generated white sludge suspension was extracted with EtOAc. The organic material was washed with saturated aqueous NaHCO3 and brine, followed by drying over MgSO4. The crude mixture was purified by column chromatography using hexane/EA (1:4) as an eluent. As a result, 2,2,2-trifluoro-1-(7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (660 mg, 2.40 mmol, 84%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.12-8.04 (m, 2H), 7.38-7.33 (m, 1H), 4.89-4.85 (m, 2H), 3.97-3.88 (m, 2H), 3.09-3.04 (m, 2H); LC/MS 275.2 [M + H+]
Step 3: Preparation of 1-(7-amino-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000020
Pd/C (10 weight%) (60 mg, 0.54 mmol) was added to compound of step 2(650 mg, 2.37 mmol) in MeOH (40 mL) at room temperature. The reaction mixture was stirred at room temperature under hydrogen balloon pressure for 4 hours. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was filtered with a celite bed and concentrated to remove MeOH. The obtained crude mixture was purified by column chromatography using EtOAc/hexane. As a result, 1-(7-amino-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (460 mg, 1.88 mmol, 80%) was obtained as a grey-white solid.
1H NMR (300 MHz, CDCl3) δ 6.97-6.92 (m, 1H), 6.59-6.54 (m, 1H), 6.46-6.43 (m, 1H), 4.68-4.63 (m, 2H), 3.86-3.78 (m, 2H), 3.64 (s, br, 2H), 2.85-2.80 (m, 2H); LC/MS 245.2 [M + H+]
Preparative Example A-4: Preparation of isochroman-7-amine
Step 1: Preparation of 2-(1,3-diethoxy-1,3-dioxopropane-2-yl)-5-nitrobenzoic acid
Figure PCTKR2018005478-appb-I000021
60% NaH (5.65 g, 141 mmol) was added to 90 ml of diethyl malonate and 2-chloro-5-nitrobenzoic acid (10 g, 49.6 mmol) in an ice bath under nitrogen atmosphere. Copper bromide (0.43 g, 0.06 mmol) was added thereto, followed by stirring at 80℃ for 3 hours. After cooling, 40 ml of water were added thereto, which was stirred and washed with hexane (40 ml x 3). PH of the reaction mixture was adjusted to 2 with conc. HCl, and the insoluble materials were removed by filtration. The precipitated solid was filtered, washed with water, and dried to give 2-(1,3-diethoxy-1,3-dioxopropane-2-yl)-5-nitrobenzoic acid (12 g, 36.9 mmol, 74%) as a cream-type solid.
1H NMR (300 MHz, CDCl3) δ 8.99 (s, 1H), 8.45 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 5.88 (s, 1H), 4.30 (q, J = 6.8 Hz, 4H), 1.32 (t, J = 6.5 Hz, 6H); LC/MS 326.3 [M + H+].
Step 2: Preparation of 2-(carboxymethyl)-5-nitrobenzoic acid
Figure PCTKR2018005478-appb-I000022
Compound of step 1 (4.0 g, 12.3 mmol) was dissolved in 30 mL of methanol, to which 30 mL of sodium hydroxide solution (2.7 g, 67.6 mmol) was added at room temperature, followed by stirring at room temperature for 5 hours. Most of methane was concentrated under reduced pressure, and pH of the residue was adjusted to 2 with conc. HCl. The solid was precipitated and filtered. The filtered cake was washed with water and dried. As a result, 2-(carboxymethyl)-5-nitrobenzoic acid (2.2 g, 9.77 mmol, 79%) was obtained as a cream type solid.
1H NMR (300 MHz, DMSO-d6) δ 13.01 (s, br, 2H), 8.62 (d, J = 2.5 Hz, 1H), 8.36 (dd, J = 8.4, 2.6 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 4.11 (s, 2H); LC/MS 226.3 [M + H+].
Step 3: Preparation of 2-(2-(hydroxymethyl)-4-nitrophenyl)ethane-1-ol
Figure PCTKR2018005478-appb-I000023
NaBH4 (1.07 g, 26.6 mmol) was added to compound of step 2 (2.0 g, 8.87 mmol) in THF (45 mL) for 5 minutes in the presence of N2. The reaction mixture was cooled down to 0℃, to which BF3 · Et2O (3.37 mL, 26.6 mmol) was added for 15 minutes, followed by stirring vigorously at room temperature for 18 hours. The reaction mixture was then cooled down to 0℃, which was treated with 1 N aqueous NaOH (35 mL). The reaction mixture was stirred at room temperature for 4 hours. THF was eliminated under reduced pressure and the generated precipitate was separated by filtration. The filtrate was extracted with MeOH/DCM. The precipitate was combined with the organic extract, which was diluted with MeOH/DCM. The mixture was dried over Na2SO4, followed by concentration under reduced pressure. As a result, 2-(2-(hydroxymethyl)-4-nitrophenyl)ethane-1-ol (1.3 g, 6.59 mmol, 74%) was obtained as a beige solid.
1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 8.4, 2.4 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 4.76 (s, 2H), 3.97 (t, J = 5.9 Hz, 2H), 3.37 (s, br, 1H), 3.05 (t, J = 5.8 Hz, 2H), 2.41 (s, br, 1H); LC/MS 198.3 [M + H+].
Step 4: Preparation of 3,4-dihydro-7-nitro-1H-2-benzopyran
Figure PCTKR2018005478-appb-I000024
Diethyl azodicarboxylate (0.9 mL, 5.78 mmol) was added to compound of stsep 4 (1.0 g, 5.07 mmol), succinimide (0.5 g, 5.07 mmol) and triphenylphosphine (1.46 g, 5.57 mmol) in THF at 0℃ for 5 minutes in the presence of N2. The mixture was stirred at 0℃ for 4 hours, followed by concentration under reduced pressure. The residue was purified by silica gel chromatography using EtOAc/hexane (10/90) as an eluent, followed by concentration. As a result, 3,4-dihydro-7-nitro-1H-2-benzopyran (600 mg, 3.35 mmol, 66%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.03 (dd, J = 8.4, 2.1 Hz, 1H), 7.89 (s, 1H), 7.28 (d, J = 8.6 Hz, 1H), 4.84 (s, 2H), 4.01 (t, J = 5.7 Hz, 2H), 2.96 (t, J = 5.7 Hz, 2H); LC/MS 180.2 [M + H+].
Step 5: Preparation of isochroman-7-amine
Figure PCTKR2018005478-appb-I000025
A mixture of PtO2 (10 mol%, 25 mg) in MeOH (15 mL) was degassed and stirred for 25 minutes under hydrogen atmosphere (balloon) to activate the catalyst. Compound of step 4 (250 mg, 1.395 mmol) in MeOH (10 ml) was added thereto. The mixture was stirred for about 2 hours under hydrogen atmosphere (balloon). Then, the catalyst was eliminated by filtration using celite. The filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel chromatography using EtOAc/Hx (1/4) as an eluent. As a result, isochroman-7-amine (200 mg, 1.34 mmol, 96%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 6.94 (d, J = 8.1 Hz, 1H), 6.56 (dd, J = 8.1, 2.2 Hz, 1H), 6.35 (s, 1H), 4.71 (s, 2H), 3.96 (t, J = 5.7 Hz, 2H), 3.58 (s, br, 2H), 2.77 (t, J = 5.7 Hz, 2H); LC/MS 150.2 [M + H+].
Preparative Example A-5: Preparation of 1-(7-amino-4,4-dimethyl-3,4-dihydroquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Step 1: Preparation of 2-methyl-2-(4-nitrophenyl)propanenitrile
Figure PCTKR2018005478-appb-I000026
Sodium tert-butoxide (662 mg, 6.47 mmol) DMF (20 mL) suspension was added to 4-nitrophenylacetonitrile (1.0 g, 6.18 mmol) at 0℃, followed by stirring for 10 minutes. Methyl iodide (400 μL, 6.47 mmol) was loaded thereto for 15 minutes. The reaction mixture was stirred at 0-10℃ for 15 minutes, followed by stirring at room temperature for 15 minutes. Sodium tert-butoxide (662 mg, 6.47 mmol) was added to the purple solution above, followed by stirring for 15 minutes. Methyl iodide (400 μL, 6.47 mmol) was loaded thereto for 15 minutes, followed by stirring overnight. The reaction mixture was extracted with 1 N HCl (50 mL) and EtOAc (75 mL). The combined organic layer was dried over Na2SO4, which was concentrated under reduced pressure. The residue was purified by column chromatography using EtOAc/Hx (1/4) as an eluent. As a result, 2-methyl-2-(4-nitrophenyl)propanenitrile (1.01 g, 5.31 mmol, 86%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 8.8 Hz, 2H), 1.79 (s, 6H); LC/MS 191.2 [M + H+].
Step 2: Preparation of 2,2,2-trifluoro-N-(2-methyl-2-(4-nitrophenyl)propyl)acetamide
Figure PCTKR2018005478-appb-I000027
BH3 THF (1.0 M) (21 mL, 21.03 mmol) was added to cold compound of step 1 (1.0 g, 5.25 mmol) THF (25 mL) solution at 0℃. The reaction mixture was stirred at 70℃ for 2 hours. The reaction was terminated with methanol, followed by concentration and drying. 1.5 N HCl (15.00 mL) was added to the residue, followed by extraction with EtOAc. The aqueous layer was basified with NaOH solution and extracted with EtOAc (2 X 50 mL). The combined organic layer was washed with sodium sulfate and the remaining mixture was subjected to the following steps without any purification process. TEA (1.5 mL, 10.3 mmol) was added to DCM solution (40 mL) of the unpurified reaction mixture (0.8 g, 4.12 mmol), to which trifluoroacetic anhydride (0.7 mL, 4.94 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. Upon completion of the reaction, water was added to the reaction mixture, followed by extraction with DCM (2 X 50 mL). The combined organic layer was washed with saturated brine solution, followed by drying over Na2SO4. The solvent was eliminated under reduced pressure. The residue mixture was purified by recrystallization. As a result, 2,2,2-trifluoro-N-(2-methyl-2-(4-nitrophenyl)propyl)acetamide (0.85 g, 2.93 mmol, 71%) was obtained as a colorless oil.
1H NMR (300 MHz, CDCl3) δ 8.24 (d, J = 8.9 Hz, 2H), 7.56 (d, J = 8.9 Hz, 2H), 6.03 (s, 1H), 3.63 (d, J = 6.5 Hz, 2H), 1.45 (s, 6H); LC/MS 291.2 [M + H+].
Step 3: Preparation of 1-(4,4-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000028
Compound of step 2 (300 mg, 1.03 mmol) was dissolved in HOAc (1.5 mL) and sulfuric acid (2.25 mL), to which paraformaldehyde (49.6 mg, 1.65 mmol) was added at room temperature. The solution above was stirred at 40℃ for 12 hours. The reaction mixture was poured carefully into approximately 100 mL of ice. The generated brown sludge suspension was extracted with EtOAc. The organic layer was washed with saturated aqueous NaHCO3 and brine, followed by drying over MgSO4. The residue mixture was purified by column chromatography using MeOH/MC (1:4) as an eluent. As a result, 1-(4,4-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (190 mg, 0.628 mmol, 61%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.18 - 8.11 (m, 1H), 8.10 - 7.99 (m, 1H), 7.56 (dd, J = 8.7, 5.1 Hz, 1H), 4.92 (s, 2H), 3.78 - 3.60 (m, 2H), 1.43 - 1.36 (m, 6H); LC/MS 303.2 [M + H+].
Step 4: Preparation of 1-(7-amino-4,4-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000029
Pd/C (10 mol %, 20 mg) in MeOH (15 mL) was stirred for 25 minutes under hydrogen atmosphere (balloon) to activate the catalyst. Compound of step 3 (180 mg, 0.595 mmol) in MeOH (10 ml) was added thereto. The mixture was stirred for about 2 hours under hydrogen atmosphere (balloon). Then, the catalyst was eliminated by filtration using celite. The filtrate was concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4) as an eluent. As a result, 1-(7-amino-4,4-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (140 mg, 0.514 mmol, 86%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 6.37 (m, 1H), 4.72 (s, 2H), 3.74 - 3.50 (m, 4H), 1.28 (s, 6H); LC/MS 273.4 [M + H+].
Preparative Example A-6: Preparation of 1-(7-amino-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Step 1: Preparation of N-phenethylisobutylamide
Figure PCTKR2018005478-appb-I000030
Isobutyryl chloride (4.83 g, 45.4 mmol) and TEA (14.42 mL, 103 mmol) were added to phenethylamine (5.0 g, 41.26 mmol) DCM (100 mL) solution. The reaction mixture was stirred at room temperature for 2 hours. Water (50 mL) was added to the reaction mixture, followed by extraction with DCM (2 X 50 mL). The combined organic layer was washed with saturated brine solution, and then dried over Na2SO4. The solvent was eliminated under reduced pressure. The residue mixture was purified by recrystallization. As a result, N-phenethylisobutylamide (7.1 g, 37.12 mmol, 90%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 7.40 - 7.27 (m, 2H), 7.32 - 7.21 (m, 1H), 7.26 - 7.17 (m, 2H), 5.46 (s, 1H), 3.54 (q, J = 6.6 Hz, 2H), 2.84 (t, J = 6.9 Hz, 2H), 2.30 (sept, J = 6.9 Hz, 1H), 1.14 (d, J = 6.9 Hz, 6H); LC/MS 192.2 [M + H+].
Step 2: Preparation of 1-isopropyl-3,4-dihydroisoquinoline
Figure PCTKR2018005478-appb-I000031
Compound of step 1 (1.0 g, 5.23 mmol) and PPA 115% (4.50 g, 46.0 mmol) were loaded in a round bottom flask. The round bottom flask was sealed with a rubber lid, followed by stirring at 130℃ for 30 minutes and then at 200℃ for 3 hours. The reaction mixture was cooled to room temperature and placed in an ice-filled beaker. Next, 25% (w/v) NH4OH aqueous solution was added to the mixture until pH of the mixture reached 9. The mixture was extracted with dichloromethane (3 x 30 mL), followed by washing with saturated NaCl solution (3 x 20 mL). The organic layer was dried over MgSO4, followed by distillation under reduced pressure. As a result, 1-isopropyl-3,4-dihydroisoquinoline (0.77 g, 4.44 mmol, 85%) was obtained as brown oil.
1H NMR (300 MHz, CDCl3) δ 7.54 (dd, J = 7.0, 1.9 Hz, 1H), 7.39 - 7.29 (m, 2H), 7.25 - 7.18 (m, 1H), 3.74 - 3.62 (m, 2H), 3.29 (sept, J = 6.8 Hz, 1H), 2.72 - 2.64 (m, 2H), 1.23 (d, J = 6.8 Hz, 6H); LC/MS 174.2 [M + H+].
Step 3: Preparation of 1-isopropyl-7-nitro-3,4-dihydroisoquinoline
Figure PCTKR2018005478-appb-I000032
Conc. sulfuric acid (2.0 mL) solution containing potassium nitrate (252 mg, 2.49 mmol) was added to conc. sulfuric acid (2.0 mL) containing compound of step 2 (400 mg, 2.31 mmol) at -5℃ with stirring. The temperature of the mixture was raised to room temperature for 2 hours, followed by heating at 60℃ for 4 hours. The reaction mixture was placed in ice-water (10 mL) and basified with potassium hydroxide pellet (pH 9). The mixture was extracted with dichloromethane, followed by drying. The solvent was eliminated under reduced pressure. The crude product was purified by column chromatography using MeOH/DCM (1:9) as an eluent. As a result, 1-isopropyl-7-nitro-3,4-dihydroisoquinoline (400 mg, 1.83 mmol, 80%) was obtained as brown oil.
1H NMR (300 MHz, CDCl3) δ 8.39 (d, J = 2.3 Hz, 1H), 8.24 (dd, J = 8.3, 2.3 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 3.80 - 3.71 (m, 2H), 3.34 (sept, J = 6.7 Hz, 1H), 2.84 - 2.74 (m, 2H), 1.26 (d, J = 6.8 Hz, 6H); LC/MS 219.3 [M + H+].
Step 4: Preparation of 2,2,2-trifluoro-1-(1-isopropyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000033
NaBH4 (138 mg, 3.66 mmol) was added to compound of step 3(400 mg, 1.83 mmol) MeOH (25 mL) solution at room temperature, followed by stirring for 2 hours. Upon completion of the reaction, HCl was added thereto. To eliminate MeOH, the mixture was concentrated. The mixture was basified with NaHCO3, followed by extraction with DCM (15 mL X 2). The reaction mixture was dried over sodium sulfate, followed by concentration. TEA (371 mg, 3.66 mmol) was added to DCM (45 mL) solution containing the reaction mixture, to which TFAA (577 mg, 2.75 mmol) was added, followed by stirring at room temperature for 2 hours. The reaction was terminated with water, followed by extraction with DCM (2 X 15 mL). The organic layer was washed with brine solution (2 X 5 mL), dried over sodium sulfate, and distillated under reduced pressure. The crude product was purified by column chromatography. As a result, 2,2,2-trifluoro-1-(1-isopropyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (440 mg, 1.39 mmol, 76%) was obtained as colorless oil.
1H NMR (300 MHz, CDCl3) δ 8.15 - 7.97 (m, 2H), 7.39 - 7.32 (m, 1H), 5.36 (d, J = 9.0 Hz, 0.8H), 4.66 - 4.55 (m, 0.2H), 4.52 (d, J = 9.9 Hz, 0.2H), 4.19 - 4.07 (m, 0.8H), 3.85 - 3.72 (m, 0.8H), 3.56 - 3.43 (m, 0.2H), 3.27 - 3.04 (m, 2H), 2.24 - 2.04 (m, 1H), 1.15 - 0.99 (m, 6H).; LC/MS 317.2 [M + H+].
Step 5: Preparation of 1-(7-amino-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000034
Pd/C (10 mol %, 80 mg) MeOH (50 mL) mixture was stirred for 25 minutes under hydrogen atmosphere (balloon) to activate the catalyst. Compound of step 4 (440 mg, 1.39 mmol) in MeOH (10 ml) was added thereto. The mixture was stirred for about 2 hours under hydrogen atmosphere (balloon). Then, the catalyst was eliminated by filtration using celite. The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel chromatography using EtOAc/Hx (1/4). As a result, 1-(7-amino-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (350 mg, 1.22 mmol, 88%) was obtained as a brown solid.
1H NMR (300 MHz, CDCl3) δ 6.95 (d, J = 8.1 Hz, 1H), 6.60 (dd, J = 8.1, 2.6 Hz, 1H), 6.54 - 6.40 (m, 1H), 5.15 (d, J = 8.8 Hz, 0.8H), 4.47 - 4.35 (m, 0.2H), 4.28 (d, J = 10.0 Hz, 0.2H), 4.06 - 3.93 (m, 0.8H), 3.81 - 3.68 (m, 0.8H), 3.64 (s, 2H), 3.53 - 3.41 (m, 0.2H), 3.03 - 2.80 (m, 2H), 2.19 - 2.08 (m, 1H), 1.12 - 0.95 (m, 6H); LC/MS 287.2 [M + H+].
Preparative Example A-7: Preparation of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Step 1: Preparation of 1,3,3-trimethyl-3,4-dihydroisoquinoline
Figure PCTKR2018005478-appb-I000035
CH3CN (0.55 mL) in hexane (10 mL) was loaded to cold conc. H2SO4 (15 mL) with magnetic stirring. Then, 2-methyl-1-methylpropanol (700 mg, 4.65 mmol) in hexane (15 mL) was added thereto. The temperature of the mixture was raised back to room temperature. The mixture was stirred at 68°C for 2.5 hours. The solution was cooled to room temperature and ice water was poured under magnetic stirring. The solution was alkalized with ammonia. The organic layer was extracted with dichloromethane and the solution was washed with saturated brine. The mixture was dried over sodium sulfate, filtered, and then concentrated under reduced pressure. The obtained crude mixture was purified by column chromatography (MeOH/MC (1:4)). As a result, 1,3,3-trimethyl-3,4-dihydroisoquinoline (600 mg, 3.46 mmol, 74%) was obtained as colorless oil.
1H NMR (300 MHz, CDCl3) δ 7.50 (d, J = 7.4Hz, 1H), 7.36 (t, J = 7.3 Hz, 1H), 7.33 - 7.28 (m, 1H), 7.16 (d, J = 7.6 Hz, 1H), 2.71 (s, 2H), 2.40 (s, 3H), 1.22 (s, 6H); LC/MS 174.2 [M + H+].
Step 2: Preparation of 1,3,3-trimethyl-7-nitro-3,4-dihydroisoquinoline
Figure PCTKR2018005478-appb-I000036
Conc. sulfuric acid (2.0 mL) solution containing potassium nitrate (252 mg, 2.49 mmol) was added to conc. sulfuric acid (2.0 mL) containing compound of step 1 (400 mg, 2.31 mmol) at -5℃ with stirring. The temperature of the mixture was raised to room temperature for 2 hours, followed by heating at 60℃ for 4 hours. The reaction mixture was placed in ice-water (10 mL) and basified with potassium hydroxide pellet (pH 9). The mixture was extracted with dichloromethane, followed by drying. The solvent was eliminated under reduced pressure. The crude product was purified by column chromatography (MeOH/DCM (1:9)). As a result, 1,3,3-trimethyl-7-nitro-3,4-dihydroisoquinoline (400 mg, 1.83 mmol, 80%) was obtained as brown oil.
1H NMR (300 MHz, CDCl3) δ 8.35 (d, J = 2.2 Hz, 1H), 8.25 (dd, J = 8.2, 2.3 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 2.82 (s, 2H), 2.47 (s, 3H), 1.24 (s, 6H); LC/MS 219.2 [M + H+].
Step 3: Preparation of 2,2,2-trifluoro-1-(1,3,3-trimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000037
NaBH4 (138 mg, 3.66 mmol) was added to compound of step 2 (400 mg, 1.83 mmol) MeOH (25 mL) solution at room temperature, followed by stirring for 2 hours. Upon completion of the reaction, HCl was added to the reaction mixture, followed by concentration to eliminate MeOH. The reaction mixture was basified with NaHCO3, followed by extraction with DCM (15 mL X 2). The mixture was dried over sodium sulfate and concentrated to obtain the crude mixture. TFAA (577 mg, 2.75 mmol was added to DCM (45 mL) solution containing the reaction mixture, to which TEA (371 mg, 3.66 mmol) was added, followed by stirring for 2 hours. The reaction was quenched with water, followed by extraction with DCM (2 X 15 mL). The organic layer was washed with brine solution (2 X 5 mL), dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by column chromatography. As a result, 2,2,2-trifluoro-1-(1,3,3-trimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (440 mg, 1.39 mmol, 76%) was obtained as a white solid.
1H NMR (500 MHz, CDCl3) δ 8.21 (dd, J = 8.2, 2.2 Hz, 1H), 8.07 (d, J = 2.2 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 5.17 (q, J = 7.0 Hz, 1H), 3.47 (d, J = 15.7 Hz, 1H), 2.84 (d, J = 15.7 Hz, 1H), 1.85 (s, 3H), 1.63 (d, J = 6.9 Hz, 3H), 1.31 (s, 3H); LC/MS 317.2 [M + H+].
Step 4: Preparation of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000038
A mixture of Pd/C (10 mol%, 80 mg) in MeOH (50 mL) was degassed and stirred for 25 minutes under hydrogen atmosphere (balloon) to activate the catalyst. Compound of step 3 (400 mg, 1.26 mmol) in MeOH (10 ml) was added thereto. The reaction mixture was stirred for about 2 hours under hydrogen atmosphere (balloon). Then, the catalyst was eliminated by filtration using celite. The filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography (EtOAc/Hx (1/4)). As a result, 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (300 mg, 1.05 mmol, 83%) was obtained as brown oil.
1H NMR (300 MHz, CDCl3) δ 6.99 (d, J = 7.9 Hz, 1H), 6.62 (d, J = 7.7 Hz, 1H), 6.50 (s, 1H), 4.88 (q, J = 7.1 Hz, 1H), 3.68 (s, 2H), 3.27 (d, J = 15.3 Hz, 1H), 2.55 (d, J = 15.1 Hz, 1H), 1.77 (s, 3H), 1.55 (d, J = 6.9 Hz, 3H), 1.28 (s, 3H); LC/MS 287.2 [M + H+].
Preparative Example A-8: Preparation of 1-(5-aminoisoindolin-2-yl)-2,2,2-trifluoroethane-1-one
Step 1: Preparation of 2,2,2-trifluoro-1-(5-nitroisoindolin-2-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000039
Trifluoroacetic anhydride (1.64 mL, 11.7 mmol) was added dropwise to cold isoindolin (400 mg, 3.35 mmol) acetonitrile (15 mL) solution at -10℃. Potassium nitrate (366 mg, 3.62 mmol) was added to the stirred mixture at once. The mixture was stirred at -10°C for 1 hour. Saturated sodium bicarbonate aqueous solution (10 mL) was slowly added to the mixture. Active gas generation was observed. The mixture was stirred for 1 hour and then the temperature of the mixture was raised to room temperature. The mixture was basified with saturated sodium carbonate (10 mL). The sticky turbid solution was filtered. The obtained solid was washed with water (20 mL) and then dissolved in dichloromethane (30 mL), followed by concentration under reduced pressure. The crude product was purified by column chromatography. As a result, 2,2,2-trifluoro-1-(5-nitroisoindolin-2-yl)ethane-1-one (600 mg, 2.30 mmol, 69%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.32 - 8.18 (m, 2H), 7.52 (dd, J = 16.3, 8.4Hz, 1H), 5.16 (s, 2H), 5.04 (s, 2H); LC/MS 260.9 [M + H+].
Step 2: Preparation of 1-(5-aminoisoindolin-2-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000040
A target compound was prepared by the same manner as described in step 4 of Preparative Example A-7 except that 2,2,2-trifluoro-1-(5-nitroisoindolin-2-yl)ethane-1-one prepared in step 1 was used instead of 2,2,2-TRIFLUORO-1-(1,3,3-TRIMETHYL-7-NITRO-3,4-DIHYDROISOQUINOLINE-2(1H)-YL)ETHANE-1-ONE.
1H NMR (300 MHz, CDCl3) δ 7.08 (dd, J = 15.9, 8.1 Hz, 1H), 6.76 - 6.52 (m, 2H), 4.94 (s, 2H), 4.83 (d, J = 4.3 Hz, 2H), 3.77 (s, 2H); LC/MS 231.2 [M + H+].
Preparative Example A-9: Preparation of 1-(7-amino-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Step 1: Preparation of N-(4-methoxyphenetyl)acetamide
Figure PCTKR2018005478-appb-I000041
Acetic anhydride (1.5 mL, 15.87 mmol) was added to 2-(3-methoxyphenyl)ethane-1-amine (2.0 g, 13.22 mmol) DCM (50 mL) solution, to which TEA (4.6 mL, 33.0 mmol) was added, followed by stirring at room temperature for 2 hours. Upon completion of the reaction, water (100 mL) was added thereto, followed by extraction with DCM (2 X 150 mL). The combined organic layer was washed with saturated brine solution and then dried over Na2SO4. The solvent was removed under vacuum. The crude mixture was purified by column chromatography (EtOAc/Hx (2:8)). As a result, N-(4-methoxyphenetyl)acetamide (2.4 g, 12.42 mmol, 94%) was obtained as yellow oil.
1H NMR (500 MHz, CDCl3) δ 7.25 (t, J = 7.8 Hz, 1H), 6.80 (dd, J = 8.0, 2.3 Hz, 2H), 6.76 (t, J = 2.0 Hz, 1H), 5.55 (s, 1H), 3.82 (s, 3H), 3.56 - 3.51 (m, 2H), 2.81 (t, J = 6.9 Hz, 2H), 1.96 (s, 3H); LC/MS 193.9 [M + H+].
Step 2: Preparation of 7-methoxy-1-methyl-3,4-dihydroisoquinoline
Figure PCTKR2018005478-appb-I000042
EtOH (1.7 mL, 28.9 mmol) was slowly added to compound of step 1 (2.0 g, 10.35 mmol) POCl3 (7.9 mL, 84.86 mmol) solution at room temperature. The reaction mixture was refluxed for overnight. The mixture was cooled down at room temperature and POCl3 was eliminated by evaporation. The crude mixture was basified with sat.NaHCO3 (aq) (1000 mL), followed by extraction with DCM (3 X 500 mL). The combined organic layer was washed with saturated brine solution and then dried over Na2SO4. The solvent was removed under vacuum. The crude mixture was purified by column chromatography (MeOH/DCM (1:9)). As a result, 7-methoxy-1-methyl-3,4-dihydroisoquinoline (1.1 g, 6.27 mmol, 61%) was obtained as brown oil.
1H NMR (300 MHz, CDCl3) δ 7.49 (d, J = 8.5 Hz, 1H), 6.83 (dd, J = 8.6, 2.6 Hz, 1H), 6.74 (d, J = 2.6 Hz, 1H), 3.87 (s, 3H), 3.69 (td, J = 7.5, 1.6 Hz, 2H), 2.81 - 2.72 (m, 2H), 2.45 (t, J = 1.4Hz, 3H); LC/MS 175.8 [M + H+].
Step 3: Preparation of 2-benzyl-6-methoxy-1-methyl-3,4-dihydroisoquinoline-2-inium bromide
Figure PCTKR2018005478-appb-I000043
Benzyl bromide (0.68 mL, 5.70 mmol) was added to compound of step 2 (500 mg, 2.853 mmol) acetonitrile (40 mL) solution, followed by stirring at 70°C for 3 hours. The solvent was evaporated. The crude mixture was purified by column chromatography (MeOH/DCM (1:9)). As a result, 2-benzyl-6-methoxy-1-methyl-3,4-dihydroisoquinoline-2-inium bromide (700 mg, 2.02 mmol, 70%) was obtained as a yellow foam-type solid.
1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 9.0 Hz, 1H), 7.48 - 7.37 (m, 3H), 7.41 - 7.32 (m, 2H), 6.99 (dd, J = 9.0, 2.6 Hz, 1H), 6.86 (dd, J = 6.5, 2.5 Hz, 1H), 5.56 (s, 2H), 4.14 (t, J = 7.6 Hz, 2H), 3.94 (s, 3H), 3.25 (t, J = 7.5 Hz, 2H), 3.08 (s, 3H); LC/MS 266.2 [M - Br+].
Step 4: Preparation of 2-benzyl-6-methoxy-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline
Figure PCTKR2018005478-appb-I000044
3.0 M MeMgCl Et2O (1.01 mL, 3.03 mmol) solution was added to compound of step 3 (700 mg, 2.021 mmol) THF (20 mL) turbid solution, followed by stirring at room temperature overnight. The reaction mixture was treated with saturated NH4Cl (aq) (150 mL) solution, followed by extraction with EtOAc (200 mL X 2). The organic layer was washed with water, and then washed again with saturated brine solution. The combined organic layer was concentrated under reduced pressure. The obtained crude mixture was purified by column chromatography (MeOH/MC (1:9)). As a result, 2-benzyl-6-methoxy-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline(300 mg, 1.066 mmol, 53%) was obtained as colorless oil.
1H NMR (500 MHz, CDCl3) δ 7.51 - 7.47 (m, 2H), 7.38 (t, J = 7.6 Hz, 2H), 7.32 - 7.24 (m, 2H), 6.82 (dd, J = 8.7, 2.8 Hz, 1H), 6.62 (d, J = 2.7 Hz, 1H), 3.83 (s, 3H), 3.78 (s, 2H), 2.76 (s, 4H), 1.54 (s, 6H); LC/MS 282.1 [M + H+].
Step 5: Preparation of 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000045
Pd/C (10 wt%) (30 mg, 0.281 mmol) was added to compound of step 4(300 mg, 1.066 mmol) methanol (30 mL) solution, followed by stirring at room temperature under hydrogen balloon pressure for 4 hours. The reaction mixture was filtered with a celite bed. The solvent was evaporated under reduced pressure. The crude mixture was dissolved in DCM (75 mL), to which trifluoroacetic anhydride (0.18 mL, 1.279 mmol) was added. Triethylamine (0.3 mL, 2.132 mmol) was added thereto. The reaction mixture was stirred at room temperature for 2 hours, quenched with water (25 mL), and extracted with DCM (120 mL X 2). The organic layer was washed with water, and then washed again with saturated brine. The combined organic layer was dried over anhydrous Na2SO4. The solvent was eliminated under reduced pressure. The obtained crude mixture was purified by column chromatography (EtOAc/Hexane). As a result, 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (200 mg, 0.696 mmol, 65%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 7.24 (d, J = 8.8 Hz, 1H), 6.86 (dd, J = 8.9, 2.8 Hz, 1H), 6.65 (d, J = 2.7 Hz, 1H), 3.83 (s, 3H), 3.72 - 3.62 (m, 2H), 2.94 - 2.85 (m, 2H), 1.83 (s, 6H); LC/MS 288.1 [M + H+].
Step 6: Preparation of 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000046
HNO3 (80 mg, 0.765 mmol) TFA solution was added to 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (200 mg, 0.696 mmol) TFA (15 mL) solution, followed by stirring at room temperature for 2 hours. The reaction mixture was evaporated to eliminate TFA and basified with sat.NaHCO3 solution. The mixture was extracted with EtOAc (15 mL X 2). The organic layer was washed with water, and then washed again with saturated brine. The combined organic layer was dried over anhydrous Na2SO4. The solvent was eliminated under reduced pressure. The obtained crude mixture was purified by column chromatography (EtOAc/Hexane (3:7)). As a result, a mixture (80 mg, 0.240 mmol, 34%) of 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-5-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethanone (70 mg 0.210 mmol, 30%) and 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (45 mg, 0.135 mmol, 20%) was obtained as a white solid.
2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-5-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethanone: 1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 9.0 Hz, 1H), 7.03 (d, J = 9.0 Hz, 1H), 3.93 (s, 3H), 3.67 (t, J = 5.4Hz, 2H), 2.96 - 2.73 (m, 2H), 1.85 (s, 6H); LC/MS 332.8 [M + H+].
2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one: 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 1H), 6.83 (s, 1H), 3.99 (s, 3H), 3.79 - 3.60 (m, 2H), 3.16 - 2.87 (m, 2H), 1.86 (s, 6H); LC/MS 332.8 [M + H+].
Step 7: Preparation of 2,2,2-trifluoro-1-(6-hydroxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000047
1.0 M BBr3 DCM (0.54 mL, 0.54 mmol) was added to 2,2,2-trifluoro-1-(6-methoxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (45 mg, 0.135 mmol) DCM (10 mL) solution at -78°C, followed by stirring at -78°C for 30 minutes. The temperature of the mixture was slowly raised to room temperature, followed by stirring for 1 hour. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was quenched with NaHCO3 solution, followed by extraction with DCM (15.0 mL). The organic layer was dried over Na2SO4, followed by evaporation under reduced pressure. The obtained crude mixture was purified by column chromatography (EtOAc/Hexane (3:7)). As a result, 2,2,2-trifluoro-1-(6-hydroxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (32 mg, 0.100 mmol, 74%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 10.40 (s, 1H), 8.09 (s, 1H), 6.93 (s, 1H), 3.85 - 3.45 (m, 2H), 3.02 - 2.83 (m, 2H), 1.86 (s, 6H); LC/MS 317.1 [M - H+].
Step 8: Preparation of 1,1-dimethyl-7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-yl trifluoromethanesulfonate
Figure PCTKR2018005478-appb-I000048
Tf2O (87 mg, 0.307 mmol) was added to 2,2,2-trifluoro-1-(6-hydroxy-1,1-dimethyl-7-nitro-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one (70 mg, 0.219 mmol) DCM (15 mL) solution, to which TEA (67 mg, 0.659 mmol) was added, followed by stirring at room temperature for 2 hours. The reaction mixture was quenched with water, followed by extraction with DCM (2 X 15 mL). The organic layer was washed with brine (2 X 5 mL), dried over Na2SO4, and then concentrated under reduced pressure. The obtained crude product was purified by column chromatography. As a result, 1,1-dimethyl-7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-yl trifluoromethanesulfonate (75 mg, 0.166 mmol, 76%) was obtained as colorless oil.
1H NMR (300 MHz, CDCl3) δ 8.14 (s, 1H), 7.23 (s, 1H), 3.77 - 3.68 (m, 2H), 3.07 - 3.00 (m, 2H), 1.90 (s, 6H); LC/MS 450.8 [M + H+].
Step 9: Preparation of 1-(7-amino-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000049
Pd/C (10 mol %, 80 mg) in MeOH (50 mL) was degassed and stirred for 25 minutes under hydrogen atmosphere (balloon) to activate the catalyst. 1,1-dimethyl-7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-yl trifluoromethanesulfonate (70 mg, 0.155 mmol) in MeOH (5 ml) was added thereto, to which Et3N (16 mg, 0.155 mmol) was added. The reaction mixture was stirred for about 2 hours under hydrogen atmosphere (balloon). Then, the catalyst was eliminated by filtration using celite. The filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography (EtOAc/Hx (1/4)). As a result, 1-(7-amino-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (30 mg, 0.110 mmol, 71%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 6.90 (d, J = 8.1 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 6.54 (dd, J = 8.0, 2.3 Hz, 1H), 3.66 - 3.58 (m, 4H), 2.82 - 2.74 (m, 2H), 1.81 (s, 6H); LC/MS 273.4 [M + H+].
Preparative Example A-10: Preparation of N-(4-aminophenyl)acrylamide
Step 1: Preparation of N-(4-nitrophenyl)acrylamide
Figure PCTKR2018005478-appb-I000050
Acryloyl chloride (344 mg, 3.80 mmol) was added to DCM (25 mL) solution containing 4-nitroaniline (500 mg, 3.62 mmol) and triethylamine (1.0 mL, 7.24 mmol) at 0°C, followed by stirring for 1 hour. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was quenched with water (25.0 mL), followed by extraction with DCM (25 mL X 2). The combined organic layer was concentrated under reduced pressure. The obtained crude mixture was purified by column chromatography (EtOAc/Hexane (1:5)). As a result, N-(4-nitrophenyl)acrylamide (500 mg, 2.60 mmol, 72%) was obtained as a yellow solid.
1H NMR (300 MHz, DMSO) δ 10.73 (s, 1H), 8.24 (d, J = 9.1 Hz, 2H), 7.93 (d, J = 8.3 Hz, 2H), 6.61 - 6.42 (m, 1H), 6.34 (d, J = 15.3 Hz, 1H), 5.87 (d, J = 9.9 Hz, 1H); LC/MS 193.2 [M + H+].
Step 2: Preparation of N-(4-aminophenyl)acrylamide
Figure PCTKR2018005478-appb-I000051
N-(4-nitrophenyl)acrylamide (200 mg, 1.04 mmol) was suspended in ethanol/water (5:1) mixture, to which Fe powder (116 mg, 2.08 mmol) and ammonium chloride solution (1 mL) were added. The mixture was heated to 80°C for 4 hours. The reaction mixture was cooled at room temperature and filtered with a celite pad. The celite above was washed with ethanol (10 mL) and ethyl acetate (50 mL). The solution above was concentrated under vacuum. The reaction residue was fractionated with DCM (50 mL) and water (20 mL). The combined organic layer was concentrated under reduced pressure. The obtained crude mixture was purified by column chromatography (EtOAc/Hexane (1:5)). As a result, N-(4-aminophenyl)acrylamide (100 mg, 0.616 mmol, 60%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 8.0 Hz, 2H), 7.12 (s, 1H), 6.66 (d, J = 8.6 Hz, 2H), 6.39 (d, J = 16.8 Hz, 1H), 6.21 (dd, J = 16.8, 10.1 Hz, 1H), 5.72 (d, J = 10.1 Hz, 1H), 3.61 (s, 2H); LC/MS 163.2 [M + H+].
Preparative Example A-11: Preparation of 7-amino-3,4-dihydroisoquinoline-1(2H)-one
Step 1: Preparation of 7-nitro-3,4-dihydroisoquinoline-1(2H)-one
Figure PCTKR2018005478-appb-I000052
Fuming nitric acid (128 mg, 2.04 mmol) was added dropwise to -5°C conc. sulfuric acid (2.0 mL) containing 3,4-dihydroisoquinolin-1(2H)-one (400 mg, 2.31 mmol) at 0℃. The temperature of the mixture was raised to room temperature for 2 hours. The reaction mixture was placed in ice-water (10 mL) and basified with potassium hydroxide pellet (pH 9). The mixture was extracted with dichloromethane, followed by drying. The solvent was eliminated under reduced pressure. The crude product was purified by column chromatography (MeOH/DCM (1:9)). As a result, 7-nitro-3,4-dihydroisoquinoline-1(2H)-one (300 mg, 1.56 mmol, 76%) was obtained as brown oil.
1H NMR (500 MHz, CDCl3) δ 8.94 (d, J = 2.5 Hz, 1H), 8.33 (dd, J = 8.3, 2.5 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 6.42 (s, 1H), 3.67 (td, J = 6.6, 2.9 Hz, 2H), 3.16 (t, J = 6.6 Hz, 2H); LC/MS 193.2 [M + H+].
Step 2: Preparation of 7-amino-3,4-dihydroisoquinoline-1(2H)-one
Figure PCTKR2018005478-appb-I000053
A target compound was prepared by the same manner as described in step 4 of Preparative Example A-7 except that 7-nitro-3,4-dihydroisoquinoline-1(2H)-one prepared in step 1 was used instead of 2,2,2-TRIFLUORO-1-(1,3,3-TRIMETHYL-7-NITRO-3,4-DIHYDROISOQUINOLINE-2(1H)-YL)ETHANE-1-ONE.
1H NMR (300 MHz, CDCl3) δ 7.20 - 7.11 (m, 1H), 6.67 - 6.58 (m, 1H), 6.48 - 6.37 (m, 1H), 4.72 (s, 2H), 3.74 - 3.50 (m, 4H), 1.28 (s, 6H); LC/MS 163.2 [M + H+].
Preparative Example B-1: Preparation of 6-chloro-N-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 2,4-dichloropyrimidine-5-carbonyl chloride
Figure PCTKR2018005478-appb-I000054
2,4-Dihydroxypyrimidine-5-carboxylic acid (10.0 g, 64 mmol) was added to POCl3 (45 mL, 71 mmol) in a round bottom flask at 0℃ little by little, to which PCl5 (46.6 g, 229 mmol) was slowly added. The temperature of the reaction mixture was raised to room temperature, and the mixture was heated to reflux for 16 hours. The mixture was concentrated to dry and slurried with DCM (dichloromethane, 30 mL). The precipitated solid was filtered and washed with DCM (2 x 20 mL). The filtrate was evaporated under reduced pressure. As a result, the target compound (10.2 g, 48 mmol, 75%) was obtained as yellow oil.
Step 2: Preparation of 2,4-dichloro-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000055
2,6-Dimethylaniline (5.81 g, 48 mmol) was added to 2,4-dichloropyrimidine-5-carbonyl chloride (10.2 g, 48 mmol) in EtOAc (400 mL) at room temperature, to which amberlyst 21 resin (2.0 g) was added. The mixture was stirred at room temperature for 12 hours, followed by filtering. The filtrate was washed serially with water, 1.5 N HCl (15 mL), NaOH, and brine in that order. The combined organic layer was dried over sodium sulfate, and then concentrated under reduced pressure. The obtained crude product was recrystallized by using DCM. As a result, 2,4-DICHLORO-N-(2,6-DIMETHYLPHENYL)PYRIMIDINE-5-CARBOXAMIDE(11.0 g, 37.14 mmol, 77%) was obtained as a grey-white solid.
1H NMR (300 MHz, CDCl3) δ 9.05 (s, 1H), 7.70 (s, br, 1H), 7.22-7.13 (m, 3H), 2.31 (s, 6H); LC/MS 296.2 [M + H+].
Step 3: Preparation of 2-chloro-N-(2,6-dimethylphenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000056
Methyl hydrazine (205 mg, 4.45 mmol) was added to 2,4-DICHLORO-N-(2,6-DIMETHYLPHENYL)PYRIMIDINE-5-CARBOXAMIDE(1.2 g, 4.05 mmol) in THF (30 mL) at room temperature, to which Et3N (1.42 mL, 10.1 mmol) was added. The mixture was stirred at room temperature for 24 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 2-CHLORO-N-(2,6-DIMETHYLPHENYL)-4-(1-METHYLHYDRAZINYL)PYRIMIDINE-5-CARBOXAMIDE(1.0 g, 3.27 mmol, 80%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.34 (s, 1H), 7.17-7.13 (m, 4H), 4.14 (s, br, 2H), 3.47 (s, 3H), 2.34 (s, 6H); LC/MS 306.2 [M + H+].
Step 4: Preparation of 6-chloro-N-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000057
PCl5 (681 mg, 3.27 mmol) was added to 2-CHLORO-N-(2,6-DIMETHYLPHENYL)-4-(1-METHYLHYDRAZINYL)PYRIMIDINE-5-CARBOXAMIDE(1.0 g, 3.27 mmol) in toluene (40 mL) at room temperature. The mixture was stirred at room temperature for 24 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 6-CHLORO-N-(2,6-DIMETHYLPHENYL)-1-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE-3-AMINE (800 mg, 2.78 mmol, 85 %) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.54 (s, 1H), 7.25-7.16 (m, 3H), 6.12 (s, br, 1H), 3.89 (s, 3H), 2.26 (s, 6H); LC/MS 288.2 [M + H+].
Preparative Example B-2: Preparation of 6-chloro-1-methyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 2,4-dichloro-N-phenyl pyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000058
Aniline (440 mg, 4.72 mmol) was added to 2,4-dichloropyrimidine-5-carbonyl chloride (1.0 g, 4.72 mmol) in EtOAc (40 mL) at room temperature, to which amberlyst 21 resin (100 mg) was added. The mixture was stirred at room temperature for 12 hours, followed by filtering. The filtrate was washed with water, 1.5 N HCl (15 mL), NaOH, and brine in that order. The combined organic layer was dried over sodium sulfate, and then concentrated under reduced pressure. The obtained crude product was recrystallized by using DCM. As a result, 2,4-dichloro-N-phenyl pyrimidine-5-carboxamide (900 mg, 3.35 mmol, 71%) was obtained as a grey-white solid.
1H NMR (300 MHz, DMSO-d6) δ 10.75 (s, 1H), 9.09 (s, 1H), 7.67 (d, J = 7.7 Hz, 2H), 7.39 (t, J = 7.6 Hz, 2H), 7.16 (t, J = 7.4 Hz, 1H); LC/MS 268.2 [M + H+].
Step 2: Preparation of 2-chloro-4-(1-methylhydrazinyl)-N-phenylpyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000059
Methyl hydrazine (47 mg, 1.02 mmol) was added to 2,4-dichloro-N-phenyl pyrimidine-5-carboxamide (250 mg, 0.932 mmol) in THF (30 mL) at room temperature, to which Et3N (0.32 mL, 2.33 mmol) was added. The mixture was stirred at room temperature for 12 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 2-chloro-4-(1-methylhydrazinyl)-N-phenylpyrimidine-5-carboxamide (210 mg, 0.756 mmol, 81%) was obtained as a white solid.
1H NMR (500 MHz, DMSO-d6) δ 10.01 (s, 1H), 8.03 (s, 1H), 7.62 (d, J = 7.85 Hz, 2H), 7.31 (t, J = 7.70 Hz, 2H), 7.05 (t, J = 7.35 Hz, 1H), 4.95 (s, 2H), 3.27 (s, 3H); LC/MS 278.2 [M + H+].
Step 3: Preparation of 6-chloro-1-methyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000060
PCl5 (150 mg, 0.720 mmol) was added to 2-chloro-4-(1-methylhydrazinyl)-N-phenylpyrimidine-5-carboxamide (200 mg, 0.720 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 100℃ for 18 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 6-chloro-1-methyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine (150 mg, 0.577 mmol, 80%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 8.76 (s, 1H), 7.47 (d, J = 7.56 Hz, 2H), 7.38 (t, J = 7.35 Hz, 2H), 7.09 (t, J = 7.23 Hz, 1H), 6.53 (s, br 1H), 3.98 (s, 3H); LC/MS 260.2 [M + H+].
Preparative Example B-3: Preparation of 6-chloro-N-(2,6-dichlorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 2,4-dichloro-N-(2,6-dichlorophenyl)pyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000061
2,6-Dichloroaniline (383 mg, 2.36 mmol) was added to 2,4-dichloropyrimidine-5-carbonyl chloride (500 mg, 2.36 mmol) in EtOAc (40 mL) at room temperature, to which amberlyst 21 resin (100 mg) was added. The mixture was stirred for 12 hours, followed by filtering. The filtrate was washed with water, 1.5 N HCl (15 mL), NaOH, and brine in that order. The combined organic layer was dried over sodium sulfate, and then concentrated under reduced pressure. The obtained crude product was recrystallized by using DCM. As a result, 2,4-dichloro-N-(2,6-dichlorophenyl)pyrimidine-5-carboxamide (650 mg, 1.93 mmol, 81%) was obtained as a grey-white solid.
1H NMR (300 MHz, DMSO-d6) δ 10.83 (s, 1H), 9.01 (s, 1H), 7.62 (d, J = 8.1 Hz, 2H), 7.44 (t, J = 7.8 Hz, 1H); LC/MS 337.2 [M + H+].
Step 2: Preparation of 2-chloro-N-(2,6-dichlorophenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000062
Methyl hydrazine (37 mg, 0.81 mmol) was added to 2,4-dichloro-N-(2,6-dichlorophenyl)pyrimidine-5-carboxamide (250 mg, 0.74 mmol) in THF (30 mL) at room temperature, to which Et3N (0.26 mL, 1.85 mmol) was added. The mixture was stirred at room temperature for 12 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 2-chloro-N-(2,6-dichlorophenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide (180 mg, 0.519 mmol, 70%) was obtained as a white solid.
1H NMR (500 MHz, DMSO-d6) δ 10.17 (s, 1H), 8.14 (s, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.37 (t, J = 8.05 Hz, 1H), 4.99 (s, 2H), 3.30 (s, 3H); LC/MS 346.2 [M + H+].
Step 3: Preparation of 6-chloro-N-(2,6-dichlorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000063
PCl5 (120 mg, 0.577 mmol) was added to 2-chloro-N-(2,6-dichlorophenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide (200 mg, 0.577 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 100℃ for 18 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 6-chloro-N-(2,6-dichlorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine (130 mg, 0.395 mmol, 68%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 8.27 (s, 1H), 7.46 (d, J = 8.1 Hz, 2H), 7.21 (t, J = 7.8 Hz, 1H), 6.40 (s, 1H), 3.95 (s, 3H); LC/MS 328.2 [M + H+].
Preparative Example B-4: Preparation of 6-chloro-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of tert-butyl-2-(2-chloro-5-((2,6-dimethylphenyl)carbamoyl)pyrimidine-4-yl)hydrazine-1-carboxylate
Figure PCTKR2018005478-appb-I000064
Tert-butyl carbazate (268 mg, 2.026 mmol) was added to 2,4-dichloro-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (500 mg, 1.688 mmol) in THF (30 mL) at room temperature, to which Et3N (0.6 mL, 4.22 mmol) was added. The mixture was stirred for 12 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, tert-butyl-2-(2-chloro-5-((2,6-dimethylphenyl)carbamoyl)pyrimidine-4-yl)hydrazine-1-carboxylate (560 mg, 1.429 mmol, 84%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 9.97 (s, br, 1H), 8.60 (s, 1H), 7.45 (s, br, 1H), 7.22-7.14 (m, 3H), 6.57 (s, br, 1H), 2.27 (s, 6H), 1.52 (s, 9H); LC/MS 391.2 [M + H+].
Step 2: Preparation of 6-chloro-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000065
PCl5 (297 mg, 1.429 mmol) was added to tert-butyl-2-(2-chloro-5-((2,6-dimethylphenyl)carbamoyl)pyrimidine-4-yl)hydrazine-1-carboxylate (560 mg, 1.429 mmol) in toluene (50 mL) at room temperature. The mixture was stirred at 100℃ for 18 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 6-chloro-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine (65 mg, 0.237 mmol, 16%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 10.31 (s, 1H), 7.69 (s, 1H), 7.24 - 7.13 (m, 3H), 6.29 (s, 1H), 2.26 (s, 6H); LC/MS 273.9 [M + H+].
Preparative Example B-5: Preparation of 6-chloro-1-cyclopentyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 2-chloro-4-(1-cyclopentylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000066
Et3N (0.24 mL, 1.68 mmol) was added to 2,4-dichloro-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (200 mg, 0.675 mmol) in THF (20 mL), to which cyclopentyl hydrazine HCl (101.5 mg, 0.742 mmol) was added at room temperature. The mixture was stirred at room temperature for 12 hours, which was concentrated to eliminate THF. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by column chromatography using EtOAc/Hx (1/4). As a result, 2-chloro-4-(1-cyclopentylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (180 mg, 0.500 mmol, 74%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.27 (s, 1H), 7.35 (s, br, 1H), 7.16-7.09 (m, 3H), 5.25 (pent, J = 8.1 Hz, 1H), 3.85 (s, 2H), 2.30 (s, 6H), 2.03 1.88 (m, 2H), 1.76-1.57 (m, 6H).; LC/MS 359.9 [M + H+].
Step 2: Preparation of 6-chloro-1-cyclopentyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000067
PCl5 (104 mg, 0.500 mmol) was added to 2-chloro-4-(1-cyclopentylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (180 mg, 0.500 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 100℃ for 18 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by column chromatography using EtOAc/Hx (1/4). As a result, 6-chloro-1-cyclopentyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine (120 mg, 0.351 mmol, 70%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.46 (s, 1H), 7.25 7.12 (m, 3H), 6.14 (s, 1H), 5.18 (pent, J = 7.8 Hz, 1H), 2.27 (s, 6H), 2.16 2.02 (m, 4H), 1.98 1.86 (m, 2H), 1.80 1.67 (m, 2H); LC/MS 342.2 [M + H+].
Preparative Example B-6: Preparation of 6-chloro-1-cyclohexyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 2-chloro-4-(1-cyclohexylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000068
Et3N (0.18 mL, 1.26 mmol) was added to 2,4-dichloro-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (150 mg, 0.506 mmol) in THF (10 mL), to which cyclohexyl hydrazine HCl (84 mg, 0.557 mmol) was added at room temperature. The mixture was stirred at room temperature for 12 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by column chromatography using EtOAc/Hx (1/4). As a result, 2-chloro-4-(1-cyclohexylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (140 mg, 0.374 mmol, 74%) was obtained as a white solid.
1H NMR (500 MHz, CDCl3) δ 8.29 (s, 1H), 7.34 (s, br, 1H), 7.18-7.12 (m, 3H), 4.75 4.65 (m, 1H), 3.85 (s, 2H), 2.34 (s, 6H), 1.95-1.90 (m, 2H), 1.85-1.77 (m, 2H), 1.76-1.74 (m, 2H), 1.55-1.45 (m, 4H), 1.22-1.11 (m, 1H); LC/MS 373.9 [M + H+].
Step 2: Preparation of 6-chloro-1-cyclohexyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000069
PCl5 (72 mg, 0.347 mmol) was added to 2-chloro-4-(1-cyclohexylhydrazinyl)-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (130 mg, 0.347 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 110℃ for 3 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by column chromatography using EtOAc/Hx (1/4). As a result, 6-chloro-1-cyclohexyl-N-(2,6-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine (90 mg, 0.253 mmol, 73%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.46 (s, 1H), 7.23 7.11 (m, 3H), 6.14 (s, br, 1H), 4.67 4.53 (m, 1H), 2.24 (s, 6H), 2.02 1.84 (m, 6H), 1.78-1.67 (m, 1H), 1.54 1.38 (m, 2H), 1.32-1.17 (m, 1H); LC/MS 356.2 [M + H+].
Preparative Example B-7: Preparation of 6-chloro-N-(2,6-dimethylphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 2-chloro-N-(2,6-dimethylphenyl)-4-(1-isopropylhydrazinyl)pyrimidine-5-carboxamide
Figure PCTKR2018005478-appb-I000070
Et3N (0.18 mL, 1.26 mmol) was added to 2,4-dichloro-N-(2,6-dimethylphenyl)pyrimidine-5-carboxamide (150 mg, 0.506 mmol) in THF (10 mL), to which isopropyl hydrazine (41 mg, 0.577 mmol) was added at room temperature. The mixture was stirred at room temperature for 2 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 2-chloro-N-(2,6-dimethylphenyl)-4-(1-isopropylhydrazinyl)pyrimidine-5-carboxamide (120 mg, 0.359 mmol, 71%) was obtained as a white solid.
1H NMR (500 MHz, CDCl3) δ 8.24 (s, 1H), 7.56 (s, br, 1H), 7.17-7.10 (m, 3H), 5.14 (sept, J = 6.7 Hz, 1H), 3.81 (s, 2H), 2.32 (s, 6H), 1.24 (d, J = 6.7 Hz, 6H); LC/MS 333.9 [M + H+].
Step 2: Preparation of 6-chloro-N-(2,6-dimethylphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000071
PCl5 (68.6 mg, 0.329 mmol) was added to 2-chloro-N-(2,6-dimethylphenyl)-4-(1-isopropylhydrazinyl)pyrimidine-5-carboxamide (110 mg, 0.329 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 110℃ for 3 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4). As a result, 6-chloro-N-(2,6-dimethylphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine (75 mg, 0.237 mmol, 72%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.46 (s, 1H), 7.22 7.12 (m, 3H), 6.03 (s, br, 1H), 5.03 (sept, J = 6.7 Hz, 1H), 2.25 (s, 6H), 1.51 (d, J = 6.7 Hz, 6H); LC/MS 316.9 [M + H+].
Preparative Example B-8: Preparation of N-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(trifluoromethyl)benzamide
Figure PCTKR2018005478-appb-I000072
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide prepared in step 4 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 9.14 (s, 1H), 8.25 (s, 1H), 8.23-8.17 (m, 1H), 8.14 (s, 1H), 8.09-8.03 (m, 1H), 7.93-7.92 (m, 1H), 7.84-7.81 (m, 1H), 7.67-7.61 (m, 2H), 2.35 (s, 3H); LC/MS 468.8 [M + H+]
Preparative Example B-9: Preparation of N-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-2,4-dimethylphenyl)-3-(trifluoromethyl)benzamide
Step 1: Preparation of 1,3-dimethyl-2,4-dinitrobenzene
Figure PCTKR2018005478-appb-I000073
Sulfuric acid (1.65 mL) was slowly added to 1,3-dimethyl-2-nitrobenzene (5.00 g, 33.1 mmol) at 0℃. Nitric acid (0.41 mL) was slowly added thereto at 0℃. The reaction mixture was stirred at room temperature for 1 hour. The reaction was terminated with ice water and the precipitate was filtered. The filtrate was distillated under reduced pressure. As a result, the target compound (6.0 g, 30.6 mmol, 92%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 2.47 (s, 3H), 2.39 (s, 3H); LC/MS 196.8 [M + H+]
Step 2: Preparation of 2,4-dimethyl-3-nitroaniline
Figure PCTKR2018005478-appb-I000074
Formic acid (4.04 mL, 107 mmol) was slowly added to TEA (16.0 mL, 115 mmol) solution containing the compound prepared in step 1 (5.00 g, 25.5 mmol) and 10% Pd/C (500 mg) at room temperature. The reaction mixture was stirred at 100℃ for 0.5 hour. The reaction was terminated with NaHCO3 (aq), followed by extraction with EtOAc (2 X 25 mL). The combined organic layer was dried over Na2SO4 and the solvent was eliminated under reduced pressure. The residue mixture was purified by silica gel column chromatography using EtOAc/Hex (3/7). As a result, the target compound (2.0 g, 12 mmol, 47%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 6.92 (d, J = 8.2 Hz, 1H), 6.68 (d, J = 8.2 Hz, 1H), 3.71 (s, 2H), 2.18 (s, 3H), 2.05 (s, 3H).
Step 3: Preparation of N-(2,4-dimethyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide
Figure PCTKR2018005478-appb-I000075
3-(trifluoromethyl)benzoyl chloride (1.09 mL, 7.22 mmol) was added to DCM solution containing the compound prepared in step 2 (1.0 g, 6.02 mmol), to which TEA (1.68 mL, 12.0 mmol) was added at 0℃. The mixture was stirred at room temperature for 0.5 hour. The reaction was terminated with water, followed by extraction with DCM (2 X 25 mL). The residue mixture was purified by silica gel column chromatography using EtOAc/Hex (3/7). As a result, the target compound (1.25 g, 3.70 mmol, 62%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.15 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.66 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 2.31 (s, 3H), 2.10 (s, 3H); LC/MS 338.8 [M + H+]
Step 4: Preparation of N-(3-amino-2,4-dimethylphenyl)-3-(trifluoromethyl)benzamide
Figure PCTKR2018005478-appb-I000076
10% Pd/C (4 mg) was added to MeOH solution containing the compound prepared in step 3 (40 mg, 0.12 mmol) at room temperature. The reaction mixture was stirred at room temperature under hydrogen balloon pressure overnight. The reaction mixture was filtered with celite, and the solvent was eliminated. The mixture was purified by column chromatography using EtOAc/Hex as an eluent. As a result, the target compound (397 mg, 1.29 mmol, 36%) was obtained as a light yellow solid.
1H NMR (300 MHz, CDCl3) δ 8.16 (s, 1H), 8.07 (d, J = 7.4 Hz, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.65-7.60 (m, 2H), 6.98 (d, J = 7.9 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 3.67 (s, 2H), 2.19 (s, 3H), 2.11 (s, 3H); LC/MS 308.9 [M + H+]
Step 5: Preparation of N-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-2,4-dimethylphenyl)-3-(trifluoromethyl)benzamide
Figure PCTKR2018005478-appb-I000077
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that N-(3-amino-2,4-dimethylphenyl)-3-(trifluoromethyl)benzamide prepared in step 4 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.15 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 7.71-7.52 (m, 3H), 7.22 (d, J = 8.2 Hz, 1H), 6.25 (s, 1H), 3.87 (s, 3H), 2.25 (s, 3H), 2.22 (s, 3H); LC/MS 474.8 [M + H+]
Preparative Example B-10: Preparation of 6-chloro-N-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 4-(2-methoxyethoxy)-2,6-dimethylaniline
Figure PCTKR2018005478-appb-I000078
Cs2CO3 (3.53 g, 10.8 mmol) and KI (75.3 mg, 0.454 mmol) were added to acetone (10 mL) solution containing 4-amino-3,5-xylenol (1.00 g, 7.29 mmol) at room temperature. 1-Bromo-2-methoxyethane (1.22 g, 8.75 mmol) was added thereto at room temperature. The mixture was stirred at 70oC for 7 hours. The reaction was terminated with water, followed by concentration until the volume was reduced to half. The mixture was extracted with EtOAc (2x). The extract was dried over Na2SO4 and then filtered. When the obtained product was concentrated to brown oil, the concentrated product was purified by silica gel column chromatography using EtOAc/hexane (1/1). As a result, the target compound (812 mg, 4.16 mmol, 39%) was obtained as brown oil.
1H NMR (300 MHz, CDCl3) δ 6.58 (s, 2H), 4.03 (t, J = 4.8 Hz, 2H), 3.69 (t, J = 4.8 Hz, 2H), 3.43 (s, 3H), 3.31 (s, br, 2H), 2.15 (s, 6H); LC/MS 195.8 [M + H+]
Step 2: Preparation of 6-chloro-N-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000079
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 4-(2-methoxyethoxy)-2,6-dimethylaniline prepared in step 1 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 7.49 (s, 1H), 6.73 (s, 2H), 5.98 (s, 1H), 4.15-4.08 (m, 2H), 3.87 (s, 3H), 3.80-3.74 (m, 2H), 3.47 (s, 3H), 2.20 (s, 6H); LC/MS 361.9 [M + H+]
Preparative Example B-11: Preparation of 6-chloro-N-(2,6-dimethyl-4-phenoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000080
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,6-dimethyl-4-phenoxybenzamine was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 7.65 (s, 1H), 7.43-7.34 (m, 2H), 7.21-7.12 (m, 1H), 7.09-7.02 (m, 2H), 6.79 (s, 2H), 5.94 (s, 1H), 3.88 (s, 3H), 2.21 (s, 6H); LC/MS 379.9 [M + H+]
Preparative Example B-12: Preparation of 4-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-3,5-dimethyl-N-(pyridine-2-yl)benzamide
Step 1: Preparation of 3,5-dimethyl-4-nitro-N-(pyridine-2-yl)benzamide
Figure PCTKR2018005478-appb-I000081
T3P (2.30 mL, 10.2 mmol) and TEA (1.42 mL, 10.2 mmol) were added to DCM (20 mL) solution containing 3,5-dimethyl-4-nitrobenzoic acid (1.00 g, 5.12 mmol) and 2-aminopyridine (482 mg, 5.12 mmol) at room temperature, followed by stirring at room temperature overnight. The reaction was terminated with NaHCO3 (aq), followed by extraction with DCM (2 X 25 mL). The combined organic layer was dried over Na2SO4 and the solvent was eliminated under reduced pressure. The residue mixture was purified by silica gel column chromatography using EtOAc/Hex (3/7). As a result, the target compound (290 mg, 1.07 mmol, 21%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.76 (s, 1H), 8.38-8.27 (m, 1H), 8.29-8.26 (m, 1H), 7.877.75 (m, 1H), 7.69 (s, 2H), 7.13-.08 (m, 1H), 2.37 (s, 6H); LC/MS 271.8 [M + H+]
Step 2: Preparation of 4-amino-3,5-dimethyl-N-(pyridine-2-yl)benzamide
Figure PCTKR2018005478-appb-I000082
10% Pd/C (30 mg) was added to MeOH (20 mL) solution containing the compound prepared in step 1 above (290 mg, 1.07 mmol) at room temperature. The reaction mixture was stirred at room temperature under hydrogen balloon pressure overnight. The reaction mixture was filtered with celite and MeOH was eliminated under reduced pressure. As a result, the target compound (245 mg, 1.02 mmol, 95%) was obtained as a light yellow solid.
1H NMR (300 MHz, CDCl3) δ 8.51 (s, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.328.25 (m, 1H), 7.797.68 (m, 1H), 7.56 (s, 2H), 7.096.99 (m, 1H), 3.99 (s, 2H), 2.23 (s, 6H); LC/MS 241.9 [M + H+]
Step 3: Preparation of 4-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-3,5-dimethyl-N-(pyridine-2-yl)benzamide
Figure PCTKR2018005478-appb-I000083
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 4-amino-3,5-dimethyl-N-(pyridine-2-yl)benzamide prepared in step 2 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.69 (s, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.34-8.29 (m, 1H), 8.02 (s, 1H), 7.81-7.72 (m, 3H), 7.15 - 7.05 (m, 1H), 6.21 (s, 1H), 3.88 (s, 3H), 2.31 (s, 6H); LC/MS 407.8 [M + H+]
Preparative Example B-13: Preparation of 6-chloro-N-(4-methoxy-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 4-methoxy-2,6-dimethylaniline
Figure PCTKR2018005478-appb-I000084
Iodomethane (0.41 mL, 6.63 mmol) was added to DMF (20 mL) solution containing 4-amino-3,5-dimethylphenol (1.00 g, 7.29 mmol) and t-BuOK (1.27 g, 11.3 mmol) at room temperature, followed by stirring at room temperature for 8 hours. The reaction was terminated with NaHCO3 (aq), and the reaction mixture was washed with brine, followed by extraction with EtOAc (2 X 25 mL). The combined organic layer was dried over Na2SO4, and the solvent was eliminated under reduced pressure. The residue mixture was purified by silica gel column chromatography using EtOAc/Hex (3/7). As a result, the target compound (556 mg, 3.68 mmol, 51 %) was obtained as brown oil.
1H NMR (300 MHz, chloroform) δ 6.54 (s, 2H), 3.71 (s, 3H), 3.27 (s, 2H), 2.15 (s, 6H).
Step 2: Preparation of 6-chloro-N-(4-methoxy-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000085
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 4-methoxy-2,6-dimethylaniline prepared in step 1 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 7.49 (s, 1H), 6.70 (s, 2H), 5.95 (s, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 2.21 (s, 6H). 317.9 [M + H+]
Preparative Example B-14: Preparation of 6-chloro-N-(2,6-diethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000086
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,4-diethylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 7.42 (s, 1H), 7.34 (dd, J = 8.5, 6.6 Hz, 1H), 7.23 (d, J = 7.4 Hz, 2H), 6.06 (s, br, 1H), 3.90 (s, 3H), 2.63 (q, J = 7.6 Hz, 4H), 1.15 (t, J = 7.5 Hz, 6H); LC/MS 315.9 [M + H+].
Preparative Example B-15: Preparation of 6-chloro-N-(2,6-diisopropylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000087
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,4-diisopropylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 7.42 (dd, J = 8.4, 7.0 Hz, 1H), 7.35 (s, 1H), 7.30 (s, 1H), 7.27 (s, 1H), 6.13 (s, 1H), 3.90 (s, 3H), 3.27 (sept, J = 6.9 Hz, 2H), 1.13 (d, J = 6.9 Hz, 12H); LC/MS 343.9 [M + H+].
Preparative Example B-16: Preparation of 6-chloro-N-(2-chloro-3,5-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000088
Step 1: Preparation of 2,4-dichloro-N-(3,5-dimethylphenyl)pyrimidine-5-carboxamide
3,5-Dimethyl aniline (143 mg, 1.18 mmol) was added to 2,4-dichloropyrimidine-5-carbonyl chloride (250 mg, 1.18 mmol) in THF (1.5 mL) at room temperature. The mixture was stirred at room temperature for 15 hours, followed by filtering. The filtrate was washed with water, 1.5 N HCl (15 mL), NaOH, and brine in that order. The combined organic layer was dried over sodium sulfate, and then concentrated under reduced pressure. The obtained crude product was recrystallized by using DCM. As a result, the target compound (251 mg, 0.847 mmol, 72%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 9.03 (s, 1H), 7.99 (s, br, 1H), 7.24 (s, 2H), 6.88 (s, 1H), 2.34 (s, 6H); LC/MS 296.9 [M + H+].
Step 2: Preparation of 2-chloro-N-(3,5-dimethylphenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide
Methyl hydrazine (26 mg, 0.557 mmol) and Et3N (0.18 mL, 1.26 mmol) were added to THF (10 mL) solution containing the compound prepared in step 1 (150 mg, 0.506 mmol). The mixture was stirred at room temperature for 2 hours, which was concentrated to eliminate THF. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4) as an eluent. As a result, 2-chloro-N-(3,5-dimethylphenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide (124 mg, 0.405 mmol, 80%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.10 (s, 1H), 7.82 (s, br, 1H), 7.26 (s, 2H), 6.83 (s, 1H), 4.09 (s, 2H), 3.43 (s, 3H), 2.34 (s, 6H); LC/MS 306.9 [M + H+].
Step 3: Preparation of 6-chloro-N-(2-chloro-3,5-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
PCl5 (82 mg, 0.392 mmol) was added to 2-chloro-N-(3,5-dimethylphenyl)-4-(1-methylhydrazinyl)pyrimidine-5-carboxamide (120 mg, 0.392 mmol) in toluene (20 mL) at room temperature. The mixture was stirred at 110℃ for 2 hours, which was concentrated to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The obtained crude product was purified by silica gel column chromatography using EtOAc/Hx (1/4) as an eluent. As a result, 6-chloro-N-(2-chloro-3,5-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine (40 mg, 0.124 mmol, 32%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 8.83 (s, 1H), 7.72 (s, 1H), 7.02 (s, 1H), 6.78 (s, 1H), 4.01 (s, 3H), 2.41 (s, 3H), 2.34 (s, 3H); LC/MS 321.9 [M + H+].
Preparative Example B-17: Preparation of 6-chloro-N-(2,4-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000089
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,4-dimethylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.29 (s, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.11 (s, 1H), 7.05 (d, J = 8.2 Hz, 1H), 6.12 (s, br, 1H), 3.94 (s, 3H), 2.35 (s, 3H), 2.31 (s, 3H); LC/MS 287.9 [M + H+].
Preparative Example B-18: Preparation of 6-chloro-1-methyl-N-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000090
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2-methylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.47 (s, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.28 7.20 (m, 2H), 7.09 (t, J = 7.4 Hz, 1H), 6.22 (s, 1H), 3.96 (s, 3H), 2.37 (s, 3H); LC/MS 273.9 [M + H+].
Preparative Example B-19: Preparation of 6-chloro-N-(3,5-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000091
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 3,5-dimethylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.72 (s, 1H), 7.05 (s, 2H), 6.74 (s, 1H), 6.39 (s, 1H), 3.98 (s, 3H), 2.34 (s, 6H); LC/MS 287.9 [M + H+].
Preparative Example B-20: Preparation of 6-chloro-N-(2,6-difluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000092
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,6-difluoroaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.21 (s, 1H), 7.37 (s, 1H), 7.327.20 (m, 1H), 6.99 (t, J = 8.2 Hz, 2H), 4.11 (s, 2H), 3.42 (s, 3H). 313.8 [M + H+]
Preparative Example B-21: Preparation of 6-chloro-N-(2,6-dimethoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000093
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,6-dimethoxyaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.13 (s, 1H), 7.18 (t, J = 8.4 Hz, 1H), 6.66 (d, J = 8.4 Hz, 2H), 6.28 (s, 1H), 3.89 (s, 3H), 3.79 (s, 6H).335.9 [M + H+]
Preparative Example B-22: Preparation of 6-chloro-N-(4-fluoro-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000094
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,5-dimethyl-4-fluoroaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 7.64 (s, 1H), 6.89 (d, J = 8.9 Hz, 2H), 5.94 (s, 1H), 3.88 (d, J = 0.7 Hz, 3H), 2.24 (s, 6H). 305.9 [M + H+]
Preparative Example B-23: Preparation of 6-chloro-N-(2,5-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000095
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2,5-dimethylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.41 (s, 1H), 7.31 (s, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 6.16 (s, 1H), 3.94 (s, 3H), 2.30 (s, 3H), 2.29 (s, 3H). 287.9 [M + H+]
Preparative Example B-24: Preparation of 6-chloro-N-(2-chloro-6-methylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000096
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2-chloro-6-methylaniline was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.00 (s, 1H), 7.39 (dd, J = 7.3, 2.2 Hz, 1H), 7.27 7.17 (m, 2H), 6.26 (s, 1H), 3.92 (s, 3H), 2.30 (s, 3H); LC/MS 308.9 [M + H+].
Preparative Example B-25: Preparation of 6-chloro-N-(5-(2-methoxyethoxy)-2-methylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Step 1: Preparation of 3-amino-4-methylphenol
Figure PCTKR2018005478-appb-I000097
10% Pd/C (100 mg) was added to 4-methyl-3-nitrophenol (1.00 g, 6.53 mmol) methanol (100 mL) solution. The mixture was stirred at room temperature under hydrogen balloon pressure overnight. The reaction mixture was filtered with celite, and MeOH was eliminated. As a result, 3-amino-4-methylphenol (750 mg, 6.09 mmol, 93%) was obtained as a light brown solid.
1H NMR (300 MHz, CDCl3) δ 6.87 (d, J = 8.1 Hz, 1H), 6.276.15 (m, 2H), 4.70 (s, 1H), 3.89 (s, 2H), 2.08 (s, 3H).
Step 2: Preparation of 5-(2-methoxyethoxy)-2-methylaniline
Figure PCTKR2018005478-appb-I000098
Cs2CO3 (1.98 g, 6.09 mmol) and KI (40 mg, 0.244 mmol) were added to 3-amino-4-methylphenol (500 mg, 4.06 mmol) acetone (20 mL) solution. The mixture was stirred at 70oC overnight. The reaction was terminated with water, followed by extraction with EtOAc (2 X 25 mL). The residue mixture was purified by silica gel column chromatography using EtOAc/Hex (3/7) as an eluent. As a result, 5-(2-methoxyethoxy)-2-methylaniline (600 mg, 3.31 mmol, 82%) was obtained as yellow oil.
1H NMR (300 MHz, CDCl3) δ 6.946.89 (m, 1H), 6.326.24 (m, 2H), 4.084.02 (m, 2H), 3.743.68 (m, 2H), 3.60 (s, 2H), 3.43 (s, 3H), 2.08 (s, 3H). 182.0 [M + H+]
Step 3: Preparation of 6-chloro-N-(5-(2-methoxyethoxy)-2-methylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000099
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 5-(2-methoxyethoxy)-2-methylaniline prepared in step 2 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, CDCl3) δ 8.56 (s, 1H), 7.257.20 (m, 1H), 7.12 (d, J = 8.3 Hz, 1H), 6.62 (dd, J = 8.3, 2.6 Hz, 1H), 6.19 (s, 1H), 4.094.02 (m, 2H), 3.95 (s, 3H), 3.753.69 (m, 2H), 3.43 (s, 3H), 2.26 (s, 3H). 347.9 [M + H+]
Preparative Example B-26: Preparation of N-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)picolineamide
Step 1: Preparation of 6-chloro-1-methyl-N-(2-methyl-5-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000100
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that 2-methyl-5-nitroanilyl was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, DMSO-d 6) δ 9.34 (s, 1H), 8.99 (d, J = 2.4 Hz, 1H), 8.89 (s, 1H), 7.80 (dd, J = 8.3, 2.5 Hz, 1H), 7.50 (d, J = 8.3 Hz, 1H), 3.89 (s, 3H). 318.9 [M + H+]
Step 2: Preparation of N1-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)-6-methylbenzene-1,3-diamine
Figure PCTKR2018005478-appb-I000101
Fe (150 mg) and 2 M HCl (2 mL) were added to EtOH (2 mL) solution containing the compound prepared in step 1 above (100 mg, 0.314 mmol) at room temperature. The reaction mixture was stirred at 70℃ for 1.5 hour. The reaction was terminated with NaHCO3 (aq), followed by extraction with EtOAc (2 X 25 mL). The combined organic layer was dried over Na2SO4 and the solvent was eliminated under reduced pressure. The residue mixture was purified by silica gel column chromatography using DCM/MeOH (9/1) as an eluent. As a result, the target compound (40 mg, 0.14 mmol, 44%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 8.54 (s, 1H), 7.00 (d, J = 8.0 Hz, 1H), 6.96 (d, J = 2.3 Hz, 1H), 6.40 (dd, J = 8.1, 2.4 Hz, 1H), 6.19 (s, 1H), 3.94 (s, 3H), 3.63 (s, 2H), 2.22 (s, 3H). 290.0 [M + H+]
Step 3: Preparation of N-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)picolineamide
Figure PCTKR2018005478-appb-I000102
Pyridine-2-carbonylchloride hydrochloride (25 mg, 0.314 mmol) and TEA (0.04 mL, 0.268 mmol) were added to DCM (2 mL) solution containing the compound prepared in step 2 above (40 mg, 0.134 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1.5 hour. The reaction was terminated with 1 M HCl (aq), followed by extraction with EtOAc (2 X 25 mL). The combined organic layer was dried over Na2SO4 and the solvent was eliminated under reduced pressure. The residue mixture was purified by silica gel column chromatography using EtOAc/Hex (5/5) as an eluent. As a result, the target compound (48 mg, 0.12 mmol, 87%) was obtained as a yellow solid.
1H NMR (300 MHz, DMSO-d 6) δ 10.52 (s, 1H), 9.11 (s, 1H), 8.74 (d, J = 4.7 Hz, 1H), 8.24 (d, J = 2.1 Hz, 1H), 8.15 (d, J = 7.8 Hz, 1H), 8.118.05 (m, 1H), 7.727.65 (m, 1H), 7.52 (dd, J = 8.1, 2.2 Hz, 1H), 7.21 (d, J = 8.2 Hz, 1H), 3.69 (s, 3H), 2.29 (s, 3H). 393.9 [M + H+]
Preparative Example B-27: Preparation of 3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide
Step 1: Preparation of N-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide
Figure PCTKR2018005478-appb-I000103
SOCl2 (5 mL) was added to 3-amino-4-methylbenzoic acid (500 mg, 3.31 mmol) solution at room temperature, followed by stirring at 90℃ for 1 hour. The reaction mixture was concentrated to eliminate SOCl2. 3-(Trifluoromethyl)aniline (799 mg, 4.96 mmol) DCM (10 mL) solution and TEA (0.92 mL, 6.62 mmol) were added thereto, followed by stirring at room temperature for 2 hours. The reaction was terminated with water, followed by extraction with DCM (2 X 25 mL). The combined organic layer was dried over Na2SO4 and the solvent was eliminated under reduced pressure. The mixture was concentrated and slurried with DCM (30 mL). The precipitated solid was filtered and washed with DCM (2 x 20 mL). The filtrate was dried under reduced pressure. As a result, the target compound (480 mg, 1.63 mmol, 49%) was obtained as an ivory solid.
1H NMR (300 MHz, DMSO-d 6) δ 10.3 (s, 1H), 8.25 (s, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.18 (s, 1H), 7.147.03 (m, 2H), 5.12 (s, 2H), 2.13 (s, 3H). 295.0 [M + H+]
Step 2: Preparation of 3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide
Figure PCTKR2018005478-appb-I000104
A target compound was prepared by the same manner as described in steps 2, 3, and 4 of Preparative Example B-1 except that N-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide prepared in step 1 above was used instead of 2,6-dimethylaniline in step 2 of Preparative Example B-1.
1H NMR (300 MHz, chloroform-d) δ 8.69 (s, 1H), 8.31 (s, 1H), 7.95 (d, J = 15.2 Hz, 2H), 7.85 (d, J = 8.2 Hz, 1H), 7.557.30 (m, 4H), 6.35 (s, 1H), 3.97 (s, 3H), 2.43 (s, 3H). 460.9 [M + H+]
Preparative Example B-28: Preparation of 1-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea
Step 1: Preparation of N 1-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)-6-methylbenzene-1,3-diamine
Figure PCTKR2018005478-appb-I000105
2.0 N HCl (5.0 mL) and Fe powder (150 mg) were added to 6-chloro-1-methyl-N-(2-methyl-5-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-amine (100 mg, 0.313 mmol) EtOH (5.0 mL) solution at room temperature, followed by stirring at 70°C for 2 hours. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was concentrated to eliminate ethanol. Sat. NaHCO3 solution (15 mL) was added thereto, followed by extraction with EtOAc (15 mL X 2). The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography (EtOAc/Hexane (1:1)). As a result, N 1-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)-6-methylbenzene-1,3-diamine (60 mg, 0.207 mmol, 66%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 8.57 (s, 1H), 7.03 (d, J = 8.0 Hz, 1H), 6.98 (d, J = 2.4Hz, 1H), 6.43 (dd, J = 8.0, 2.3 Hz, 1H), 6.17 (s, 1H), 3.97 (s, 3H), 3.63 (s, 2H), 2.24 (s, 3H); LC/MS 289.2 [M + H+].
Step 2: Preparation of 1-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea
Figure PCTKR2018005478-appb-I000106
1-Isocyanato-3-(trifluoromethyl)benzene (21 mg, 0.113 mmol) was added to N1-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)-6-methylbenzene-1,3-diamine (30 mg, 0.103 mmol) DCM (10 mL) solution at 0°C, to which Et3N (20 mg, 0.206 mmol) was added, followed by stirring for 2 hours. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was quenched with water, followed by extraction with DCM (25 mL X 2). The organic layer was washed with saturated brine solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography (EtOAc/Hexane (1:1)). As a result, 1-(3-((6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea (30 mg, 0.063 mmol, 61%) was obtained as a yellow solid.
1H NMR (300 MHz, CD3OD) δ 8.88 (s, 1H), 7.82 (s, 1H), 7.71 (s, 1H), 7.57 (d, J = 8.4Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 1H), 7.17 (d, J = 7.8 Hz, 1H), 7.13 (d, J = 7.8 Hz, 1H), 3.88 (s, 3H), 2.31 (s, 3H); LC/MS 475.2 [M + H+].
Example 1: Preparation of 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone
Figure PCTKR2018005478-appb-I000107
The compound prepared in Preparative Example A-1 ( 29.7 mg, 0.156 mmol) and pTSA.H2O (33 mg, 0.173 mmol) were added to IPA (2.0 mL) solution containing the compound prepared in Preparative Example B-1 (50 mg, 0.173 mmol) at room temperature, followed by stirring at 90℃ for 12 hours. TLC analysis indicated the complete consumption of the starting material. The solid obtained from the reaction mixture was filtered and washed with ethanol (2 mL). The filtered solid was dissolved in EtOAc (15 mL) and washed with saturated NaHCO3 solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using MeOH/DCM (1/4) as an eluent. As a result, 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone(60 mg, 0.135 mmol, 78%) was obtained as a grey-white solid.
Example 2: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000108
HBr (48% in H2O) (10 mL) was added to the compound of Example 1 (45 mg, 0.101 mmol) at room temperature. The mixture was heated to reflux at 100℃ for 12 hours. TLC analysis indicated the complete consumption of the starting material. Saturated NaHCO3 solution was added to the reaction mixture, which was extracted with EtOAc. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using MeOH/DCM (1/4) as an eluent. As a result, N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine (20 mg, 0.050 mmol, 50%) was obtained as a grey-white solid.
Example 3: Preparation of 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone
Figure PCTKR2018005478-appb-I000109
1-(6-amino-7-methoxy-3,4 dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (17 mg, 0.062 mmol) and pTSA.H2O (13 mg, 0.069 mmol) were added to IPA (2.0 mL) solution containing the compound prepared in Preparative Example B-1 (6-CHLORO-N-(2,6-DIMETHYLPHENYL)-1-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE-3-AMINE, 20 mg, 0.069 mmol) at room temperature, followed by stirring at 90℃ for 12 hours. TLC analysis indicated the complete consumption of the starting material. The solid obtained from the reaction mixture was filtered and washed with ethanol (2 mL). The filtered solid was dissolved in EtOAc (15 mL) and washed with saturated NaHCO3 solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using EtOAc/hexane (1/1) as an eluent. As a result, 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone (28 mg, 0.053 mmol, 77%) was obtained as a grey-white solid.
Example 4: Preparation of N3-(2,6-dimethylphenyl)-N6-(7-methoxy-1,2,3,4-tetrahydroisoquinoline-6-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000110
Lithium hydroxide monohydrate (2.5 mg, 0.057 mmol) was added to THF (1.0 mL), MeOH (0.5 mL), and H2O (0.5 mL) containing the compound of Example 3 (1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone, 15 mg, 0.028 mmol) at room temperature, followed by stirring at room temperature for 1 hour. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was concentrated to eliminate THF and methanol. Water (5.0 mL) was added thereto, followed by extraction with EtOAc (15mL Х 2). The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using MeOH/DCM (1:9) as an eluent. As a result, N3-(2,6-dimethylphenyl)-N6-(7-methoxy-1,2,3,4-tetrahydroisoquinoline-6-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine (10 mg, 0.023 mmol, 83%) was obtained as a grey-white solid.
Example 5: Preparation of 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone
Figure PCTKR2018005478-appb-I000111
Acetic anhydride (8.5 mg, 0.084 mmol) and Et3N (17.6 mg, 0.175 mmol) were added to DCM (10 mL) solution containing the compound of Example 4 (30 mg, 0.070 mmol) at 0℃, followed by stirring at room temperature for 2 hours. TLC analysis indicated the complete consumption of the starting material. Water was added thereto, followed by extraction with DCM (15 mL). The mixture was washed with saturated NaHCO3 solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using MeOH/DCM (1/4) as an eluent. As a result, 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone (28 mg, 0.059 mmol, 85%) was obtained as a grey-white solid.
Example 6: Preparation of 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone
Figure PCTKR2018005478-appb-I000112
A target compound was prepared by the same manner as described in Example 3 except that the compound prepared in Preparative Example A-2 was used instead of 1-(6-amino-7-methoxy-3,4 dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one in Example 3.
Example 7: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000113
A target compound was prepared by the same manner as described in Example 4 except that the compound of Example 6 was used instead of the compound of Example 3 in Example 4.
Example 8: Preparation of 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone
Figure PCTKR2018005478-appb-I000114
A target compound was prepared by the same manner as described in Example 5 except that the compound of Example 7 was used instead of the compound of Example 4 in Example 5.
Example 9: Preparation of 2,2,2-trifluoro-1-(7-(1-methyl-3-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone
Figure PCTKR2018005478-appb-I000115
A target compound was prepared by the same manner as described in Example 3 except that the compound prepared in Preparative Example A-3 was used instead of 1-(6-amino-7-methoxy-3,4 dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one and the compound prepared in Preparative Example B-2 was used instead of the compound prepared in Preparative Example B-1 in Example 3
Example 10: Preparation of 1-methyl-N3-phenyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000116
A target compound was prepared by the same manner as described in Example 4 except that the compound of Example 9 was used instead of the compound of Example 3 in Example 4.
Example 11: Preparation of 1-(7-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone
Figure PCTKR2018005478-appb-I000117
A target compound was prepared by the same manner as described in Example 9 except that the compound of Preparative Example B-3 was used instead of the compound of Preparative Example B-2 in Example 9.
Example 12: Preparation of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000118
A target compound was prepared by the same manner as described in Example 10 except that the compound of Example 11 was used instead of the compound of Example 9 in Example 10.
Example 13: Preparation of 1-(7-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone
Figure PCTKR2018005478-appb-I000119
Acetic anhydride (2.7 mg, 0.027 mmol) and Et3N (5.5 mg, 0.055 mmol) were added to DCM (10 mL) solution containing the compound of Example 12 (N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine, 10 mg, 0.022 mmol) at 0℃, followed by stirring at room temperature for 2 hours. TLC analysis indicated the complete consumption of the starting material. Water was added thereto, followed by extraction with DCM (15 mL). The mixture was washed with saturated NaHCO3 solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using MeOH/DCM (1/4) as an eluent. As a result, 1-(7-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone (10 mg, 0.020 mmol, 90%) was obtained as a grey-white solid.
Example 14: Preparation of 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)prop-2-en -1-one
Figure PCTKR2018005478-appb-I000120
Acryloyl chloride (2.7 mg, 0.03 mmol) and Et3N (6.3 mg, 0.06 mmol) were added to DCM (10 mL) solution containing the compound of Example 2 (N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine, 10 mg, 0.02 mmol) at 0℃, followed by stirring at room temperature for 2 hours. TLC analysis indicated the complete consumption of the starting material. Water was added thereto, followed by extraction with DCM (15 mL). The mixture was washed with saturated NaHCO3 solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using MeOH/DCM (1/4) as an eluent. As a result, 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)prop-2-en -1-one (10 mg, 0.022 mmol, 88%) was obtained as a grey-white solid.
Example 15: Preparation of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Step 1: Preparation of 1-(6-((3-((2,6-dichlorophenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000121
A target compound was prepared by the same manner as described in Example 6 except that the compound prepared in Preparative Example B-3 was used instead of the compound of Preparative Example B-1 in Example 6.
1H NMR (300 MHz, CDCl3) δ 8.10 (s, 1H), 7.57 (d, J = 8.6 Hz, 2H), 7.44 (s, 1H), 7.42 (s, 1H), 7.38 (s, 1H), 7.20 - 7.09 (m, 2H), 6.38 (s, 1H), 4.79-4.75 (m, 2H), 3.96 - 3.83 (m, 5H), 3.02-2.96 (m, 2H); LC/MS 537.2 [M + H+].
Step 2: Preparation of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000122
A target compound was prepared by the same manner as described in Example 7 except that the compound prepared in step 1 above was used instead of the compound of Example 6 in Example 7.
Example 16: Preparation of 1-(6-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone
Figure PCTKR2018005478-appb-I000123
A target compound was prepared by the same manner as described in Example 13 except that the compound of Example 15 was used instead of the compound of Example 12 in Example 13.
Example 17: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000124
Formalin (35%) (1.5 mg, 0.05 mmol) was added to MeOH (1.0 mL) and acetic acid (0.1 mL) containing the compound of Example 2 (1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)prop-2-en -1-one, 10 mg, 0.025 mmol) at 0℃, followed by stirring at room temperature for 30 minutes. NaCNBH3 (2.3 mg, 0.037 mmol) was added to the reaction mixture, which was stirred for 30 minutes. The reaction mixture was quenched with NaHCO3 solution, followed by extraction with EtOAc. The reactant was dried over sodium sulfate and concentrated. The obtained crude mixture was purified by column chromatography using MeOH/MC as an eluent. As a result, N3-(2,6-dimethylphenyl)-1-methyl-N6-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine (8.0 mg, 0.019 mmol, 77%) was obtained as a grey-white solid.
Example 18: Preparation of N3-(2,6-dimethylphenyl)-N6-(isochroman-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000125
The compound prepared in Preparative Example A-4 (25 mg, 0.165 mmol), and pTSA.H2O (33 mg, 0.173 mmol) were added to IPA (1.0 mL) solution containing the compound prepared in Preparative Example B-1 (50 mg, 0.173 mmol) at room temperature, followed by stirring at 90℃ for 12 hours. TLC analysis indicated the complete consumption of the starting material. The solid obtained from the reaction mixture was filtered and washed with ethanol (2 mL). The filtered solid was dissolved in EtOAc (50 mL) and washed with saturated NaHCO3 solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using MeOH/DCM (1/4) as an eluent. As a result, N3-(2,6-dimethylphenyl)-N6-(isochroman-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine (50 mg, 0.125 mmol, 75%) was obtained as a grey-white solid.
Example 19: Preparation of N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Step 1: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000126
A target compound was prepared by the same manner as described in Example 9 except that the compound of Preparative Example B-4 was used instead of the compound of Preparative Example B-2 in Example 9.
1H NMR (300 MHz, CDCl3) δ 9.65 (s, br, 1H), 7.63 (s, 1H), 7.58-7.52 (m, 1H), 7.38-7.31 (m, 2H), 7.23-7.14 (m, 3H), 7.11 (t, J = 8.1 Hz, 1H), 6.05 (s, 1H), 4.80-4.75 (m, 2H), 3.89-3.82 (m, 2H), 2.97-2.86 (m, 2H), 2.29 (s, 6H); LC/MS 481.9 [M + H+].
Step 2: Preparation of N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000127
A target compound was prepared by the same manner as described in Example 10 except that the compound prepared in step 1 above was used instead of the compound of Example 9 in Example 10.
Example 20: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000128
Step 1: A target compound was prepared by the same manner as described in Example 3 except that 1-methyl-1,2,3,4-tetrahydroisoquinoline-7-amine was used instead of 1-(6-amino-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one in Example 3.
Step 2: A target compound was prepared by the same manner as described in Example 4 except that the compound prepared in step 1 above was used instead of the compound of Example 3 in Example 4.
Example 21: Preparation of N3-(2,6-dimethylphenyl)-N6-(2-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000129
Acetone (0.01 mL) and NaCNBH3 (9.4 mg, 0.15 mmol) were added to MeOH (4 mL) and acetic acid solution (0.05 mL) containing the compound of Example 2 (40 mg, 0.10 mmol) at room temperature, followed by stirring at room temperature for 10 hours. The aqueous solution layer was washed with pH 2 DCM (2 X 25 mL). The combined organic layer was dried over Na2SO4, and the solvent was eliminated under reduced pressure. The residue mixture was purified by silica gel column chromatography using DCM/MeOH (9/1) as an eluent. As a result, the target compound (17 mg, 0.038 mmol, 39%) was obtained as a yellow solid.
Example 22: Preparation of 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxyethanone
Figure PCTKR2018005478-appb-I000130
Glycolic acid (9.2 mg, 0.12 mmol), HATU (56 mg, 0.15 mmol) and DIPEA (0.44 mL, 0.25 mmol) were added to THF (4 mL) and DMF (2 mL) containing the compound of Example 2 (40 mg, 0.10 mmol) at room temperature, followed by stirring at room temperature for 10 hours. The reaction was terminated with water and brine, followed by extraction with EtOAc (2 X 25 mL). The combined organic layer was dried over Na2SO4, and the solvent was eliminated under reduced pressure. The residue mixture was purified by silica gel column chromatography using DCM/MeOH (9/1) as an eluent. As a result, the target compound (27 mg, 0.059 mmol, 59%) was obtained as a white solid.
Example 23: Preparation of cyclopropyl(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)methanone
Figure PCTKR2018005478-appb-I000131
A target compound was prepared by the same manner as described in Example 22 except that cyclopropanecarboxylic acid was used instead of glycolic acid in Example 22.
Example 24: Preparation of 2-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-ol
Figure PCTKR2018005478-appb-I000132
A target compound was prepared by the same manner as described in Example 22 except that iodoethanol was used instead of glycolic acid in Example 22.
Example 25: Preparation of 1-cyclopentyl-N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000133
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-5 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 26: Preparation of 1-cyclohexyl-N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000134
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-6 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 27: Preparation of N3-(2,6-dimethylphenyl)-1-isopropyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000135
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-7 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 28: Preparation of N-(4-methyl-3-((1-methyl-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(trifluoromethyl)benzamide
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-8 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 29: Preparation of N-(2,4-dimethyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)-3-(trifluoromethyl)benzamide
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-9 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 30: Preparation of N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-10 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 31: Preparation of 2-(dimethylamino)-1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethanone
Figure PCTKR2018005478-appb-I000136
A target compound was prepared by the same manner as described in Example 22 except that N,N-dimethylglycine was used instead of glycolic acid in Example 22.
Example 32: Preparation of N3-(2,6-dimethylphenyl)-N6-(2-ethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000137
A target compound was prepared by the same manner as described in Example 22 except that iodoethane was used instead of glycolic acid in Example 22.
Example 33: Preparation of N3-(2,6-dimethyl-4-phenoxyphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-11 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 34: Preparation of 3,5-dimethyl-4-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)-N-(pyridine-2-yl)benzamide
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-12 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 35: Preparation of N3-(4-methoxy-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-13 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 36: Preparation of N3-(2,6-diethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-14 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 37: Preparation of N3-(2,6-diisopropylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-15 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 38: Preparation of N3-(2-chloro-3,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 10 except that the compound of Preparative Example B-16 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 39: Preparation of N3-(2,4-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-17 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 40: Preparation of 1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-o-tolyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-18 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 41: Preparation of N3-(3,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-19 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 42: Preparation of N3-(2,6-difluorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-20 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 43: Preparation of N3-(2,6-dimethoxyphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-21 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 44: Preparation of N3-(4-fluoro-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-22 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 45: Preparation of N3-(2,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-23 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 46: Preparation of N6-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 20 except that the compound of Preparative Example A-5 was used instead of 1-methyl-1,2,3,4-tetrahydroisoquinoline-7-amine in Example 20.
Example 47: Preparation of N-(4-methyl-3-(1-methyl-6-(1-methyl-1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)-3-(trifluoromethyl)benzamide
A target compound was prepared by the same manner as described in Example 20 except that the compound of Preparative Example B-8 was used instead of the compound of Preparative Example B-1 in Example 20.
Example 48: Preparation of N3-(2-chloro-6-methylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-24 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 49: Preparation of N3-(2,6-dimethylphenyl)-N6-(1-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 20 except that the compound of Preparative Example A-6 was used instead of 1-methyl-1,2,3,4-tetrahydroisoquinoline-7-amine in Example 20.
Example 50: Preparation of N3-(5-(2-methoxyethoxy)-2-methylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-25 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 51: Preparation of N-(4-methyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)picolineamide
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-26 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 52: Preparation of 4-methyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide
A target compound was prepared by the same manner as described in Example 19 except that the compound of Preparative Example B-27 was used instead of the compound of Preparative Example B-4 in Example 19.
Example 53: Preparation of N6-(3,3-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
A target compound was prepared by the same manner as described in Example 20 except that 3,3-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-amine was used instead of 1-methyl-1,2,3,4-tetrahydroisoquinoline-7-amine in Example 20.
Example 54: Preparation of 4-(3-((2,6-dimethylphenyl)amino)-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-1-yl)cyclohexane-1-ol
Step 1: Preparation of tert-butyl2-(1,4-dioxaspiro[4.5]decane-8-yl)hydrazine-1-carboxylate
Figure PCTKR2018005478-appb-I000138
Methanol (30 mL) solution containing 1,4-dioxaspiro[4.5]decane-8-one (1.0 g, 6.40 mmol) and t-butylcarbazate (0.84 g, 6.40 mmol) was stirred at room temperature for 20 hours. Then, the reaction mixture was concentrated under reduced pressure. Acetic acid, water, and NaCNBH3 (400 mg, 6.40 mmol) were added thereto, followed by stirring at room temperature for 3 hours. Upon completion of the reaction, the reaction mixture was concentrated under reduced pressure, and the residue was basified with 1 NaOH (pH 8). The residue was diluted with DCM, and the organic layer was concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc/Hx (1:2). As a result, the target compound (1.34 g, 4.92 mmol, 77%) was obtained as a white solid.
1H NMR (500 MHz, CDCl3) δ 6.13 (s, 1H), 4.02 (s, 1H), 3.92 (s, 4H), 3.00 - 2.85 (m, 1H), 1.84 - 1.72 (m, 4H), 1.58 - 1.46 (m, 4H), 1.44 (s, 9H); LC/MS 273.2 [M + H+].
Step 2: Preparation of tert-butyl-2-(2-chloro-5-((2,6-dimethylphenyl)carbamoyl)pyridine-4-yl-2-(1,4-dioxaspiro[4.5]decane-8-yl)hydrazine-1-carboxylate
Figure PCTKR2018005478-appb-I000139
The compound prepared in step 1 above (202 mg, 0.742 mmol) and Et3N (0.24 mL, 1.68 mmol) were added to THF (10 mL) solution containing the compound prepared in step 2 of Preparative Example B-1 (200 mg, 0.675 mmol) at room temperature, followed by stirring at room temperature for 12 hours. The mixture was concentrated under reduced pressure. The reaction mixture was washed with water, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The crude product was purified by column chromatography (EtOAc/Hx (1/4)). As a result, the target compound (200 mg, 0.375 mmol, 55%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.68 (s, 1H), 8.42 (s, 1H), 7.23 - 7.11 (m, 3H), 6.98 (s, 1H), 4.36 (s, 1H), 3.96 (s, 4H), 2.32 (s, 6H), 2.07 (s, 1H), 1.87 - 1.67 (m, 7H), 1.43 (s, 9H); LC/MS 532.9 [M + H+].
Step 3: Preparation of 6-chloro-N-(2,6-dimethylphenyl)-1-(1,4-dioxaspiro[4.5]decane-8-yl)-1H-pyrazole[3,4-d]pyrimidine-3-amine
Figure PCTKR2018005478-appb-I000140
PCl5 (78 mg, 0.375 mmol) was added to toluene (20 mL) solution containing the compound prepared in step 2 above (200 mg, 0.375 mmol) at room temperature, followed by stirring at 110°C for 3 hours. The mixture was concentrated under reduced pressure to eliminate toluene. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The crude product was purified by column chromatography (EtOAc/Hx (1/4)). As a result, the target compound (80 mg, 0.193 mmol, 51%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.48 (s, 1H), 7.25 - 7.12 (m, 3H), 6.17 (s, 1H), 4.72 (tt, J = 11.7, 3.9 Hz, 1H), 4.01 (s, 4H), 2.43 - 2.27 (m, 2H), 2.25 (s, 6H), 2.02 - 1.89 (m, 4H), 1.87 - 1.73 (m, 2H); LC/MS 413.9 [M + H+].
Step 4: Preparation of 4-(6-chloro-3-((2,6-dimethylphenyl)amino)-1H-pyrazole[3,4-d]pyrimidine-1-yl)cyclohexane-1-one
Figure PCTKR2018005478-appb-I000141
2 N HCl (3.0 mL) was added to acetone (10 mL) solution containing the compound prepared in step 3 above (60 mg, 0.145 mmol) at room temperature, followed by stirring at 50°C for 3 hours. The mixture was concentrated under reduced pressure to eliminate acetone. The reaction mixture was washed with sodium bicarbonate, and the organic layer was dried over sodium sulfate, followed by concentration under reduced pressure. The crude product was purified by column chromatography (EtOAc/Hx (1/4)). As a result, the target compound (45 mg, 0.121 mmol, 84%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.56 (s, 1H), 7.27 - 7.13 (m, 3H), 6.12 (s, 1H), 5.19 - 5.05 (m, 1H), 2.67 - 2.40 (m, 6H), 2.35 - 2.28 (m, 2H), 2.26 (s, 6H); LC/MS 369.9 [M + H+].
Step 5: Preparation of 4-(6-chloro-3-((2,6-dimethylphenyl)amino)-1H-pyrazole[3,4-d]pyrimidine-1-yl)cyclohexane-1-ol
Figure PCTKR2018005478-appb-I000142
NaBH4　(1.53 mg, 0.040 mmol) MeOH was slowly added to methanol (1.0 mL) solution containing the compound prepared in step 4 above (15 mg, 0.040 mmol) at room temperature. Then, methanol was eliminated therefrom, and the residue was extracted with EtOAc (2 x 20 mL). The EtOAc layer was dried over MgSO4, and filtered, followed by reducing pressure. The obtained crude product was purified by column chromatography (EtOAc/Hx (1/4)). As a result, the target compound (8 mg, 0.021 mmol, 53%) was obtained as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.50 (s, 1H), 7.24 - 7.15 (m, 3H), 6.12 (s, 1H), 4.74 - 4.60 (m, 1H), 3.87 - 3.68 (m, 1H), 2.26 (s, 6H), 2.19 - 2.11 (m, 2H), 2.05 - 1.98 (m, 2H), 1.65 - 1.49 (m, 4H); LC/MS 372.2 [M + H+].
Step 6: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidine-1-yl)amino)-3,4-dihydroquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000143
A target compound was prepared by the same manner as described in Example 9 except that the compound of Preparative Example B-4 was used instead of the compound of Preparative Example B-2 in Example 9.
1H NMR (300 MHz, CDCl3) δ 7.73 - 7.61 (m, 1H), 7.44 - 7.30 (m, 2H), 7.25 - 7.07 (m, 5H), 5.92 (d, J = 4.6 Hz, 1H), 4.85 - 4.76 (m, 2H), 4.52 - 4.39 (m, 1H), 3.95 - 3.86 (m, 2H), 3.85 - 3.75 (m, 1H), 2.95 (q, J = 5.9 Hz, 2H), 2.29 (s, 6H), 2.26 - 2.12 (m, 4H), 2.11 - 2.08 (m, 2H), 1.65 - 1.47 (m, 4H); LC/MS 580.2 [M + H+].
Step 7: Preparation of 4-(3-((2,6-dimethylphenyl)amino)-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-1-yl)cyclohexane-1-ol
Figure PCTKR2018005478-appb-I000144
A target compound was prepared by the same manner as described in Example 10 except that the compound prepared in step 1 above was used instead of the compound of Example 9 in Example 10.
Example 55: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,3,3-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Step 1: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000145
1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (47.2 mg, 0.165 mmol) and pTSA.H2O (33 mg, 0.173 mmol) were added to IPA (1.0 mL) solution containing the compound prepared in Preparative Example B-1 (6-CHLORO-N-(2,6-DIMETHYLPHENYL)-1-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE-3-AMINE (50 mg, 0.173 mmol)) at room temperature, followed by stirring at 90°C for 12 hours. TLC analysis indicated the complete consumption of the starting material. The solid obtained from the reaction mixture was filtered and washed with ethanol (2.0 mL). The filtered solid was dissolved in EtOAc (50 mL), which was washed with sat. NaHCO3 solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography (MeOH/DCM (1/4)). As a result, 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (70 mg, 0.130 mmol, 75%) was obtained as a light yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.65 (d, J = 2.2 Hz, 1H), 7.48 (dd, J = 8.1, 2.2 Hz, 1H), 7.42 (s, 1H), 7.35 (s, 1H), 7.17 (d, J = 7.8 Hz, 4H), 6.03 (s, 1H), 5.02 (q, J = 6.9 Hz, 1H), 3.82 (s, 3H), 3.36 (d, J = 15.4Hz, 1H), 2.65 (d, J = 15.4Hz, 1H), 2.29 (s, 6H), 1.80 (s, 3H), 1.60 (d, J = 6.9 Hz, 3H), 1.31 (s, 3H); LC/MS 538.2 [M + H+].
Step 2: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,3,3-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000146
MeOH (1 mL), H2O (0.5 mL), and lithium hydroxide monohydrate (15.5 mg, 0.372 mmol) were added to 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one (50 mg, 0.093 mmol) THF (5 mL) solution at room temperature, followed by stirring at 70°C for 48 hours. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was concentrated to eliminate THF. Methanol and water (5 mL) were added thereto, followed by extraction with EtOAc (15 mL X 2). The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography (MeOH/DCM (1:9)). As a result, the target compound (30 mg, 0.067 mmol, 73%) was obtained as a light yellow solid.
Example 56: Preparation of tert-butyl-5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-carboxylate
Step 1: Preparation of 1-(5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000147
A target compound was prepared by the same manner as described in step 1 of Example 55 except that the compound prepared in Preparative Example A-8 was used instead of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
1H NMR (300 MHz, CDCl3) δ 7.85 (d, J = 15.6 Hz, 1H), 7.52 - 7.45 (m, 1H), 7.44 (s, 1H), 7.31 - 7.24 (m, 2H), 7.23 - 7.15 (m, 3H), 5.92 (s, 1H), 5.04 (d, J = 10.4Hz, 2H), 4.93 (d, J = 13.3 Hz, 2H), 3.84 (s, 3H), 2.30 (s, 6H); LC/MS 482.2 [M + H+]
Step 2: Preparation of tert-butyl-5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-carboxylate
Figure PCTKR2018005478-appb-I000148
A target compound was prepared by the same manner as described in step 2 of Example 55 except that 1-(5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-yl)-2,2,2-trifluoroethane-1-one prepared in step 1 above was used instead of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 7.5 Hz, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.42 (s, 1H), 7.37 (s, 1H), 7.25 - 7.11 (m, 4H), 5.99 (s, 1H), 4.76 - 4.61 (m, 4H), 3.82 (d, J = 2.6 Hz, 3H), 2.29 (s, 6H), 1.54 (s, 9H); LC/MS 486.2 [M + H+].
Step 3: Preparation of N3-(2,6-dimethylphenyl)-N6-(isoindolin-5-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine hydrochloride
Figure PCTKR2018005478-appb-I000149
4.0 N HCl dioxane (0.2 mL) solution was added to tert-butyl-5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-carboxylate (22 mg, 0.045 mmol) DCM (5 mL) solution at room temperature, followed by stirring at room temperature for 1 hour. TLC analysis indicated the complete consumption of the starting material. The solid obtained from the reaction mixture was filtered and washed with DCM. As a result, the target compound (N3-(2,6-dimethylphenyl)-N6-(isoindolin-5-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine hydrochloride (16 mg, 0.041 mmol, 84%)) was obtained as a white solid HCL salt.
Example 57: Preparation of 1-(4-methyl-3-((1-methyl-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea
Step 1: Preparation of 1-(4-methyl-3-((1-methyl-6-((2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea
Figure PCTKR2018005478-appb-I000150
A target compound was prepared by the same manner as described in step 1 of Example 55 except that the compound prepared in Preparative Example B-28 was used instead of the compound prepared in Preparative Example B-1 and the compound prepared in Preparative Example A-2 was used instead of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
1H NMR (300 MHz, MeOD) δ 8.48 (s, 1H), 7.72 - 7.46 (m, 5H), 7.34 (t, J = 7.9 Hz, 1H), 7.20 (d, J = 7.7 Hz, 1H), 7.17 - 7.04 (m, 3H), 4.83 - 4.71 (m, 2H), 3.87 - 3.81 (m, 2H), 3.81 - 3.75 (m, 3H), 2.98 - 2.88 (m, 3H), 2.25 (s, 3H); LC/MS 683.8 [M + H+].
Step 2: Preparation of 1-(4-methyl-3-((1-methyl-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea
Figure PCTKR2018005478-appb-I000151
A target compound was prepared by the same manner as described in step 2 of Example 55 except that 1-(4-methyl-3-((1-methyl-6-((2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea prepared in step 1 above was used instead of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
Example 58: Preparation of N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Step 1: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one
Figure PCTKR2018005478-appb-I000152
A target compound was prepared by the same manner as described in step 1 of Example 55 except that the compound prepared in Preparative Example A-9 was used instead of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
1H NMR (300 MHz, CDCl3) δ 7.94 (s, 1H), 7.42 (s, 1H), 7.28 - 7.21 (m, 2H), 7.20 - 7.13 (m, 3H), 7.06 (d, J = 8.2 Hz, 1H), 5.91 (s, 1H), 3.80 (s, 3H), 3.66 (t, J = 5.2 Hz, 2H), 2.87 (t, J = 5.2 Hz, 2H), 2.27 (s, 6H), 1.88 (s, 6H); LC/MS 523.9 [M + H+].
Step 2: Preparation of N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000153
A target compound was prepared by the same manner as described in step 2 of Example 55 except that 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one prepared in step 1 above was used instead of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
Example 59: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,1,2-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000154
A target compound was prepared by the same manner as described in Example 17 except that N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine prepared in Example 58 was used instead of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 60: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000155
A target compound was prepared by the same manner as described in Example 13 except that N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine prepared in Example 58 was used instead of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 61: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1-methyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000156
A target compound was prepared by the same manner as described in Example 13 except that the compound prepared in Example 20 was used instead of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 62: Preparation of N6-(1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000157
A target compound was prepared by the same manner as described in Example 17 except that the compound prepared in Example 20 was used instead of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 63: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000158
A target compound was prepared by the same manner as described in Example 17 except that the compound prepared in Example 46 was used instead of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 64: Preparation of N-(3-((6-((1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(trifluoromethyl)benzamide
Figure PCTKR2018005478-appb-I000159
A target compound was prepared by the same manner as described in Example 17 except that the compound prepared in Example 47 was used instead of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 65: Preparation of N3-(2,6-dimethylphenyl)-N6-(1-isopropyl-2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000160
A target compound was prepared by the same manner as described in Example 17 except that the compound prepared in Example 49 was used instead of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 66: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(2,3,3-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000161
A target compound was prepared by the same manner as described in Example 17 except that the compound prepared in Example 53 was used instead of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 67: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,3-tetramethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000162
A target compound was prepared by the same manner as described in Example 17 except that the compound prepared in Example 55 was used instead of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 68: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-4,4-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000163
A target compound was prepared by the same manner as described in Example 13 except that the compound prepared in Example 46 was used instead of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 69: Preparation of N-(3-((6-((2-acetyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(trifluoromethyl)benzamide
Figure PCTKR2018005478-appb-I000164
A target compound was prepared by the same manner as described in Example 13 except that the compound prepared in Example 47 was used instead of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 70: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000165
A target compound was prepared by the same manner as described in Example 13 except that the compound prepared in Example 49 was used instead of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 71: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,3-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000166
A target compound was prepared by the same manner as described in Example 13 except that the compound prepared in Example 53 was used instead of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 72: Preparation of 1-(5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000167
A target compound was prepared by the same manner as described in Example 13 except that the compound prepared in Example 56 was used instead of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 73: Preparation of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000168
A target compound was prepared by the same manner as described in Example 13 except that the compound prepared in Example 55 was used instead of N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 74: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(2-methylisoindolin-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000169
A target compound was prepared by the same manner as described in Example 17 except that the compound prepared in Example 56 was used instead of N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
Example 75: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(5,6,7,8-tetrahydronaphthalene-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000170
A target compound was prepared by the same manner as described in step 1 of Example 55 except that 5,6,7,8-tetrahydronaphthalene-2-amine was used instead of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
Example 76: Preparation of N-(4-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)phenyl)acrylamide
Figure PCTKR2018005478-appb-I000171
A target compound was prepared by the same manner as described in step 1 of Example 55 except that the compound prepared in Preparative Example A-10 was used instead of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
Example 77: Preparation of 7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-1(2H)-one
Figure PCTKR2018005478-appb-I000172
A target compound was prepared by the same manner as described in step 1 of Example 55 except that the compound prepared in Preparative Example A-11 was used instead of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
Example 78: Preparation of N6-(1-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Step 1: Preparation of 2,2,2-trifluoro-1-(1-isopropyl-7-((3-((4-(2-methoxyethoxy)-2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000173
A target compound was prepared by the same manner as described in step 1 of Example 55 except that the compound prepared in Preparative Example B-10 was used instead of the compound prepared in Preparative Example B-1 and the compound prepared in Preparative Example A-6 was used instead of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
1H NMR (300 MHz, CDCl3) δ 7.74 - 7.57 (m, 1H), 7.42 - 7.35 (m, 2H), 7.28 (s, 1H), 7.12 (dd, J = 8.3, 3.8 Hz, 1H), 6.75 (s, 2H), 5.85 (s, 1H), 5.25 (d, J = 9.0 Hz, 0.8H), 4.59 - 4.43 (m, 0.2H), 4.42 - 4.36 (m, 0.2H), 4.18 - 4.12 (m, 2H), 4.10 - 3.98 (m, 0.8H), 3.81 (s, 3H), 3.80 - 3.77 (m, 2H), 3.76 - 3.72 (m, 1H), 3.50 (s, 3H), 3.10 - 2.92 (m, 2H), 2.25 (s, 6H), 2.21 - 2.09 (m, 1H), 1.21 - 1.00 (m, 6H); LC/MS 611.9 [M + H+].
Step 2: Preparation of N6-(1-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000174
A target compound was prepared by the same manner as described in step 2 of Example 55 except that 2,2,2-trifluoro-1-(1-isopropyl-7-((3-((4-(2-methoxyethoxy)-2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one prepared in step 1 above was used instead of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
Example 79: Preparation of N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Step 1: Preparation of 2,2,2-trifluoro-1-(7-((3-((4-(2-methoxyethoxy)-2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one
Figure PCTKR2018005478-appb-I000175
A target compound was prepared by the same manner as described in step 1 of Example 55 except that the compound prepared in Preparative Example B-10 was used instead of the compound prepared in Preparative Example B-1 and the compound prepared in Preparative Example A-9 was used instead of 1-(7-amino-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
1H NMR (300 MHz, CDCl3) δ 7.95 (s, 1H), 7.40 (s, 1H), 7.32 - 7.29 (m, 1H), 7.22 (s, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.75 (s, 2H), 5.81 (s, 1H), 4.15 (dd, J = 5.7, 3.6 Hz, 2H), 3.81 (s, 3H), 3.79 (dd, J = 3.8, 2.5 Hz, 2H), 3.72 - 3.66 (m, 2H), 3.50 (s, 3H), 2.90 (d, J = 5.2 Hz, 2H), 2.26 (s, 6H), 1.91 (s, 6H); LC/MS 597.9 [M + H+].
Step 2: Preparation of N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000176
A target compound was prepared by the same manner as described in step 2 of Example 55 except that 2,2,2-trifluoro-1-(7-((3-((4-(2-methoxyethoxy)-2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one prepared in step 2 above was used instead of 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethane-1-one.
The chemical structures of the compounds of Examples 1 to 79 according to the present invention are shown in Tables 1 and 2 below, and the analytical data on the compound structure are shown in Tables 3 to 5 below.
Figure PCTKR2018005478-appb-T000001
Figure PCTKR2018005478-appb-I000177
Figure PCTKR2018005478-appb-I000178
Figure PCTKR2018005478-appb-T000002
Figure PCTKR2018005478-appb-I000179
Figure PCTKR2018005478-appb-I000180
Example NMR/ Mass Data
1 1H NMR (300 MHz, CDCl3) δ 9.65-9.63 (m, 1H), 8.35 (s, 1H), 8.10 (s, 1H), 7.68 (s, 1H), 7.62 (d, J = 8.3 Hz, 1H), 7.11-7.09 (m, 4H), 4.62-4.57 (m, 2H), 3.67-3.65 (m, 2H), 3.62 (s, 3H), 2.80-2.69 (m, 2H), 2.20 (s, 6H), 2.10-2.08 (m, 3H); LC/MS 442.2 [M + H+].
2 1H NMR (300 MHz, CDCl3) δ 7.39-7.37 (m, 2H), 7.34 (s, br, 1H), 7.18-7.12 (m, 3H), 7.07-7.03 (m, 2H), 5.85 (s, br, 1H), 4.02 (s, 2H), 3.79 (s, 3H), 3.14 (t, J = 6.0 Hz, 2H), 2.76 (t, J = 5.8 Hz, 2H), 2.26 (s, 6H), 1.77 (s, br, 1H); LC/MS 400.2 [M + H+].
3 1H NMR (500 MHz, CDCl3) δ 8.46-8.45 (m, 1H), 7.77 (s, 1H), 7.45 (s, 1H), 7.20-7.16 (m, 3H), 6.65-6.62 (m, 1H), 5.94 (s, br, 1H), 4.77-4.72 (m, 2H), 3.97-3.86 (m, 5H), 3.84 (s, 3H), 2.99-2.95 (m, 2H), 2.29 (s, 6H); LC/MS 526.2 [M + H+].
4 1H NMR (300 MHz, CDCl3) δ 8.32 (s, 1H), 7.69 (s, 1H), 7.41 (s, 1H), 7.18-7.11 (m, 3H), 6.51 (s, 1H), 5.87 (s, br, 1H), 3.97 (s, 2H), 3.83 (s, 3H), 3.81 (s, 3H), 3.14 (t, J = 5.9 Hz, 2H), 2.78 (t, J = 5.7 Hz, 2H), 2.27 (s, 6H), 1.80 (s, br, 1H); LC/MS 430.2 [M + H+].
5 1H NMR (300 MHz, CDCl3) δ 8.41-8.38 (m, 1H), 7.75 (s, 1H), 7.41 (s, 1H), 7.20-7.13 (m, 3H), 6.63-6.59 (m, 1H), 6.07 (s, br, 1H), 4.68-4.57 (m, 2H), 3.87-3.83 (m, 4H), 3.81 (s, 3H), 3.67 (t, J = 5.8 Hz, 1H), 2.91-2.81 (m, 2H), 2.27 (s, 6H), 2.18-2.17 (m, 3H); LC/MS 472.2 [M + H+].
6 1H NMR (500 MHz, CDCl3) δ 7.54-7.52 (m, 2H), 7.43 (s, 1H), 7.21-7.08 (m, 5H), 5.93 (s, 1H), 4.78-4.74 (m, 2H), 3.92-3.85 (m, 2H), 3.82 (s, 3H), 3.00-2.95 (m, 2H), 2.29 (s, 6H); LC/MS 496.2 [M + H+].
7 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 8.3 Hz, 1H), 7.42 (s, 1H), 7.41 (s, 1H), 7.20 (s, br, 1H), 7.17-7.15 (m, 3H), 6.99 (d, J = 8.3 Hz, 1H), 5.95 (s, 1H), 4.01 (s, 2H), 3.81 (s, 3H), 3.16 (t, J = 5.9 Hz, 2H), 2.83 (t, J = 5.8 Hz, 2H), 2.29 (s, 6H), 1.87 (s, br, 1H);LC/MS 400.2 [M + H+].
8 1H NMR (500 MHz, CDCl3) δ 7.81-7.70 (m, 1H), 7.56-7.52 (m, 2H), 7.38 (s, 1H), 7.21-7.16 (m, 3H), 7.14-7.07 (m, 1H), 6.13 (s, 1H), 4.72-4.61 (m, 2H), 3.84 (t, J = 5.9 Hz, 1H), 3.82 (s, 3H), 3.69 (t, J = 5.9 Hz, 1H), 2.94-2.86 (m, 2H), 2.29 (s, 6H), 2.21-2.20 (m, 3H); LC/MS 442.2 [M + H+].
9 1H NMR (300 MHz, CDCl3) δ 8.62-8.61 (m, 1H), 7.70-7.61 (m, 1H), 7.56 - 7.32 (m, 6H), 7.18 (t, J = 8.5 Hz, 1H), 7.03 (t, J = 7.2 Hz, 1H), 6.46 (s, 1H), 4.85-4.79 (m, 2H), 3.96 - 3.86 (m, 5H), 2.98 - 2.95 (m, 2H);LC/MS 468.2 [M + H+]
10 1H NMR (500 MHz, DMSO) δ 9.64 (s, 1H), 9.30 (s, 1H), 9.00 (s, 1H), 7.68 (d, J = 7.8 Hz, 2H), 7.59 (d, J = 8.3 Hz, 1H), 7.55 (s, 1H), 7.31 (t, J = 7.9 Hz, 2H), 7.00 (d, J = 8.3 Hz, 1H), 6.88 (t, J = 7.3 Hz, 1H), 3.84 (s, 2H), 3.78 (s, 3H), 2.94 (t, J = 5.8 Hz, 2H), 2.64 (t, J = 5.6 Hz, 2H); LC/MS 372.2 [M + H+].
11 1H NMR (300 MHz, CDCl3) δ 8.09-8.08 (m, 1H), 7.69 - 7.59 (m, 1H), 7.52 - 7.41 (m, 4H), 7.16 (t, J = 8.1 Hz, 2H), 6.44 (s, 1H), 4.83-4.77 (m, 2H), 3.94 - 3.86 (m, 5H), 2.97 - 2.94 (m, 2H); LC/MS 536.2 [M + H+].
12 1H NMR (500 MHz, DMSO) δ 9.60 (s, 1H), 8.71 (s, 1H), 8.68 (s, 1H), 7.56 (d, J = 8.1 Hz, 3H), 7.52 (s, 1H), 7.30 (t, J = 8.1 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 3.83 (s, 2H), 3.63 (s, 3H), 2.94 (t, J = 5.8 Hz, 2H), 2.63 (t, J = 5.7 Hz, 2H); LC/MS 441.2 [M + H+].
13 1H NMR (500 MHz, CDCl3) δ 8.08-8.06 (m, 1H), 7.65-7.41 (m, 5H), 7.17-7.12 (m, 2H), 6.46 (s, 1H), 4.77-4.64 (m, 2H), 3.85 (s, 3H), 3.70 (t, J = 5.9 Hz, 2H), 2.91-2.83 (m, 2H), 2.21-2.20 (m, 3H); LC/MS 483.2 [M + H+].
14 1H NMR (500 MHz, CDCl3) δ 7.64-7.51 (m, 1H), 7.43-7.33 (m, 2H), 7.23-7.03 (m, 5H), 6.70-6.64 (m, 1H), 6.36 (d, J = 16.7 Hz, 1H), 5.93 (s, 1H), 5.75 (d, J = 10.6 Hz, 1H), 4.83-4.74 (m, 2H), 3.91-3.79 (m, 5H), 2.90-2.88 (m, 2H), 2.29-2.27 (m, 6H); LC/MS 454.2 [M + H+].
15 1H NMR (300 MHz, CDCl3) δ 8.08 (s, 1H), 7.48 (d, J = 8.5 Hz, 1H), 7.44 (s, 2H), 7.41 (s, 1H), 7.25 (s, 1H), 7.15 (t, J = 8.1 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.34 (s, 1H), 4.02 (s, 2H), 3.86 (s, 3H), 3.17 (t, J = 6.0 Hz, 2H), 2.84 (t, J = 5.7 Hz, 2H); LC/MS 441.2 [M + H+].
16 1H NMR (300 MHz, CDCl3) δ 8.07 (s, 1H), 7.52-7.50 (m, 2H), 7.42 (s, 1H), 7.39 (s, 1H), 7.34 (s, 1H), 7.18 - 7.05 (m, 2H), 6.36 (s, 1H), 4.70-4.59 (m, 2H), 3.83 (s, 3H), 3.82-3.81 (m, 1H), 3.68 (t, J = 5.9 Hz, 1H), 2.94-2.84 (m, 2H), 2.18-2.17 (m, 3H); LC/MS 483.2 [M + H+].
17 1H NMR (300 MHz, CDCl3) δ 7.43-7.40 (m, 3H), 7.20-7.15 (m, 3H), 7.10-7.08 (m, 2H), 5.86 (s, 1H), 3.82 (s, 3H), 3.64 (s, 2H), 2.92 (t, J = 5.8 Hz, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.50 (s, 3H), 2.29 (s, 6H) ); LC/MS 414.2 [M + H+].
18 1H NMR (300 MHz, CDCl3) δ 7.39-7.36 (m, 3H), 7.20-7.11 (m, 4H), 7.08 (d, J = 8.0 Hz, 1H), 5.91 (s, 1H), 4.78 (s, 2H), 3.97 (t, J = 5.7 Hz, 2H), 3.79 (s, 3H), 2.82 (t, J = 5.7 Hz, 2H), 2.26 (s, 6H).; LC/MS 401.2 [M + H+].
19 1H NMR (300 MHz, DMSO-d6) δ 11.86 (s, 1H), 9.39 (s, 1H), 8.34 (s, 1H), 7.92 (s, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.41 (s, 1H), 7.16-7.02 (m, 3H), 6.95 (d, J = 8.4 Hz, 1H), 3.79 (s, 2H), 2.92 (t, J = 5.6 Hz, 2H), 2.62 (d, J = 5.5 Hz, 2H), 2.19 (s, 6H); LC/MS 386.2 [M + H+].
20 1H NMR (500 MHz, CDCl3) δ 7.62 (s, 1H), 7.42 (s, 1H), 7.34 (dd, J = 8.2, 2.1 Hz, 1H), 7.31 (s, 1H), 7.20 7.15 (m, 3H), 7.06 (d, J = 8.2 Hz, 1H), 6.01 (s, 1H), 4.14 (q, J = 6.5 Hz, 1H), 3.82 (s, 3H), 3.30 (dt, J = 12.5, 5.0 Hz, 1H), 3.07 3.01 (m, 1H), 2.89-2.84 (m 1H), 2.73 (dt, J = 16.2, 4.4 Hz, 1H), 2.29 (s, 6H), 1.74 (s, br, 1H), 1.52 (d, J = 6.7 Hz, 3H).; LC/MS 414.2 [M + H+].
21 1H NMR (300 MHz, DMSO + D2O) δ 8.34 (s, 1H), 7.75 (s, 1H), 7.70-7.66 (m, 1H), 7.277.10 (m, 4H), 4.38 (d, J = 9.0 Hz, 2H), 3.67-3.61(m, 5H), 3.32-3.22 (m, 2H), 3.152.94 (m, 22H), 2.20 (s, 6H), 1.37 (d, J = 6.5 Hz, 6H); 441.9 [M + H+]
22 1H NMR (300 MHz, DMSO) δ 9.65-9.62 (m, 1H), 8.34 (s, 1H), 8.09 (s, 1H), 7.737.59 (m, 2H), 7.167.04 (m, 4H), 4.63-4.54 (m, 3H), 4.19-4.17 (m, 2H), 3.733.53 (m, 5H), 2.82-2.69 (m, 2H), 2.20 (s, 6H).457.9 [M + H+]
23 1H NMR (300 MHz, CDCl3) δ 7.647.49 (m, 2H), 7.45-7.35 (m, 2H), 7.197.06 (m, 4H), 6.18 (s, 1H), 4.86-4.78 (m, 2H), 3.953.81 (m, 2H), 3.78 (s, 3H), 2.98-2.86 (m, 1H), 2.80 (s, 1H), 2.26 (s, 6H), 1.88-1.75 (m, 1H), 1.05-1.00 (m, 2H), 0.850.73 (m, 2H).467.9 [M + H+]
24 1H NMR (300 MHz, CDCl3) δ 7.45-7.36 (m, 3H), 7.33 (s, 1H), 7.18-7.16 (m, 3H), 7.08 (d, J = 7.9 Hz, 1H), 6.02 (s, 1H), 3.81 (s, 3H), 3.76-3.72 (m, 4H), 2.90-2.83 (m, 4H), 2.792.71 (m, 2H), 2.28 (s, 6H).443.9 [M + H+]
25 1H NMR (300 MHz, CDCl3) δ 7.3-7.33 (m, 3H), 7.21-7.10 (m, 3H), 7.06 7.01 (m, 2H), 5.86 (s, 1H), 4.99 (pent, J = 7.9 Hz, 1H), 4.02 (s, 2H), 3.14 (t, J = 5.9 Hz, 2H), 2.76 (t, J = 5.9 Hz, 2H), 2.27 (s, 6H), 2.20-2.05 (m, 4H), 2.03 1.89 (m, 2H), 1.84 (s, br, 1H), 1.76-1.68 (m, 2H); LC/MS 454.2 [M + H+].
26 1H NMR (300 MHz, CDCl3) δ 7.51 (s, 1H), 7.37 (s, 1H), 7.32 7.26 (m, 1H), 7.19 7.14 (m, 3H), 7.06 (d, J = 8.6 Hz, 2H), 5.97 (s, 1H), 4.51 4.38 (m, 1H), 4.05 (s, 2H), 3.17 (t, J = 6.0 Hz, 2H), 2.78 (t, J = 6.0 Hz, 2H), 2.29 (s, 6H), 2.10 1.99 (m, 4H), 1.99 1.90 (m, 2H), 1.82 1.75 (m, 1H), 1.53 1.40 (m, 2H), 1.38 1.27 (m, 1H); LC/MS 468.3 [M + H+].
27 1H NMR (300 MHz, CDCl3) δ 7.44 7.33 (m, 3H), 7.22 7.14 (m, 3H), 7.11 7.03 (m, 2H), 5.90 (s, 1H), 4.89 (sept, J = 6.7 Hz, 1H), 4.04 (s, 2H), 3.16 (t, J = 5.9 Hz, 2H), 2.78 (t, J = 5.9 Hz, 2H), 2.29 (s, 6H), 1.55 (d, J = 6.7 Hz, 6H); LC/MS 428.2 [M + H+].
Example NMR/ Mass Data
28 1H NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 8.10 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.94 (d, J = 2.2 Hz, 1H), 7.85 (s, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.60 (t, J = 7.8 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.39 (s, 1H), 7.28 (s, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.07 (d, J = 8.3 Hz, 1H), 6.16 (s, 1H), 4.03 (s, 2H), 3.85 (s, 3H), 3.16 (t, J = 6.0 Hz, 2H), 2.78 (t, J = 6.0 Hz, 2H), 2.32 (s, 3H), 1.77 (s, 2H).572.8 [M + H+]
29 1H NMR (300 MHz, CDCl3) δ 8.17 (s, 1H), 8.07 (d, J = 7.7 Hz, 1H), 7.98 (s, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.667.54 (m, 3H), 7.467.39 (m, 2H), 7.32 (s, 1H), 7.21 (d, J = 8.2 Hz, 1H), 7.05 (d, J = 8.2 Hz, 1H), 6.10 (s, 1H), 4.00 (s, 2H), 3.79 (s, 2H), 3.14 (t, J = 5.9 Hz, 2H), 2.77 (t, J = 5.9 Hz, 2H), 2.28 (s, 3H), 2.25 (s, 3H).586.9 [M + H+]
30 1H NMR (300 MHz, CDCl3) δ 7.417.33 (m, 3H), 7.20 (s, 1H), 7.04 (d, J = 8.1 Hz, 1H), 6.72 (s, 2H), 5.85 (s, 1H), 4.154.09 (m, 2H), 4.02 (s, 2H), 3.803.74 (m, 5H), 3.47 (s, 3H), 3.14 (t, J = 5.9 Hz, 2H), 2.76 (t, J = 5.9 Hz, 2H), 2.22 (s, 6H), 1.84 (s, 2H).473.9 [M + H+]
31 1H NMR (300 MHz, CDCl3) δ 7.60 (s, 1H), 7.457.33 (m, 3H), 7.17-7.07 (m, 5H), 5.87 (s, 1H), 4.76 (d, J = 9.6 Hz, 3H), 3.843.76 (m, 5H), 3.20 (s, 2H), 2.892.81 (m, 2H), 2.31 (s, 6H), 2.27 (s, 6H).484.9 [M + H+]
32 1H NMR (300 MHz, CDCl3) δ 7.447.34 (m, 3H), 7.257.10 (m, 4H), 7.06 (d, J = 8.1 Hz, 1H), 5.99 (s, 1H), 3.78 (s, 3H), 3.66 (s, 2H), 2.89 (t, J = 5.9 Hz, 2H), 2.77 (t, J = 5.9 Hz, 2H), 2.62 (q, J = 7.2 Hz, 2H), 2.26 (s, 26H), 1.281.18 (m, 3H).428.0 [M + H+]
33 1H NMR (300 MHz, CDCl3) δ 7.52 (s, 1H), 7.437.34 (m, 4H), 7.28 (s, 1H), 7.16 7.10 (m, 1H), 7.087.03 (m, 3H), 6.79 (s, 2H), 5.83 (s, 1H), 4.03 (s, 2H), 3.79 (s, 3H), 3.16 (t, J = 6.0 Hz, 2H), 2.78 (t, J = 6.0 Hz, 2H), 2.48 (s, 3H), 2.23 (s, 6H).491.8 [M + H+]
34 1H NMR (300 MHz, CDCl3) δ 8.61 (s, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.348.31 (m, 1H), 7.84-7.68 (m, 4H), 7.487.35 (m, 2H), 7.22 (s, 1H), 7.157.01 (m, 2H), 5.94 (s, 1H), 4.03 (s, 2H), 3.80 (s, 3H), 3.15 (s, 2H), 2.77 (t, J = 6.0 Hz, 2H), 2.33 (s, 6H), 1.79 (s, 2H).519.8 [M + H+]
35 1H NMR (300 MHz, CDCl3) δ 7.457.32 (m, 3H), 7.137.02 (m, 2H), 6.69 (s, 2H), 5.76 (s, 1H), 4.02 (s, 2H), 3.79 (d, J = 9.9 Hz, 6H), 3.14 (t, J = 5.9 Hz, 2H), 2.76 (t, J = 6.0 Hz, 2H), 2.24 (s, 6H).429.9 [M + H+]
36 1H NMR (300 MHz, CDCl3) δ 7.43 7.34 (m, 2H), 7.29-7.27 (m, 2H), 7.21 (d, J = 7.6 Hz, 2H), 7.15 (s, 1H), 7.07 (d, J = 8.2 Hz, 1H), 5.97 (s, 1H), 4.04 (s, 2H), 3.81 (s, 3H), 3.16 (t, J = 5.9 Hz, 2H), 2.78 (t, J = 6.0 Hz, 2H), 2.67 (q, J = 7.5 Hz, 4H), 1.16 (t, J = 7.5 Hz, 6H); LC/MS 428.3 [M + H+].
37 1H NMR (300 MHz, CDCl3) δ 7.44 7.34 (m, 3H), 7.26 (d, J = 7.6 Hz, 2H), 7.21 (s, 1H), 7.12 (s, 1H), 7.06 (d, J = 8.2 Hz, 1H), 5.99 (s, 1H), 4.04 (s, 2H), 3.81 (s, 3H), 3.34 (sept, J = 6.9 Hz, 2H), 3.16 (t, J = 5.9 Hz, 2H), 2.78 (t, J = 5.9 Hz, 2H), 1.14 (d, J = 6.9 Hz, 12H); LC/MS 456.2 [M + H+].
38 1H NMR (300 MHz, DMSO-d6) δ 9.68 (s, 1H), 8.99 (s, 1H), 8.28 (s, 1H), 7.82 (s, 1H), 7.58 (d, J = 9.7 Hz, 2H), 7.00 (d, J = 8.1 Hz, 1H), 6.78 (d, J = 2.0 Hz, 1H), 3.84 (s, 2H), 3.78 (s, 3H), 2.94 (t, J = 5.8 Hz, 2H), 2.63 (t, J = 5.9 Hz, 2H), 2.33 (s, 3H), 2.26 (s, 3H); LC/MS 434.4 [M + H+].
39 1H NMR (300 MHz, CDCl3) δ 8.23 (s, 1H), 7.46 (dd, J = 8.2, 2.3 Hz, 1H), 7.43 7.37 (m, 2H), 7.25 (s, 1H), 7.12 7.06 (m, 2H), 7.02 (d, J = 8.1 Hz, 1H), 6.02 (s, 1H), 4.06 (s, 2H), 3.85 (s, 3H), 3.17 (t, J = 5.9 Hz, 2H), 2.79 (t, J = 5.9 Hz, 2H), 2.34 (s, 3H), 2.31 (s, 3H); LC/MS 400.2 [M + H+].
40 1H NMR (300 MHz, CDCl3) δ 8.39 (s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.47 (dd, J = 8.2, 2.4 Hz, 1H), 7.43 (s, 1H), 7.28 7.19 (m, 3H), 7.10 (d, J = 8.3 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 6.11 (s, 1H), 4.06 (s, 2H), 3.87 (s, 3H), 3.18 (t, J = 5.9 Hz, 2H), 2.80 (t, J = 5.9 Hz, 2H), 2.36 (s, 3H); LC/MS 386.2 [M + H+].
41 1H NMR (300 MHz, CDCl3) δ 8.57 (s, 1H), 7.48 (d, J = 8.2 Hz, 1H), 7.43 (s, 1H), 7.24 (s, 1H), 7.11 (d, J = 8.3 Hz, 1H), 7.01 (s, 2H), 6.68 (s, 1H), 6.27 (s, 1H), 4.07 (s, 2H), 3.88 (s, 3H), 3.18 (t, J = 5.9 Hz, 2H), 2.80 (t, J = 6.0 Hz, 2H), 2.33 (s, 6H); LC/MS 400.2 [M + H+].
42 1H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 8.79 (s, 1H), 8.68 (s, 1H), 7.607.51 (m, 2H), 7.25-7.14 (m, 3H), 7.00 (d, J = 8.3 Hz, 1H), 3.84 (s, 2H), 3.64 (s, 3H), 2.95 (t, J = 5.8 Hz, 2H), 2.65 (d, J = 5.9 Hz, 2H), 2.302.23 (m, 1H); LC/MS 407.9 [M + H+]
43 1H NMR (300 MHz, CDCl3) δ 8.00 (s, 1H), 7.467.36 (m, 2H), 7.14 (t, J = 8.4 Hz, 1H), 7.06 (d, J = 7.5 Hz, 2H), 6.65 (d, J = 8.4 Hz, 2H), 6.13 (s, 1H), 4.03 (s, 2H), 3.823.76 (m, 9H), 3.193.11 (m, 2H), 2.76 (t, J = 6.0 Hz, 2H), 1.65 (s, 1H); LC/MS 431.9 [M + H+]
44 1H NMR (300 MHz, CDCl3) δ 7.46 (s, 1H), 7.38 (d, J = 20.2 Hz, 3H), 7.106.99 (m, 2H), 6.87 (d, J = 9.0 Hz, 2H), 5.69 (s, 1H) 4.02 (s, 2H), 3.79 (s, 3H), 3.14 (t, J = 6.0 Hz, 2H), 2.792.73 (m, 2H), 2.26 (s, 6H) ; LC/MS 417.9 [M + H+]
45 1H NMR (300 MHz, CDCl3) δ 8.34 (s, 1H), 7.497.35 (m, 2H), 7.33 (s, 1H), 7.22 (s, 1H), 7.09 (t, J = 6.8 Hz, 2H), 6.81 (d, J = 7.5 Hz, 1H), 6.03 (s, 1H), 4.04 (s, 2H), 3.85 (s, 3H), 3.15 (t, J = 6.0 Hz, 2H), 2.78 (t, J = 6.0 Hz, 2H), 2.29 (s, 3H), 2.28 (s, 3H). LC/MS 399.9 [M + H+]
46 1H NMR (500 MHz, CDCl3) δ 7.47 (dd, J = 8.3, 2.4 Hz, 1H), 7.42 (s, 1H), 7.31 (d, J = 8.5 Hz, 2H), 7.22 7.15 (m, 3H), 7.10 (s, 1H), 5.88 (s, 1H), 4.04 (s, 2H), 3.82 (s, 3H), 2.89 (s, 2H), 2.29 (s, 6H), 1.84 (s, 1H), 1.29 (s, 6H); LC/MS 428.2 [M + H+].
47 1H NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 8.12 (s, 1H), 8.03 (d, J = 7.7 Hz, 1H), 7.95 (s, 1H), 7.91 (s, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.66 (s, 1H), 7.61 (t, J = 7.8 Hz, 1H), 7.40 (dd, J = 8.2, 2.3 Hz, 1H), 7.33 (s, 1H), 7.31 7.26 (m, 1H), 7.21 (d, J = 8.1 Hz, 1H), 7.08 (d, J = 8.3 Hz, 1H), 6.19 (s, 1H), 4.15 (q, J = 6.8 Hz, 1H), 3.88 (s, 3H), 3.31 (dt, J = 12.5, 5.0 Hz, 1H), 3.10 3.02 (m, 1H), 2.93 2.83 (m, 1H), 2.74 (dt, J = 16.2, 4.6 Hz, 1H), 2.34 (s, 3H), 1.69 (s, 1H), 1.54 (d, J = 6.7 Hz, 3H); LC/MS 587.4 [M + H+].
48 1H NMR (300 MHz, DMSO) δ 9.57 (s, 1H), 8.56 (s, 1H), 8.40 (s, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.52 (s, 1H), 7.39 (d, J = 7.1 Hz, 1H), 7.27 (d, J = 7.4 Hz, 1H), 7.19 (t, J = 7.7 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 3.82 (s, 2H), 3.62 (s, 3H), 2.93 (t, J = 5.8 Hz, 2H), 2.62 (t, J = 5.8 Hz, 2H), 2.24 (s, 3H); LC/MS 420.2 [M + H+].
49 1H NMR (500 MHz, CDCl3) δ 7.60 (s, 1H), 7.42 (s, 1H), 7.35 (dd, J = 8.2, 2.2 Hz, 1H), 7.23 (s, 1H), 7.20 7.15 (m, 3H), 7.06 (d, J = 8.2 Hz, 1H), 5.97 (s, 1H), 3.96 (d, J = 3.8 Hz, 1H), 3.81 (s, 3H), 3.36 3.30 (m, 1H), 2.99 2.91 (m, 1H), 2.88 2.79 (m, 1H), 2.71 2.64 (m, 1H), 2.45 2.36 (m, 1H), 2.29 (s, 6H), 1.54 (s, 1H), 1.17 (d, J = 6.9 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H); LC/MS 442.2 [M + H+].
50 1H NMR (300 MHz, CDCl3) δ8.46 (s, 1H), 7.507.38 (m, 2H), 7.22 (d, J = 2.7 Hz, 1H), 7.18 (s, 1H), 7.09 (d, J = 8.2 Hz, 2H), 6.55 (dd, J = 8.4, 2.6 Hz, 1H), 6.03 (s, 1H), 4.124.02 (m, 4H), 3.66 (s, 3H), 3.743.69 (m, 2H), 3.43 (s, 3H), 3.16 (t, J = 6.0 Hz, 2H), 2.79 (t, J = 5.9 Hz, 2H), 2.26 (s, 3H), 1.68 (s, 1H). LC/MS 459.9 [M + H+]
51 1H NMR (300 MHz, chloroform-d) δ 9.96 (s, 1H), 8.648.51 (m, 2H), 8.26 (d, J = 7.7 Hz, 1H), 8.078.03 (m, 1H), 7.917.83 (m, 1H), 7.507.32 (m, 5H), 7.20 (d, J = 8.2 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 6.22 (s, 1H), 4.03 (s, 2H), 3.87 (s, 3H), 3.15 (t, J = 5.9 Hz, 2H), 2.77 (t, J = 5.9 Hz, 2H), 2.31 (s, 3H), 1.79 (s, 2H). LC/MS 505.9 [M + H+]
52 1H NMR (300 MHz, chloroform-d) δ 8.53 (s, 1H), 8.25 (s, 1H), 8.13 (s, 1H), 7.93 (s, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.537.27 (m, 7H), 7.08 (d, J = 8.2 Hz, 1H), 6.21 (s, 1H), 4.03 (s, 2H), 3.86 (s, 3H), 3.15 (t, J = 5.9 Hz, 2H), 2.78 (t, J = 5.6 Hz, 1H), 2.40 (s, 3H), 2.40 (s, 1H). LC/MS 572.9 [M + H+]
53 1H NMR (300 MHz, CDCl3) δ 7.47 - 7.37 (m, 3H), 7.22 - 7.14 (m, 4H), 7.03 (d, J = 8.0 Hz, 1H), 5.94 (s, 1H), 4.07 (s, 2H), 3.81 (s, 3H), 2.62 (s, 2H), 2.29 (s, 6H), 1.64 (s, 1H), 1.21 (s, 6H); LC/MS 428.2 [M + H+].
54 1H NMR (300 MHz, MeOD) δ 7.95 (s, 1H), 7.57 (s, 1H), 7.43 (d, J = 8.7 Hz, 1H), 7.19-7.13 (m, 3H), 7.06 (d, J = 8.3 Hz, 1H), 4.45 - 4.32 (m, 1H), 3.98 (s, 2H), 3.74 - 3.63 (m, 1H), 3.10 (t, J = 6.0 Hz, 2H), 2.82 (t, J = 5.9 Hz, 2H), 2.27 (s, 6H), 2.19 - 2.02 (m, 4H), 2.01 - 1.92 (m, 2H), 1.58 - 1.38 (m, 2H); LC/MS 483.9 [M + H+].
Example NMR/ Mass Data
55 1H NMR (300 MHz, CDCl3) δδ 7.69 (s, 1H), 7.42 (s, 1H), 7.35 (dd, J = 8.3, 2.3 Hz, 1H), 7.23 - 7.13 (m, 4H), 7.03 (d, J = 8.2 Hz, 1H), 5.89 (s, 1H), 4.16 (q, J = 6.7 Hz, 1H), 3.83 (s, 3H), 2.71 (d, J = 15.8 Hz, 1H), 2.57 (d, J = 15.9 Hz, 1H), 2.29 (s, 6H), 1.54 (d, J = 6.5 Hz, 3H), 1.29 (s, 3H), 1.13 (s, 3H); LC/MS 428.2 [M + H+].
56 1H NMR (300 MHz, DMSO-d6) δδ 10.10 (s, 1H), 9.74 (s, 2H), 8.53 (s, 1H), 8.37 (s, 1H), 7.96 (s, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.20 - 7.01 (m, 3H), 4.59-4.41 (m, 4H), 3.64 (s, 3H), 2.21 (s, 6H); LC/MS 386.2 [M + H+].
57 1H NMR (300 MHz, MeOD) δδ 8.67 (s, 1H), 7.86 (s, 1H), 7.78 (s, 1H), 7.65 - 7.52 (m, 3H), 7.46 (t, J = 8.0 Hz, 1H), 7.28 (d, J = 7.7 Hz, 1H), 7.20 - 7.13 (m, 2H), 7.08 (d, J = 8.2 Hz, 1H), 4.00 (s, 2H), 3.78 (s, 3H), 3.12 (t, J = 6.1 Hz, 2H), 2.83 (t, J = 6.0 Hz, 2H), 2.31 (s, 3H); LC/MS 587.8 [M + H+].
58 1H NMR (500 MHz, CDCl3) δδ 7.73 (s, 1H), 7.40 (s, 1H), 7.26 - 7.24 (m, 1H), 7.19 - 7.12 (m, 4H), 7.02 (d, J = 8.2 Hz, 1H), 5.87 (s, 1H), 3.80 (s, 3H), 3.14 (t, J = 5.9 Hz, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.27 (s, 6H), 1.50 (s, 6H); LC/MS 427.9 [M + H+].
59 1H NMR (300 MHz, CDCl3) δδ 7.81 (s, 1H), 7.41 (s, 1H), 7.32 - 7.27 (m, 1H), 7.21 - 7.11 (m, 4H), 7.04 (d, J = 8.3 Hz, 1H), 5.87 (s, 1H), 3.80 (s, 3H), 3.14 - 3.04 (m, 2H), 2.99 - 2.91 (m, 2H), 2.58 (s, 3H), 2.27 (s, 6H), 1.59 (s, 6H); LC/MS 441.9 [M + H+].
60 1H NMR (300 MHz, CDCl3) δδ 7.92 (s, 1H), 7.41 (s, 1H), 7.29 (s, 1H), 7.23 (dd, J = 8.2, 2.2 Hz, 1H), 7.18 - 7.11 (m, 3H), 7.03 (d, J = 8.2 Hz, 1H), 5.94 (s, 1H), 3.80 (s, 3H), 3.60 - 3.53 (m, 2H), 2.82 (t, J = 5.3 Hz, 2H), 2.27 (s, 6H), 2.21 (s, 3H), 1.88 (s, 6H); LC/MS 469.9 [M + H+].
61 1H NMR (300 MHz, CDCl3) δδ 7.66 - 7.51 (m, 1H), 7.40 (d, J = 6.0 Hz, 1H), 7.38 - 7.29 (m, 1H), 7.23 (s, 1H), 7.19 - 7.11 (m, 3H), 7.11 - 7.02 (m, 1H), 5.91 (s, 1H), 5.66 (q, J = 6.8 Hz, 0.6H), 4.94 (q, J = 6.8 Hz, 0.4H), 4.74 - 4.65 (m, 0.4H), 3.84-3.83 (m, 0.4H), 3.80 (s, 3H), 3.52 (ddd, J = 13.9, 10.6, 4.4Hz, 0.7H), 3.07 - 2.64 (m, 2.5H), 2.27 (s, 6H), 2.20 (s, 1H), 2.17 (s, 2H), 1.58 (d, J = 6.8 Hz, 1H), 1.48 (d, J = 6.8 Hz, 2H); LC/MS 456.2 [M + H+].
62 1H NMR (300 MHz, CDCl3) δδ 7.59 - 7.52 (m, 1H), 7.40 (s, 1H), 7.33 (dd, J = 8.3, 2.4Hz, 1H), 7.24 - 7.08 (m, 4H), 7.05 (d, J = 8.3 Hz, 1H), 5.86 (s, 0.7H), 5.18 (s, 0.3H), 3.83 - 3.78 (m, 3H), 3.66 (q, J = 6.7 Hz, 1H), 3.15 - 3.04 (m, 1H), 2.93 - 2.76 (m, 2H), 2.75 - 2.63 (m, 1H), 2.52 (s, 3H), 2.27 (s, 6H), 1.47 (d, J = 6.6 Hz, 3H); LC/MS 427.9 [M + H+].
63 1H NMR (300 MHz, CDCl3) δδ 7.45 (d, J = 8.4Hz, 1H), 7.39 (s, 1H), 7.31 (s, 1H), 7.26 - 7.24 (m, 1H), 7.21 - 7.12 (m, 3H), 7.07 (s, 1H), 5.84 (s, 1H), 3.79 (s, 3H), 3.54 (s, 2H), 2.42 (s, 3H), 2.39 (s, 2H), 2.27 (s, 6H), 1.30 (s, 6H); LC/MS 441.9 [M + H+].
64 1H NMR (500 MHz, CDCl3) δδ 8.63 (s, 1H), 8.13 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.98 (s, 1H), 7.92 (s, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.66 (s, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.41 (dd, J = 8.2, 2.3 Hz, 1H), 7.36 (s, 1H), 7.30 - 7.26 (m, 1H), 7.22 (d, J = 8.1 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 6.20 (s, 1H), 3.88 (s, 3H), 3.82 - 3.75 (m, 1H), 3.23 - 3.14 (m, 1H), 2.98 - 2.88 (m, 2H), 2.85 - 2.79 (m, 1H), 2.59 (s, 3H), 2.35 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H); LC/MS 600.9 [M + H+].
65 1H NMR (300 MHz, CDCl3) δδ 7.53 (s, 1H), 7.40 (s, 1H), 7.32 (dd, J = 8.2, 2.3 Hz, 1H), 7.20 - 7.11 (m, 4H), 7.05 (d, J = 8.2 Hz, 1H), 5.88 (s, 1H), 3.79 (s, 3H), 3.33 - 3.20 (m, 2H), 2.84 - 2.64 (m, 3H), 2.50 (s, 3H), 2.27 (s, 6H), 2.10 - 1.98 (m, 1H), 1.09 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.7 Hz, 3H); LC/MS 455.9 [M + H+].
66 1H NMR (300 MHz, CDCl3) δδ 7.44 (s, 1H), 7.41 - 7.35 (m, 2H), 7.22 - 7.10 (m, 4H), 7.03 (d, J = 8.2 Hz, 1H), 5.88 (s, 1H), 3.84 (s, 2H), 3.80 (s, 3H), 2.73 (s, 2H), 2.45 (s, 3H), 2.27 (s, 6H), 1.18 (s, 6H); LC/MS 441.9 [M + H+].
67 1H NMR (500 MHz, CDCl3) δδ 7.72 (s, 1H), 7.43 (s, 1H), 7.38 - 7.32 (m, 1H), 7.25 (s, 1H), 7.21 - 7.15 (m, 3H), 7.04 (d, J = 8.3 Hz, 1H), 5.93 (s, 1H), 3.82 (s, 3H), 3.14-3.03 (m, 1H), 2.64 - 2.45 (m, 5H), 2.29 (s, 6H), 1.69 (s, 3H), 1.47 (s, 3H), 1.15-1.04 (m, 3H); LC/MS 455.9 [M + H+].
68 1H NMR (300 MHz, CDCl3) δδ 7.57 - 7.46 (m, 1H), 7.43 - 7.38 (m, 2H), 7.34 - 7.28 (m, 1H), 7.25 - 7.22 (m, 1H), 7.19 - 7.12 (m, 3H), 5.90 (s, 1H), 4.82 - 4.62 (m, 2H), 3.80 (s, 3H), 3.64 - 3.34 (m, 2H), 2.27 (s, 6H), 2.23 - 2.16 (m, 3H), 1.35 - 1.23 (m, 6H); LC/MS 469.9 [M + H+].
69 1H NMR (500 MHz, CDCl3 ) δδ 8.66 - 8.60 (m, 1H), 8.14 (d, J = 2.4Hz, 1H), 8.05 (d, J = 8.3 Hz, 1H), 8.00 (d, J = 5.5 Hz, 1H), 7.97 - 7.93 (m, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.69 - 7.60 (m, 2H), 7.53 - 7.40 (m, 2H), 7.33 - 7.30 (m, 1H), 7.25 - 7.21 (m, 1H), 7.16 - 7.09 (m, 1H), 6.22 - 6.21 (m, 1H), 5.72 - 5.66 (m, 0.7H), 5.00 - 4.96 (m, 0.3H), 4.76 - 4.70 (m, 0.3H), 3.90 - 3.88 (m, 3H), 3.87 - 3.82 (m, 0.7H), 3.59 - 3.51 (m, 0.8H), 3.08 - 3.01 (m, 0.2H), 2.98 - 2.73 (m, 2H), 2.35 (s, 3H), 2.23 (s, 1H), 2.19 (s, 2H), 1.50 (d, J = 6.8 Hz, 2H), 1.30 - 1.28 (m, 1H); LC/MS 628.9 [M + H+].
70 1H NMR (300 MHz, CDCl3) δδ 7.64 - 7.53 (m, 1H), 7.43 - 7.31 (m, 2H), 7.22 - 7.04 (m, 5H), 5.88 (s, 1H), 5.34 - 5.25 (m, 0.65H), 4.57 - 4.44 (m, 0.36H), 4.31 - 4.24 (m, 0.35H), 3.79 (s, 3H), 3.70 (t, J = 6.6 Hz, 1.24H), 3.37 - 3.19 (m, 0.36H), 3.04 - 2.79 (m, 2H), 2.27 (s, 6H), 2.18 - 2.14 (m, 3H), 2.03 - 1.95 (m, 1H), 1.13 - 0.96 (m, 6H); LC/MS 483.9 [M + H+].
71 1H NMR (300 MHz, CDCl3) δδ 7.57 (s, 1H), 7.50 (dd, J = 8.0, 2.2 Hz, 1H), 7.42 (s, 1H), 7.21 - 7.08 (m, 5H), 5.87 (s, 1H), 4.39 (s, 2H), 3.81 (s, 3H), 2.73 (s, 2H), 2.27 (s, 6H), 2.20 (s, 3H), 1.46 (s, 6H); LC/MS 469.9 [M + H+].
72 1H NMR (300 MHz, CDCl3) δδ 7.85 - 7.72 (m, 1H), 7.46 (d, J = 8.4Hz, 1H), 7.41 (s, 1H), 7.30 - 7.27 (m, 1H), 7.24 - 7.11 (m, 4H), 5.89 (s, 1H), 4.86 - 4.73 (m, 4H), 3.80 (d, J = 1.9 Hz, 3H), 2.27 (s, 6H), 2.17 (s, 3H); LC/MS 427.9 [M + H+].
73 1H NMR (300 MHz, CDCl3) δδ 7.51 (dd, J = 8.1, 2.2 Hz, 1H), 7.46 (s, 1H), 7.42 (s, 1H), 7.21 - 7.09 (m, 5H), 5.85 (s, 1H), 4.83 - 4.71 (m, 1H), 3.80 (s, 3H), 3.21 (d, J = 15.2 Hz, 1H), 2.52 (d, J = 15.2 Hz, 1H), 2.27 (s, 6H), 2.25 (s, 3H), 1.75 (s, 3H), 1.49 (d, J = 7.0 Hz, 3H), 1.24 (s, 3H); LC/MS 484.0 [M + H+].
74 1H NMR (300 MHz, CDCl3) δδ 7.61 (s, 1H), 7.47 - 7.38 (m, 2H), 7.22 - 7.08 (m, 5H), 5.83 (s, 1H), 4.04 - 3.95 (m, 4H), 3.79 (s, 3H), 2.65 (s, 3H), 2.27 (s, 6H); LC/MS 399.9 [M + H+].
75 1H NMR (300 MHz, CDCl3) δδ 7.42 - 7.31 (m, 3H), 7.15 (s, 3H), 7.02 (d, J = 8.5 Hz, 2H), 5.84 (s, 1H), 3.79 (s, 3H), 2.81 - 2.68 (m, 4H), 2.27 (s, 6H), 1.85-1.75 (m, 4H); LC/MS 399.5 [M + H+].
76 1H NMR (300 MHz, CDCl3) δδ 7.64 (d, J = 8.9 Hz, 2H), 7.55 (d, J = 8.7 Hz, 2H), 7.41 (s, 1H), 7.30 (s, 2H), 7.21 - 7.10 (m, 3H), 6.44 (d, J = 16.8 Hz, 1H), 6.24 (dd, J = 16.9, 10.1 Hz, 1H), 5.91 (s, 1H), 5.76 (d, J = 10.1 Hz, 1H), 3.80 (s, 3H), 2.27 (s, 6H); LC/MS 414.1 [M + H+].
77 1H NMR (500 MHz, CDCl3) δδ 8.33 (d, J = 2.4Hz, 1H), 7.92 (dd, J = 8.2, 2.5 Hz, 1H), 7.54 (s, 1H), 7.44 (s, 1H), 7.22 (d, J = 8.3 Hz, 1H), 7.19 - 7.14 (m, 3H), 6.30 (s, 1H), 6.08 (s, 1H), 3.84 (s, 3H), 3.58 (td, J = 6.6, 2.8 Hz, 2H), 2.99 (t, J = 6.6 Hz, 2H), 2.29 (s, 6H); LC/MS 414.2 [M + H+].
78 1H NMR (300 MHz, CDCl3) δδ 7.59 (s, 1H), 7.41 - 7.33 (m, 2H), 7.13 - 7.02 (m, 2H), 6.75 (s, 2H), 5.75 (s, 1H), 4.18 - 4.12 (m, 2H), 3.96 (d, J = 3.7 Hz, 1H), 3.82 - 3.76 (m, 5H), 3.50 (s, 3H), 3.39 - 3.27 (m, 1H), 3.00 - 2.75 (m, 2H), 2.73 - 2.62 (m, 1H), 2.48 - 2.36 (m, 1H), 2.25 (s, 6H), 1.17 (d, J = 6.9 Hz, 3H), 0.82 (d, J = 6.8 Hz, 3H); LC/MS 516.2 [M + H+].
79 1H NMR (300 MHz, CDCl3) δδ 7.72 (s, 1H), 7.37 (s, 1H), 7.26 - 7.22 (m, 1H), 7.09 (s, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.72 (s, 2H), 5.74 (s, 1H), 4.15 - 4.10 (m, 2H), 3.79 (s, 3H), 3.78 - 3.71 (m, 2H), 3.47 (s, 3H), 3.14 (t, J = 5.9 Hz, 2H), 2.74 (t, J = 5.8 Hz, 2H), 2.23 (s, 6H), 1.59 (s, 1H), 1.50 (s, 6H); LC/MS 502.2 [M + H+].
Comparative Example 1: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(4-(piperidine-4-yl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000181
Step 1: Preparation of tert-butyl 4-(4-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
Figure PCTKR2018005478-appb-I000182
Tert-butyl 4-(4,4,5,5-tetramethyl-cyclohexyl-3-en-1-carboxylate (1.68 g, 5.44 mmol) and sodium carbonate (1.05 g, 9.90 mmol) were added to dioxane (40 mL) and H2O (10 mL) containing 1-bromo-4-nitrobenzene (1.0 g, 4.95 mmol) at room temperature. The reaction mixture was purged with nitrogen for 10 minutes. PdCl2 (dppf) (202 mg, 0.247 mmol) was added to the reaction mixture, which was heated to reflux for 2 hours. Upon completion of the reaction, the solvent was concentrated under reduced pressure to remove the solvent. The crude mixture was diluted with water (100 mL), followed by extraction with ethylacetate (2 x 150 mL). The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure. The obtained crude mixture was purified by column chromatography using EtOAc/hexane (1:1) as an eluent. As a result, the target compound (1.15 g, 3.77 mmol, 76%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 8.21 (d, J = 8.9 Hz, 2H), 7.53 (d, J = 8.9 Hz, 2H), 6.25 (s, br, 1H), 4.19-4.10 (m, 2H), 3.68 (t, J = 5.7 Hz, 2H), 2.63-2.50 (m, 2H), 1.52 (s, 9H); LC/MS 305.2 [M + H+].
Step 2: Preparation of tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate
Figure PCTKR2018005478-appb-I000183
Pd/C (10 weight%) (110mg, 1.04mmol) was added to MeOH (10 mL) solution containing the compound prepared in step 1 above (1.1 g, 3.61 mmol) at room temperature. The reaction mixture was stirred at room temperature under hydrogen balloon pressure for 2 hours. TLC analysis indicated the complete consumption of the starting material. The reaction mixture was filtered with a celite bed and concentrated to remove MeOH. The obtained crude mixture was purified by column chromatography using EtOAc/hexane. As a result, the target compound (850 mg, 3.07 mmol, 85%) was obtained as a white solid.
1H NMR (300 MHz, CDCl3) δ 6.98 (d, J = 8.3 Hz, 2H), 6.63 (d, J = 8.4 Hz, 2H), 4.19-4.12 (m, 2H), 3.57 (s, br, 2H), 2.76 (t, J = 12.3 Hz, 2H), 2.56-2.48 (m, 1H), 1.79-1.75 (m, 2H), 1.58-1.52 (m, 2H), 1.47 (s, 9H); LC/MS 277.2 [M + H+].
Step 3: Preparation of N3-(2,6-dimethylphenyl)-1-methyl-N6-(4-(piperidine-4-yl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
Figure PCTKR2018005478-appb-I000184
The compound prepared in step 2 above (17.1 mg, 0.062 mmol) and pTSA.H2O (13.1 mg, 0.069 mmol) were added to IPA (1.0 mL) solution containing the compound of Preparative Example B-1 (20 mg, 0.069 mmol) at room temperature, followed by stirring at 90℃ for 12 hours. TLC analysis indicated the complete consumption of the starting material. The solid obtained from the reaction mixture was filtered and washed with ethanol (2 mL). The filtered solid was dissolved in EtOAc (15 mL) and washed with saturated NaHCO3 solution. The combined organic layer was concentrated under reduce pressure. The obtained crude mixture was purified by column chromatography using MeOH/DCM (1/4) as an eluent. As a result, the target compound (20 mg, 0.046 mmol, 68%) was obtained as a grey-white solid.
1H NMR (500 MHz, CDCl3) δ 7.60 (d, J = 8.5 Hz, 2H), 7.43 (s, 1H), 7.21 (d, J = 8.5 Hz, 2H), 7.19-7.16 (m, 3H), 7.13 (s, br, 1H), 5.86 (s, br, 1H), 3.83 (s, 3H), 3.21 (d, J = 12.1 Hz, 2H), 2.76 (t, J = 12.2 Hz, 2H), 2.64-2.58 (m, 1H), 2.29 (s, 6H), 1.85 (d, J = 12.4 Hz, 2H), 1.69-1.66 (m, 2H), 1.63 (s, br, 1H);
Comparative Example 2: Preparation of 1-(4-(4-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)phenyl)piperidine-1-yl)ethaneone
Figure PCTKR2018005478-appb-I000185
Acetic anhydride (8.5 mg, 0.084 mmol) and Et3N (17.6 mg, 0.175 mmol) were added to DCM (10 mL) solution containing the compound of Comparative Example 1 (30 mg, 0.070 mmol) at 0°C, followed by stirring at room temperature for 2 hours. TLC analysis indicated the complete consumption of the starting material. Water was added to the reaction mixture, which was extracted with DCM (15mL). The extract was washed with saturated NaHCO3 solution. The combined organic layer was concentrated under reduced pressure. The obtained crude product was purified by column chromatography using MeOH/DCM (1/4) as an eluent. As a result, 1-(4-(4-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)phenyl)piperidine-1-yl)ethaneone (28 mg, 0.059 mmol, 85%) was obtained as a grey-white solid.
1H NMR (300 MHz, CDCl3) δ 7.61 (d, J = 8.5 Hz, 2H), 7.53 (s, br, 1H), 7.38 (s, 1H), 7.20-7.15 (m, 5H), 5.99 (s, br, 1H), 4.78 (d, J = 13.4 Hz, 1H), 3.93 (d, J = 13.4 Hz, 1H), 3.79 (s, 3H), 3.16 (t, J = 12.8 Hz, 1H), 2.75-2.70 (m, 1H), 2.67-2.57 (m, 1H), 2.26 (s, 6H), 2.13 (s, 3H), 1.89 (t, J = 9.6 Hz, 2H), 1.67-1.58 (m, 2H); LC/MS 470.2 [M + H+].
Experimental Example 1: Evaluation of BTK inhibitory activity of the compound of the present invention
1-1. Experimental method
The following experiment was performed in order to evaluate the Bruton's tyrosine kinase inhibitory activity of the derivatives of the present invention and the result are shown in Table 5.
BTK enzyme evaluation with each compound of examples of the invention was performed by using BTK enzyme inhibition diagnosis kit (Cisbio, Codolet, France). ATP (adenosine triphosphate), BTK, peptide (biotin-Aca-AAAEEIYGEI-NH2) and each compound of examples of the invention were mixed, followed by reaction for 30 minutes. Then, EDTA (ethylenediaminetetraacetic acid) was added thereto in order to terminate the reaction. At this time, the EDTA solution contained europium-containing antibody (antiphosphoresidue antibody) and straptavidin-XL665 (SA-XL665, Cisbio). After incubation for 1 hour, fluorescence was measured. The emission values of 665 nm and 620 nm excited at 337 nm were measured with Envision reader. IC50 values were determined using GraphPad prism (version 5). Herein, the curve indicates a non-linear regression model, which was determined by logarithmic functions and reaction values.
1-2. Experiment results
Example Btk IC50 (uM)
1 0.0006
2 0.0006
4 0.1
6 0.01
7 0.0008
8 0.001
11 0.386
12 0.003752
13 0.003
14 0.002
15 0.00067
16 0.003
17 0.0012
18 0.0005
19 0.0003
20 0.0005
21 0.0002
22 0.0004
23 0.0003
24 0.0003
25 0.0003
26 0.002
27 0.001
28 0.003
29 0.008
30 0.002
31 0.0008
32 0.0007
33 0.005
34 0.015
35 0.003
36 0.044
39 0.0028
44 0.0017
46 0.002849
47 0.005421
48 0.001275
49 0.001615
53 0.0005228
54 0.001142
55 0.000847
56 0.0007455
57 0.02669
58 0.001687
59 0.001837
60 0.004012
61 0.001035
62 0.001208
63 0.002128
64 0.005223
65 0.007742
Comparative Example 1 0.01
Comparative Example 2 0.02
As shown in Table 6, the compounds of the present invention were confirmed to have excellent inhibitory activity against Bruton's tyrosine kinase (BTK). In particular, the compounds of the present invention having the structure in which an amine substituted at the 6-position of pyrazolopyrimidine is substituted with a phenyl to which a heterocyclic ring is conjugated have more excellent activity than the compound of Comparative Example 1 or Comparative Example 2 having the structure in which an amine substituted at the 6-position of pyrazolopyrimidine is substituted with a phenyl substituted with a heterocyclic ring.
Therefore, the pyrazolopyrimidine derivative compounds of the present invention are excellent in inhibiting Bruton's tyrosine kinase (BTK) activity, so that the compounds can be effectively used as an active ingredient for a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
Experimental Example 2: Evaluation of BTK inhibitory activity in TMD8 cells
2-1. Experimental method
TDM-8 cells, the ABC (activated B-cell) type DLBCL (diffuse large B cell lymphoma) cell line sensitive to BTK signaling, were seeded in a 96-well plate at 30% confluency. Then, the compounds of the invention were treated thereto at different concentrations. 72 hours later, WST-1 reagent was added thereto. One hour later, absorbance was measured at 450 nm by using a spectramax spectrophotometer. IC50 values were measured using GraphPad prism program and the results are shown in Table 7.
2-2. Experiment results
Example TMD8 IC50 (uM)
1 0.0411
2 0.0301
4 0.572
6 0.159
7 0.046
8 0.093
11 0.243
12 0.089
13 0.118
14 0.032
15 0.041
16 0.061
17 0.036
18 0.1339
19 0.0494
20 0.008277
21 0.1387
22 0.04637
23 0.08792
24 0.04007
25 0.09028
26 0.06495
27 0.03538
28 0.01795
29 0.117
30 0.04106
31 0.06425
32 0.0379
33 0.6687
34 0.1779
35 0.09935
36 0.9679
38 0.8316
39 0.2918
40 0.3971
42 0.397
44 0.06898
45 0.72
46 0.04723
47 0.01377
48 0.05019
49 0.01957
52 0.08323
53 0.0319
54 0.06086
55 0.01679
56 0.05887
57 0.2213
58 0.008772
59 0.009269
60 0.1594
61 0.09638
62 0.02791
63 0.02085
64 0.01007
65 0.2744
66 0.0285
67 0.02364
68 0.1213
69 0.02452
70 0.02452
71 0.1137
72 0.2660
73 0.0878
74 0.3578
75 0.6674
76 0.07518
77 0.1465
78 0.02624
79 0.01299
As shown in Table 7, the compounds of the present invention were confirmed to have excellent inhibitory activity against TMD8 cells. Based on such activity as the above, the compounds of the present invention were confirmed to be very effective in treating B-cell malignant tumor.
Therefore, the compounds of the present invention can be effectively used as an active ingredient for a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
Experimental Example 3: Evaluation of BTK inhibitory activity in human peripheral blood mononuclear cells (HPBMC)
3-1. Experimental method
20 ug/ml of human serum albumin (HAS) solution was prepared and distributed in a 96-well plate (200 ㎕/well). Reaction was induced at 4℃ for overnight and then 10% FBS solution was treated thereto (200 ㎕/well), followed by elimination. Lastly, 10 ug/ml of anti-HSA antibody was treated thereto (200 ㎕/well) for 1 hour, followed by elimination. An appropriate number of monocytes of human peripheral blood mononuclear cells (human PBMC) were distributed in the prepared 96-well plate. The target compounds were treated thereto at different concentration via serial dilution method, followed by culture for overnight. TNFa concentration in the culture medium was measured by ELISA (enzyme liked immunosorbent assay) as shown in Figure 1. A schematic diagram of the experimental procedure is shown in Figure 1. IC50 values of the compounds were determined by confirming the TNFa inhibition activity of the compounds between the maximum concentration (positive control) and the minimum concentration (negative control) of TNFa, and the results are shown in Table 8.
3-2. Experiment results
Example hPBMC IC50 (uM)
1 0.035
2 0.0077
4 0.209
6 0.113
7 0.020
8 0.0048
10 0.202
12 0.0026
13 0.0055
14 0.031
15 0.0013
16 0.0032
As shown in Table 8, the compounds of the present invention were confirmed to have excellent inhibitory activity against human PBMC. Therefore, the compounds of the present invention can be effectively used as an active ingredient for a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
The pyrazolopyrimidine derivative of the present invention displays an excellent Bruton's tyrosine kinase (BTK) inhibitory activity, so that a composition comprising the derivative as an active ingredient can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease. The pyrazolopyrimidine derivative of the present invention can be used for immunotherapy because it does not inhibit ITK (Interlukin-2 receptor inducible T-cell kinase) and can be used as an autoimmune disease therapeutic agent for long-term administration because it is a reversible inhibitor. The derivative of the invention also shows an excellent pharmaceutical effect on Abl and Abl mutants along with excellent BBB permeability, so that it can be effectively used for the treatment of Parkinson's disease.
Manufacturing Example 1: Preparation of powders
Derivative of formula 1 2 g
Lactose 1 g
Powders were prepared by mixing all the above components, which were filled in airtight packs according to the conventional method for preparing powders.
Manufacturing Example 2: Preparation of tablets
Derivative of formula 1 100 ㎎
Corn starch 　　　　　　　　　　　 　 100 ㎎
Lactose 　　　　　　　　　　　　　　　　　　 　 100 ㎎
Magnesium stearate 　　　　　　　 　 2 ㎎
Tablets were prepared by mixing all the above components by the conventional method for preparing tablets.
Manufacturing Example 3: Preparation of capsules
Derivative of formula 1 100 ㎎
Corn starch　　　　　　　　　　　　　　 　　　　　　　　　　　 100 ㎎
Lactose 　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　 100 ㎎
Magnesium stearate　　　　　　 2 ㎎
Capsules were prepared by mixing all the above components, which were filled in gelatin capsules according to the conventional method for preparing capsules.
Manufacturing Example 4: Preparation of injectable solution
Derivative of formula 1 100 ㎎
Mannitol 180 ㎎
Na2HPO4ㆍ2H2O 26 ㎎
Distilled water 974 ㎎
Injectable solutions were prepared by mixing all the above components by the conventional method for preparing injectable solutions.
Manufacturing Example 5: Preparation of health food
Derivative of formula 1 500 ng
Vitamin complex proper amount
Vitamin A acetate 70 ㎎
Vitamin E 1.0 ㎎
Vitamin B1 0.13 ㎎
Vitamin B2 0.15 ㎎
Vitamin B6 0.5 ㎎
Vitamin B12 0.2 ㎍
Vitamin C 10 ㎎
Biotin 10 ㎍
Nicotinic acid amide 1.7 ㎎
Folic acid 50 ㎍
Calcium pantothenate 0.5 ㎎
Minerals proper amount
Ferrous sulfate 1.75 ㎎
Zinc oxide 0.82 ㎎
Magnesium carbonate 25.3 ㎎
Potassium phosphate monobasic 15 ㎎
Potassium phosphate dibasic 55 ㎎
Potassium citrate 90 ㎎
Calcium carbonate 100 ㎎
Magnesium chloride 24.8 ㎎
Vitamins and minerals were mixed according to the preferable composition rate for health food. However, the composition rate can be adjusted. The constituents were mixed according to the conventional method for preparing health food and then the composition for health food was prepared according to the conventional method.
Manufacturing Example 6: Preparation of health beverages
Derivative of formula 1 1000 ㎎
Citric acid 1000 ㎎
Oligosaccharide 100 g
Maesil (Prunus mume) Extract 2 g
Taurine 1 g
Purified water up to 900 ㎖
The above constituents were mixed according to the conventional method for preparing health beverages. The mixture was heated at 85℃ for 1 hour with stirring and then filtered. The filtrate was loaded in 2 liter sterilized containers, which were sealed and sterilized again, stored in a refrigerator until they would be used for the preparation of a composition for health beverages.
The constituents appropriate for favorite beverages were mixed according to the preferred mixing ratio but the composition ratio can be adjusted according to regional and national preferences, etc.
Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended Claims.
The pyrazolopyrimidine derivative of the present invention demonstrates an excellent Bruton's tyrosine kinase (BTK) inhibitory activity, so that a pharmaceutical composition comprising the compound of the invention as an active ingredient can be effectively used for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

Claims (24)

  1. A compound represented by formula 1 below or a pharmaceutically acceptable salt of the same:
    [Formula 1]
    Figure PCTKR2018005478-appb-I000186
    (In formula 1,
    A is 3 ~ 8 membered heterocyclic ring containing one or more hetero atoms selected from the group consisting of N, O and S or C3-10 cycloalkane;
    R1 and R2 are independently one or more substituents selected from the group consisting of hydrogen, carbonyl(=O), straight or branched C1-5 alkyl, C1-5 dialkyl, C1-5 alkoxy or hydroxy C1-5 alkyl, and -(C=O)R7, R7 is straight or branched C1-5 alkyl, C2-5 alkenyl having one or more double bonds, halo C1-5 alkyl or hydroxy C1-5 alkyl; C3-9 cycloalkyl; or -N(CH2)nR8R9; R8 and R9 are independently hydrogen or straight or branched C1-5 alkyl, and n is an integer of 0 ~ 5;
    R3, R4, and R5 are independently hydrogen, straight or branched C1-5 alkyl or C3-8 cycloalkyl, at this time, the alkyl or cycloalkyl can be substituted with one or more hydroxy; and
    R6 is one or more substituents selected from the group consisting of hydrogen, -OH, -CN, -NO2, halogen, straight or branched C1-5 alkyl, C2-5 alkenyl or C2-5 alkynyl, -OR10, -NH(C=O)R10, -(C=O)NHR10, and -NH(C=O)NHR10, R10 is straight or branched C1-5 alkyl or C1-5 alkyloxy C1-5 alkyl; C6-10 aryl; or 5 ~ 12 membered heteroaryl containing one or more hetero atoms selected from the group consisting of N, O, and S; and the aryl or heteroaryl can be substituted with one or more substituents selected from the group consisting of straight or branched C1-5 alkyl, C1-5 alkoxy and C1-5 haloalkyl).
  2. The compound or the pharmaceutically acceptable salt of the same according to claim 1, wherein:
    A is 3 ~ 6 membered heterocyclic ring containing one or more hetero atoms selected from the group consisting of N, O and S or C5-7 cycloalkane;
    R1 and R2 are independently one or more substituents selected from the group consisting of hydrogen, carbonyl(=O), straight or branched C1-3 alkyl, C1-3 dialkyl, C1-3 alkoxy or hydroxy C1-3 alkyl, and -(C=O)R7, R7 is straight or branched C1-3 alkyl, C2-3 alkenyl, halo C1-3 alkyl or hydroxy C1-3 alkyl; C3-6 cycloalkyl; or -N(CH2)nR8R9; R8 and R9 are independently hydrogen or straight or branched C1-3 alkyl, and n is an integer of 1 ~ 3;
    R3, R4, and R5 are independently hydrogen, straight or branched C1-3 alkyl or C3-6 cycloalkyl, at this time, the alkyl or cycloalkyl can be substituted with hydroxy; and
    R6 is one or more substituents selected from the group consisting of hydrogen, straight or branched C1-3 alkyl, -OR10, -NH(C=O)R10, -(C=O)NHR10, and -NH(C=O)NHR10, R10 is straight or branched C1-3 alkyl or C1-3 alkyloxy C1-3 alkyl; C5-10 aryl; or 6 ~ 10 membered heteroaryl containing one or more nitrogen atoms; and the aryl or heteroaryl can be substituted with one or more substituents selected from the group consisting of straight or branched C1-3 alkyl, C1-3 alkoxy and C1-3 haloalkyl.
  3. The compound or the pharmaceutically acceptable salt of the same according to claim 1, wherein:
    A is piperidine, tetrahydropyrane, pyrrolidine, or cyclohexane;
    R1 is one or more substituents selected from the group consisting of hydrogen, carbonyl(=O), -CH3, -CH2CH3, -(CH3)2, -CH(CH3)2, -CH2CH2OH, -(C=O)CH3, -(C=O)CF3,-(C=O)CHCH2, -(C=O)cyclopropyl, -(C=O)CH2OH, and -(C=O)CH2N(CH3)2;
    R2 is hydrogen or methoxy;
    R3 is hydrogen;
    R4 is hydrogen, methyl, isopropyl, cyclopentyl, cyclohexyl, or (4-hydroxy)cyclohexyl;
    R5 is hydrogen; and
    R6 is one or more substituents selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, methoxy, chloro, fluoro, methoxyethoxy, phenoxy,
    Figure PCTKR2018005478-appb-I000187
    ,
    Figure PCTKR2018005478-appb-I000188
    ,
    Figure PCTKR2018005478-appb-I000189
    ,
    Figure PCTKR2018005478-appb-I000190
    and
    Figure PCTKR2018005478-appb-I000191
    .
  4. The compound or the pharmaceutically acceptable salt of the same according to claim 1, wherein the compound represented by formula 1 is selected from the group consisting of the following compounds:
    (1) 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
    (2) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (3) 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone;
    (4) N3-(2,6-dimethylphenyl)-N6-(7-methoxy-1,2,3,4-tetrahydroisoquinoline-6-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (5) 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
    (6) 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone;
    (7) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (8) 1-(6-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
    (9) 2,2,2-trifluoro-1-(7-(1-methyl-3-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
    (10) 1-methyl-N3-phenyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (11) 1-(7-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethaneone;
    (12) N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (13) 1-(7-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
    (14) 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)prop-2-en -1-one;
    (15) N3-(2,6-dichlorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (16) 1-(6-(3-(2,6-dichlorophenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethaneone;
    (17) N3-(2,6-dimethylphenyl)-1-methyl-N6-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (18) N3-(2,6-dimethylphenyl)-N6-(isochroman-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (19) N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (20) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (21) N3-(2,6-dimethylphenyl)-N6-(2-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (22) 1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxyethanone;
    (23) cyclopropyl(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)methanone;
    (24) 2-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-ol;
    (25) 1-cyclopentyl-N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (26) 1-cyclohexyl-N3-(2,6-dimethylphenyl)-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (27) N3-(2,6-dimethylphenyl)-1-isopropyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (28) N-(4-methyl-3-((1-methyl-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(trifluoromethyl)benzamide;
    (29) N-(2,4-dimethyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)-3-(trifluoromethyl)benzamide;
    (30) N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (31) 2-(dimethylamino)-1-(7-(3-(2,6-dimethylphenylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-yl)ethanone;
    (32) N3-(2,6-dimethylphenyl)-N6-(2-ethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (33) N3-(2,6-dimethyl-4-phenoxyphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (34) 3,5-dimethyl-4-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)-N-(pyridine-2-yl)benzamide;
    (35) N3-(4-methoxy-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (36) N3-(2,6-diethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (37) N3-(2,6-diisopropylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (38) N3-(2-chloro-3,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (39) N3-(2,4-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (40) 1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-o-tolyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (41) N3-(3,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (42) N3-(2,6-difluorophenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (43) N3-(2,6-dimethoxyphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (44) N3-(4-fluoro-2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (45) N3-(2,5-dimethylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (46) N6-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (47) N-(4-methyl-3-(1-methyl-6-(1-methyl-1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)-3-(trifluoromethyl)benzamide;
    (48) N3-(2-chloro-6-methylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (49) N3-(2,6-dimethylphenyl)-N6-(1-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (50) N3-(5-(2-methoxyethoxy)-2-methylphenyl)-1-methyl-N6-(1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (51) N-(4-methyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)phenyl)picolineamide;
    (52) 4-methyl-3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinoline-7-ylamino)-1H-pyrazolo[3,4-d]pyrimidine-3-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide;
    (53) N6-(3,3-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (54) 4-(3-((2,6-dimethylphenyl)amino)-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-1-yl)cyclohexane-1-ol;
    (55) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,3,3-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (56) tert-butyl-5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-carboxylate;
    (57) 1-(4-methyl-3-((1-methyl-6-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea;
    (58) N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (59) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,1,2-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (60) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
    (61) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1-methyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
    (62) N6-(1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (63) N3-(2,6-dimethylphenyl)-1-methyl-N6-(2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (64) N-(3-((6-((1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(trifluoromethyl)benzamide;
    (65) N3-(2,6-dimethylphenyl)-N6-(1-isopropyl-2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (66) N3-(2,6-dimethylphenyl)-1-methyl-N6-(2,3,3-trimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (67) N3-(2,6-dimethylphenyl)-1-methyl-N6-(1,2,3,3-tetramethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (68) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-4,4-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
    (69) N-(3-((6-((2-acetyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-yl)amino)-4-methylphenyl)-3-(trifluoromethyl)benzamide;
    (70) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
    (71) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,3-dimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
    (72) 1-(5-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)isoindolin-2-yl)ethane-1-one;
    (73) 1-(7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-1,3,3-trimethyl-3,4-dihydroisoquinoline-2(1H)-yl)ethane-1-one;
    (74) N3-(2,6-dimethylphenyl)-1-methyl-N6-(2-methylisoindolin-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (75) N3-(2,6-dimethylphenyl)-1-methyl-N6-(5,6,7,8-tetrahydronaphthalene-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (76) N-(4-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)phenyl)acrylamide;
    (77) 7-((3-((2,6-dimethylphenyl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)amino)-3,4-dihydroisoquinoline-1(2H)-one;
    (78) N6-(1-isopropyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine;
    (79) N6-(1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-N3-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine.
  5. A preparation method of the compound represented by formula 1 comprising the step of preparing the compound represented by formula 1 by reacting the compound represented by formula 2 with the compound represented by formula 3 (step 1), as shown in reaction formula 1 below:
    [Reaction Formula 1]
    Figure PCTKR2018005478-appb-I000192
    (In reaction formula 1,
    A, R1, R2, R3, R4, and R5 are as defined in formula 1 of claim 1, and X is F, Br, Cl, or I).
  6. A pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of cancer.
  7. The pharmaceutical composition according to claim 6, wherein the compound is characterized by being effective in preventing or treating cancer by inhibiting Bruton's tyrosine kinase (BTK).
  8. The pharmaceutical composition according to claim 6, wherein the cancer is solid cancer or blood cancer.
  9. The pharmaceutical composition according to claim 6, wherein the solid cancer is selected from the group consisting of brain tumor, benign astrocytoma, malignant astrocytoma, pituitary adenoma, meningioma, brain lymphoma, oligodendroglioma, intracranial tumor, ependymoma, brain stem tumor, head and neck tumor, laryngeal cancer, uveal cancer, nasal cancer, nasopharyngeal cancer, salivary gland cancer, hypopharyngeal cancer, thyroid cancer, oral cancer, thoracic tumor, small cell lung cancer, non-small cell lung cancer, thymic cancer, mediastinal tumor, esophageal cancer, breast cancer, male breast cancer, abdominal tumor, stomach cancer, liver cancer, gallbladder cancer, biliary cancer, pancreatic cancer, small bowel cancer, colon cancer, anal cancer, bladder cancer, kidney cancer, male genital tumor, penile cancer, prostate cancer, female genital tumor, cervix cancer, endometrial cancer, ovarian cancer, uterine sarcoma, vaginal cancer, female external gonadal cancer, female urethral cancer, and skin cancer.
  10. The pharmaceutical composition according to claim 6, wherein the blood cancer is leukemia, malignant lymphoma, multiple myeloma, or aplastic anemia.
  11. A pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of autoimmune disease.
  12. The pharmaceutical composition according to claim 11, wherein the compound is characterized by being effective in preventing or treating autoimmune disease by inhibiting Bruton's tyrosine kinase (BTK).
  13. The pharmaceutical composition according to claim 11, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, lupus, diabetes mellitus, myasthenia gravis, Hashimoto's thyroiditis, Graves' disease, Sjogren's syndrome, multiple sclerosis, Guilin Barre syndrome, acute sporadic encephalomyelitis, Addison's disease, ocular hepatocellular seizure-epileptic syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, chronic digestive dysfunction, Goodpasture syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary dysplasia cirrhosis, Takayasu arteritis, temporal arteritis, autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, systemic alopecia, Behcet's disease, chronic fatigue, autonomic nystagmus, endometriosis, interstitial cystitis, neuromuscular dystrophy, scleroderma, and vulvar pain.
  14. A pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of Parkinson's disease.
  15. A health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of cancer.
  16. A health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of autoimmune disease.
  17. A health functional food comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient for the prevention or improvement of Parkinson's disease.
  18. A method of treating a subject having cancer, autoimmune disease or Parkinson's disease comprising administering an effective amount of the compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
  19. A method for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease comprising the step of administering the pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof as an active ingredient to a subject in need.
  20. A use of the pharmaceutical composition comprising the compound represented by formula 1 or the pharmaceutically acceptable salt thereof for the prevention or treatment of cancer, autoimmune disease or Parkinson's disease.
  21. A compound represented by formula 1 or the pharmaceutically acceptable salt thereof thereof for use in the treatment of cancer, autoimmune disease or Parkinson's disease.
  22. A composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use in the treatment of cancer, autoimmune disease or Parkinson's disease.
  23. A composition comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof for use as a medicament.
  24. A medicament comprising a compound represented by formula 1 or the pharmaceutically acceptable salt thereof.
PCT/KR2018/005478 2017-05-12 2018-05-14 Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient WO2018208132A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/612,592 US11084824B2 (en) 2017-05-12 2018-05-14 Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0059165 2017-05-12
KR20170059165 2017-05-12
KR10-2018-0051686 2018-05-04
KR1020180051686A KR102128018B1 (en) 2017-05-12 2018-05-04 pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient

Publications (1)

Publication Number Publication Date
WO2018208132A1 true WO2018208132A1 (en) 2018-11-15

Family

ID=64104794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005478 WO2018208132A1 (en) 2017-05-12 2018-05-14 Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient

Country Status (1)

Country Link
WO (1) WO2018208132A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019212256A1 (en) * 2018-05-02 2019-11-07 제이더블유중외제약 주식회사 Novel heterocycle derivative
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022197641A1 (en) * 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
WO2022270994A1 (en) * 2021-06-25 2022-12-29 한국화학연구원 Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
KR20230000983A (en) * 2021-06-25 2023-01-03 한국화학연구원 New bifunctional heterocyclic compounds for degrading BTK via ubiquitin proteosome pathway and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024680A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2015048689A1 (en) * 2013-09-30 2015-04-02 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024680A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2015048689A1 (en) * 2013-09-30 2015-04-02 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEUNG, C. S. ET AL.: "Methyl Effects on Protein-Ligand Binding", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 9, 2012, pages 4489 - 4500, XP055556365 *
WU, S. ET AL.: "Ack1 is a dopamine transporter endocytic brake that rescues a trafficking-dysregulated ADHD coding variant", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 50, 2015, pages 15480 - 15485, XP055556362 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019212256A1 (en) * 2018-05-02 2019-11-07 제이더블유중외제약 주식회사 Novel heterocycle derivative
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022197641A1 (en) * 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
WO2022270994A1 (en) * 2021-06-25 2022-12-29 한국화학연구원 Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
KR20230000983A (en) * 2021-06-25 2023-01-03 한국화학연구원 New bifunctional heterocyclic compounds for degrading BTK via ubiquitin proteosome pathway and uses thereof
KR102637915B1 (en) 2021-06-25 2024-02-19 한국화학연구원 New bifunctional heterocyclic compounds for degrading BTK via ubiquitin proteosome pathway and uses thereof

Similar Documents

Publication Publication Date Title
WO2018208132A1 (en) Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient
WO2021112538A1 (en) Glp-1 receptor agonist
WO2020149723A1 (en) Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient
WO2014061970A1 (en) Sodium channel blockers, preparation method thereof and use thereof
WO2015160192A1 (en) Pharmaceutical composition for treating and preventing leukemia, containing thienopyrimidine derivative or pharmaceutically acceptable salt thereof
WO2020149715A1 (en) Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
WO2014109530A1 (en) 2-(phenylethynyl)thieno[3,4-b]pyrazine derivative and pharmaceutical composition comprising same for preventing or treating cancer
WO2020096372A1 (en) Novel piperidine-2,6-dione derivative and use of same
WO2018021826A1 (en) Novel pyrimidine-2,4-diamine derivative and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
WO2016006974A2 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A2 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2011049274A1 (en) Imidazole derivatives and compositions for treating melanoma
WO2022139304A1 (en) Novel quinazoline derivative compound as sos1 inhibitor, and use thereof
WO2010032986A2 (en) Novel 5-(4-aminophenyl)-isoquinoline derivative, pharmaceutically acceptable salt thereof, production method for same, and composition containing same as active ingredient for prophylaxis and treatment of medical condition induced by raf kinase hyperactivity
AU2019344240B2 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
WO2020263058A1 (en) Aminocyanopyridine derivative and use thereof
WO2021040422A1 (en) Novel pyrimido[4,5-d]pyrimidine-2-one derivative having protein kinase inhibitory activity
EP3166945A2 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2021086077A1 (en) Isoquinolinone derivative, preparation method therefor, and pharmaceutical composition, comprising same as active ingredient, for prevention or treatment of poly(adp-ribose)polymerase-1 (parp-1)-associated disease
WO2019039905A1 (en) Novel tryptophan hydroxylase inhibitor and pharmaceutical composition including same
WO2021201576A1 (en) Benzothiazole derivative compound
WO2020106059A1 (en) Novel tricyclic compound as irak4 inhibitor
WO2022270977A1 (en) Novel pyridine derivative compound as ron inhibitor
WO2022270980A1 (en) Novel urea derivative compound as ron inhibitor
WO2019107922A1 (en) Arylpyrazolylpiperazine or arylpyrazolyldiazepane derivative acting as 5-ht7 receptor regulator and pharmaceutical composition comprising same for treatment or prevention of central nervous system disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18798751

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18798751

Country of ref document: EP

Kind code of ref document: A1